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2Abstract
The benefits of llama antibodies compared to conventional  IgG (most particularly low 
manufacturing cost and stability) have been well published in literature and this lends 
them to potential applications in the home and personal care industry.  Llama antibody 
fragments  have  been  fused  to  a  cellulose  binding  domain  moiety  and  used  as  a 
bifunctional  protein  to  aid  deposition  of particles  to  cellulosic  surfaces.  The  initial 
anticipated  applications  for  this  technology  is  in  the  delivery of actives  to  fabrics  in 
laundry, however due to the ubiquitous nature of cellulose a number of other possible 
applications are envisaged.
Efficacy  of  the  protein  was  first  demonstrated  in  a  model  particle  system  using 
coacervate particles coated with a dye-based antigen using ELISA, Biacore and particle 
deposition studies.  Determined antibody affinities correlated with those in literature.  A 
number of different  fusion  formats  were  investigated,  and it was  found that  although 
addition  of  a  fusion  partner  adversely  affected  antibody  affinity,  a  single 
antibody/double  cellulose  binding  domain  format  gave  enhanced  particle  deposition, 
over a particle only control.
The  success  of the  hypothesis  in  the  model  system  prompted  study  of a  potential 
commercial  equivalent.  A particle consisting a melamine urea formaldehyde polymer 
was chosen.  A protein from a range of possible candidates produced by a commercial 
manufacturer  was  selected  and  a  purification  process  was  developed  that  allowed 
production  of protein  on  the  gram  scale,  with  potential  for  scale-up.  The  binding, 
bifunctionality and stability of the protein was then studied using gel densitometry and 
UV based assays.  A substantial increase in particle depositions was demonstrated with 
a UV microscopy based assay.
Use of the protein to enhance particle delivery to cellulosic surfaces showed promise in 
both systems studied when compared to particles alone, and has potential applications in 
product  fields  such  as  home  and  personal  care,  the  agrochemical  industry  and  paper 
processing.
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141.0 Introduction
1.1 Structure and characteristics of antibodies and antibody fragments
1.1.1 Antibody background
Antibodies  are  key components  of the  mammalian  immune  system.  The  role  of the 
immune  system  of mammals  is  to  detect  any potentially harmful  foreign  material  or 
pathogen and elicit an appropriate response against it (Liddel  and Weeks,  1995).  The 
immune  system  can  be  split  into  two  components:  the  innate  and  the  adaptive.  The 
innate is a non-specific defense system, used primarily as the first line of resistance to 
invasion, whereas the adaptive is more specifically designed to elicit an immunological 
challenge that is highly specific for the target pathogen (Roitt et al.,  1998).
The innate system consists of a variety of cells (known as phagocytes and natural killer 
(NK)) and humoral factors which work in concert to engulf and destroy foreign cells or 
host  cells  that  have  been  taken  over  by  the  invading  body.  In  some  cases,  this 
mechanism  is  not  enough  to  clear  the  challenge  upon  the  host,  and  the  adaptive 
immunity mechanism is needed to overcome it.  The innate immune  system  does not 
change  the  nature  of its  response  each  time  it  is  challenged;  however  the  adaptive 
immune  system  improves  with  each  successive  encounter  with  the  same  challenge. 
This confers life long “immunity” to diseases such as measles and diphtheria after the 
initial  infection has been cleared (Roitt et al.,  1998).  This process makes possible the 
vaccination  of many  diseases,  using  an  attenuated  or  weakened  form  to  promote  an 
initial immune response.
A key component of the adaptive system is the production of specific humoral factors 
that  aid  the  action  of phagocytes  in  the  recognition  of foreign  particles,  known  as 
antibodies (Ab) or immunoglobulins (Ig).  At present, antibodies are believed to be the 
most  important  part  of the  immune  system  (Liddel  and  Weeks,  1995).  The  immune 
system possesses an enormous diversity of immunoglobulins capable of binding almost 
any foreign invading particle, known as an antigen.
151.1.2  Antibody Structure
Antibodies are glycoproteins secreted by plasma cells derived from [3-lymphocytes that 
have been stimulated to produce them by the presence of the antigen.  There  are  five 
classes of antibody or Ig molecules, known as IgM, IgG, IgD, IgA, and IgE.
IgG  proteins  are  the  most  common  in  the  bloodstream  (70-75%  of  the  total 
immunoglobulin  pool)  and  are  homodimers,  consisting  of two  identical  polypeptide 
chains  of 450  amino  acids  known  as  the  heavy  chains  and  two  identical  chains  250 
amino  acids  known  as  the  light  chains.  The  structure  of  each  domain  has  a 
characteristic  fold  that  consists  of  two  antiparallel  P-sheets  with  an  intramolecular 
disulphide bond.
As  can  be  seen  from  figure  1,  the  molecules  consist  of variable  and  non-variable 
regions.  The N-terminal domains of each chain consist of three loops connecting the (3- 
sheets,  and  these  loops  vary  greatly  in  length  and  sequence.  The  six  hypervariable 
loops are known as complementary determining regions (CDR) and are responsible for 
binding  of the  antigen  (Maynard  and  Georgiou,  2000).  The  area  that  represents  the 
actual  binding site  is known  as the paratope and this binds to the  relevant  section  of 
antigen, known as the epitope (Arbabi  et al.,  1997;  Rees et al.,  1994).  Most antigens 
have a number of possible binding sites (epitopes) on their surface, and each antibody 
consequently recognises a specific epitope, rather than the whole antigen.
Although the antibody molecule binds to an antigen specifically, it also plays a further 
role in the immune system.  The basic structure of the antibody molecule is similar in 
each molecule, and the non-antigen binding section is responsible  for interacting with 
other elements of the immune system,  such as phagocytes, or activating the  important 
process of complement (used to lyse the attacking pathogenic cells).  Thus the antibody 
acts as a flexible adaptor molecule,  linking various elements of the immune system to 
recognise specific pathogens and their products (Roitt et al.,  1998).
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Figure 1:  Diagram of a conventional antibody.  The disulphide bridges are visible linking the 
two heavy chains together.
17Although the binding of antibodies to antigens is something that happens regularly in 
vivo, it can also occur successfully in vitro, opening the door to a host of applications 
for antibodies in the biotechnology and biomedical industry.  The most commonly used 
immunoglobulin in biotechnology is the IgG molecule (Maynard and Georgiou, 2000).
1.1.3  Antibody Function
As discussed previously, hypervariable regions are clustered at the end of the IgG arms 
(in  a  region  known  as  Fab  region),  and  it  is  these  particular  residues  that  interact 
specifically with the antigen.  The framework residues do not usually form bonds with 
the  antigen,  although  are  important  in  maintaining  the  structure  and  integrity  of the 
binding site.
The binding reaction of antibody to antigen involves the formation of a number of non- 
covalent bonds between amino acids in the antibody and the binding site consisting of a 
mixture  of  hydrogen  bonds,  electrostatic  attractions,  Van  der  Waals  forces  and 
hydrophobic attractions.  Individually these bonds are very weak compared to covalent 
bonds, but the cumulative effect of a large number of them is considerable (Roitt et al., 
1998).
The strength of these bonds is heavily dependent on the distance between the interacting 
groups,  and  in  order  for  binding  to  occur  there  must  be  a  highly  complementary 
paratope and epitope, both in terms of atomic structure on pairing sides of the antibody 
and antigen, and also overall  shape.  If sufficient complementarity is present, then the 
nature  of forces  will  be  strong enough to overcome thermodynamic  disruption of the 
bond.  However if the electron clouds of the antigen and antibody overlap, very strong 
repulsive forces come into play (Roitt et al., 1998).
These forces are responsible for determining the specificity of the antibody molecule for 
a particular antigen, as any sufficiently different antigen will simply possess too great a 
total  repulsive  force,  and  prevent  binding.  The  sum  of the  attractive  and  repulsive 
forces  gives  rise  to  a  measure  of the  strength  of the  bond,  known  as  the  antibody 
affinity,  discussed  further  in  section  1.5.  Antibodies  also  have  another  measure  of 
strength of binding to an antigen, known as avidity, which is the strength of the binding
18i.e.  the  sum  of the  binding  strength  of all  domains  present.  This  term  allows  for 
multivalent antibody binding (Roitt et al., 1998).
1.1.4  Polyclonal and Monoclonal antibodies
A wide variety of animal  hosts have been used to produce antibodies.  A response  is 
elicited  by  inoculation  of  a  selected  antigen  in  sufficient  quantities  to  stimulate 
production, which is then extracted from the animals blood.  Most large molecules such 
as proteins will elicit a response, for example a human protein will elicit a response in a 
rabbit,  assuming there  is no homologous protein already in  the rabbit.  Obviously the 
larger the animal, the more antibody can be extracted.  Commonly used animals include 
mice, rabbits and goats.
In animal sera many antibodies of differing structure and configuration will be produced 
from  different  p-lymphocytes.  These  antibodies  are  known  as  polyclonal.  Early 
advances in antibody technology were hampered by the need for animal immunization 
or expression  of engineered  antibodies  in  a  eukaryotic  host  (Maynard  and  Georgiou, 
2000),  and the  amount that could be produced was  limited.  The  fact that  antibodies 
(being proteins) were highly antigenic  themselves  in non-host organisms  also  limited 
their potential.
In  1975,  Kohler and Millstein  fused myeloma cells  with  p-cells  from  an  immunized 
animal.  The  resultant  cells  possess  both  antibody  production  ability  and  relative 
longevity  in  culture  and  are  called  hybridoma  cells.  Single  antibody  secreting 
hybridoma cells can then be selected and cloned so that all progeny produce exactly the 
same antibody. These identical antibodies are known as monoclonal, and can be created 
in response to a specific antigen.
Thousands  of  hybridoma  cell  lines  have  now  been  created  using  this  technology 
(Maynard  and  Georgiou,  2000),  facilitated  by  the  cloning  of  relevant  antibody 
expression genes using the polymerase chain reaction (PCR) and subsequent expression 
in bacterial systems (Pluckthun and Skerra,  1989).  In the last ten years techniques that 
allow high throughput screening of candidates and efficient humanization of antibodies 
to  prevent  them  eliciting  an  immune  response  have  further advanced production  and 
understanding.
19Currently  the  principle  application  for  antibodies  is  in  the  pharmaceutical  industry  - 
there are a number of monoclonal antibodies in production for treatment of cancer and 
other  conditions.  There  are  also  a  number  of  antibodies  in  clinical  trials.  Other 
applications  are  in  diagnostics.  Both  of these  applications  require  a  relatively  small 
amount of protein, and allow a high cost due to their market.  However, other markets 
(such as home and personal care and agrochemical)  in the biotechnology industry will 
require a large amount of product at low cost.
1.1.5  Selective protease digestion of the IgG molecule gives antibody fragments
The binding sites for antigen and effector receptors are assigned to different parts of the 
antibody.  The Fc part of the molecule is responsible for the effector functions, and is 
labelled as the effector domains  in fig  1.  For some applications this domain can be a 
hindrance,  as  many  cells  possess  Fc  receptors  to  which  the  Fc  region  will  bind 
regardless of specificity of the  molecule.  The  size  of an  antibody molecule  can  also 
often cause problems when it comes to the application.  As such it is often an advantage 
to remove or cleave off the effector domain (Fc) section of the antibody.
A  long  established  method  of  cleaving  this  unwanted  portion  of  antibody  is  by 
proteolytic enzyme digestion.  A non-specific protease, Papain, splits the antibody in the 
hinge  region,  resulting  in  the  formation of two monovalent  Fab  fragments  and  an  Fc 
fragment.  Bivalent fragments can be made by treatment of the antibody with Pepsin, 
bromelain or ficin that digest away only the effector region (Liddell and Weeks,  1995).
1.2  Heavy chain only antibody fragments
1.2.1  Making the fragment simpler
The Fv containing the two variable domains (Vh and Vl) known as scFV, is considered 
the smallest fully functioning molecule of IgG and engineered fragments (see figure 2). 
A large genetic library has been created with these fragments using PCR, considered a 
major  breakthrough  in  molecular  biology.  However  the  technique  is  not  easy:  the 
cloning of the two correctly spliced gene fragments (V h and V l) is an error-prone step; 
generating a library is time consuming and the constructs are commonly unstable in the 
bacterial host.  Further more the  expression,  yield,  stability and functionality of scFV 
often turn out to be problematic.
20Ward et al. (1989) used an approach whereby the VH  domain in the absence of the Vl 
domain was isolated and used.  This approach avoids the introduction of a peptide linker 
used  in  production  of scFV  constructs  that  might  create  additional  problems  such  as 
reduced affinity, aggregation or proteolytic  cleavage.  However the  insolubility of the 
isolated Vh domains expressed in bacteria and their reduced antigen affinity relative to 
the original Vh-Vl combination made them impractical for use.
1.2.2  Naturally simpler antibodies
Certain  mammals  belonging  to  the  camelid  family  produce,  amongst  the  normal 
complement  of mammalian  antibodies,  an  unusual  type  of antibody that  has  no  light 
chain.  In  1993  Hamers-Casterman  et  al.  reported  the  existence  of heavy  chain  only 
antibodies in Camelus dromedaries.  It was later found that these antibodies are found 
in all camelidae, including llamas and alpacas.
In the Llama (Lama glama) six  IgG subclasses have been described, two of which are 
conventional IgG molecules:  IgGyla and IgGylb.  The other four are heavy chain only 
antibodies (IgG2a, IgG2b, IgG2c and IgG3) (Vu,  1997), consisting of only the variable 
domain of the heavy chain, as demonstrated below, known as VHH.  Heavy chain only 
antibodies lack a ChI  domain and instead have either a long (29 or 35 amino acids) or 
short  (12  amino  acids)  hinge  region.  Figures  2  and  3  illustrate  the  main  differences 
between the conventional IgG molecule and the VHH molecule.
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Figure 2: Conventional antibody molecules used in biotechnology:
a: IgG molecule; b: Fab fragment; c: Fv fragment; d: scFv fragment (joined by peptide
linker).
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Figure 3: Camelid antibody molecules:
a: Fleavy chain IgG molecule (long hinge); b: Heavy chain IgG molecule (short hinge)VHH 
fragment; c: VHH fragment.
22Nguyen et al. (1999) have described heavy chain only antibodies as being the result of 
mutations  in  the  splice  consensus  signal  of  the  ChI  domain  of  conventional  IgG 
molecules  and  not  somatic  hypermutation  of the  Vh  genes.  This  loss  of consensus 
splice signal is similar to heavy chain disease in humans and mice, but has not resulted 
in  the  functional  defects  that  can  be  observed  with  the  condition.  They  also  have 
comparable  affinities  with  conventional  IgG  fragments,  Fab  and  scFV  raised  to  the 
identical antigens.  Nguyen et al. have released further publications (2002) that confirm 
that these antibodies have evolved from existing conventional antibody genes.
It  is  likely that these  heavy chain  antibody genes  have been  preserved  in  the  camelid 
species  due  to  a  conferred  selective  advantage.  This  is  believed  to  be  due  to  the 
function of the heavy chain only antibodies in recognising novel  and unusual  epitopes 
(Nguyen et al. 2003).
Frenken et al. (2000) have described how the simpler VHFI molecule fragments can be 
produced at high levels in S.  cerevisiae (up to 250mg/l in shake flasks and  lg/1 in high 
density fermentations).  These molecules have been found to overcome the folding and 
aggregation problems  associated with  more  conventional  antibody fragments  in  lower 
eukaryotes.  The  binding  domain  or  VHH  section  is  less  hydrophobic  than  the  Fv 
domain of conventional IgG molecules, believed to result in higher secretion efficiency 
(Thomassen et al, 2002).
It is possible to link two heavy chain only antibodies together to create a bispecific and 
bivalent antibody.  Conrath et al. (2001), tethered two fragments by the structural upper 
hinge  of  a  conventional  IgG  molecule  to  generate  bispecific  molecules.  These 
molecules  are  particularly  easy  to  generate,  making  them  ideal  for  use  in  many 
applications.
1.2.3  The source of heavy chain only antibodies used in industry
Llamas produce considerably less heavy chain only IgG molecules than camels (around 
45% of total antibody content compared to 75%) and show different binding to Proteins 
A and G, possibly due to structural or sequence differences.  They are however the most 
common source of heavy chain only antibodies, as they are smaller and easier to keep 
than camels, and are therefore more practical (van der Linden et al.,  1999).
231.2.4  Occurrence in other species
No  further  heavy  chain  only  antibodies  have  been  identified  in  other  mammals, 
although some shark species have also been seen to possess an antibody like structure 
designated new  or nurse  shark  antigen  receptor (NAR)  (Greenberg et  al.,  1995).  No 
ligands have been identified as yet for this molecule.
Camelid VHH  molecules  show about a  75% homology to mammalian  VH   sequences. 
NAR molecules however show only a 25% homology to mammalian Vh sequences and 
are more similar to VL  and T cell receptor molecules, indicating that they have evolved 
separately (Greenburg,  1995).  Similar antigen binding molecules have been found in 
the Ratfish known as the Cos5-antibodies (Rast et al.,  1998).
1.3  Structure of the VHH molecule and function in relation to conventional IgG 
molecules
1.3.1  Structure
The antigen-binding domain of the VHH molecule is approximately half the size of that 
in a conventional IgG molecule.  This structural difference has an important effect on 
antigen recognition.  Desmyter et al. (1996) have shown that camel VHH molecules can 
bind to novel epitopes unrecognized by conventional antibodies, for instance the active 
sites of certain enzymes.  Two out of the six VHH molecules isolated bind to epitopes 
not recognized by monoclonal  antibodies of mouse origin.  This is obviously a major 
advantage to the camelid in terms of additional immune protection.
Desmyter et al.  (1996) and Decanniere et al. (1999) note that camelid VHH molecules 
bind according to the geometric surface of the antigen, and also ionic and hydrophobic 
interactions.  Although  conventional  IgG  molecules prefer to bind to planar surfaces, 
camelid  VHH  prefer  to  bind  to  grooves  or  cavities  using  extended  Complementary 
Determining Regions (CDRs).  The affinities found for the heavy chain only antibodies 
have been found to be in the low nanomolar range, comparable to that of Fab and scFv 
fragments.
Conventional  IgG’s  recognize  large  protein  antigens  through  a  large  antigen-binding 
surface that is flat, but suitable for high affinity interaction.  Small antigens tend to be
24bound by conventional IgG antibodies in the groove between the heavy and light chain. 
Obviously the heavy chain only antibodies are devoid of light chains and hence require 
the extended CDR to allow binding.
1.3.2  Function
The  physico-chemical  characteristics  of camelid  VHHs  also  differ  from  conventional 
IgG molecules.  The temperature stability of llama VHH molecules has been shown to 
be significantly greater than that of conventional IgG.  Many llama VHH molecules can 
be incubated for up to 2 hours at 90°C without significant loss of binding activity (van 
der Linden et al (1999).  Some have also been shown to bind antigens at temperatures of 
up to 90°C.  This makes them ideal in processes that have environmental stresses (such 
as pasteurization) without losing the ability of antigen binding.
The extra stability of the VHH molecule has been associated with an additional disulfide 
bond between CDR 1   and CDR 3 as present in the majority of VHHs (Gharoudi et al.,
1997).  However although  this  extra  disulphide  bond  is  found  in  camels  it  is  not  so 
prevalent  in  llama  VHH,  which  still  exhibit  the  extra  stability,  indicating  that  the 
disulphide bond is not the sole effector.
Not all VHHs exhibit the ability to function at high temperatures, but they do show the 
ability to function at normal temperatures after exposure to high temperatures. Perez et 
al.  (2001)  have  noted  that  this  stability is  a  result  of the  reversibility  of the  thermal 
unfolding process,  unlike conventional  IgG molecules that exhibit irreversibility upon 
exposure to heat.
The specificity of llama VHH molecules was examined by van der Linden et al (1999) 
by examining a fragment specific  for the azo dye Reactive Red 6.  This antibody was 
examined for affinity with other, chemically similar azo dyes Reactive Red 120 (a dimer 
of RR6), Direct Red 80, Reactive Black 6 and Direct Green 26.  No affinity was shown 
for  any  of these  molecules  except  the  Reactive  Red  6.  The  RR-6  llama  VHH  is 
therefore  highly  specific  for  RR6,  demonstrating  the  ability  of  llama  VHH  to 
discriminate between highly homologous molecules.  It was also shown that llama VHH 
could be raised against different epitopes on the same molecule, for example the alpha 
and beta subunits of the hCG protein, or the intact protein.
25Llama antibodies have also been found that successfully transmigrate across the human 
blood  brain barrier,  raising  the  possibilities  of novel  compounds  that  can  be  used  to 
target  brain  diseases.  Normal  IgG’s  cannot  cross  this  barrier  (Muruganandam  et  al. 
2002).
1.3.3  Applications of llama antibodies
A number of bulk applications for economical antibody fragments exist, as suggested by 
Frenken  et  al.  (2000)  including  their  use  in  waste  water  treatment,  industrial  scale 
separations,  antibody-enzyme  conjugates/fusions,  as  an  ingredient  in  novel  consumer 
goods with new  or improved  functionality.  The  potential  also  exists  to  use  antibody 
based technologies to  aid  in  environmental  pollution  management  (Harris,  1999).  All 
these applications require large amounts of inexpensive molecules.
Although  production  of  conventional  IgG  molecule  fragments  is  becoming  more 
efficient,  bulk  production  at  low  costs  is  extremely  difficult  due  to  high  costs  in 
downstream  processing  and  the  fact  that  large-scale  production  has  not  yet  been 
described in detail.  Conventional IgG molecules are most commonly used in medical 
and diagnostic application because of this high production cost.  Llama VHH molecules 
are  cheaper to  produce  and  offer  a  more  discriminating product  due  to  their  smaller 
novel target sites.
As well as medical use, VHH molecules can be used in large-scale applications across 
the  biotechnology  industry,  their  principle  advantage  being  a  long  shelf life  due  to 
increased stability.  The use of llama antibodies in detergents (for example to control 
dandruff  in  shampoos,  and  as  targeted  whiteners  in  laundry  detergents)  is  a  good 
example of where conventional IgG molecules would not be able to withstand the harsh 
environmental  conditions  needed  (Linden,  2000).  Llama  antibodies  have  also  been 
suggested as a possible treatment for prevention of dandruff by inhibiting the growth of 
organisms which contribute to dandruff.  Furthermore they have been found to be stable 
in shampoos (Dolk et al., 2005).
26Furthermore,  camelid  heavy  chain  antibodies  have  been  shown  to  be  potent  enzyme 
inhibitors,  demonstrated  to  actively  compete  for  the  active  site,  where  conventional 
antibodies do not bind (Lauwereys et al,  1998).  They have been shown to mimic the 
carbohydrate  substrate  of lysozyme  and  thus  inhibit  enzyme  binding  (Transue  et  al.,
1998).
Other potential uses for these antibodies include the foods industry.  Camelid antibodies 
have  also  successfully  been  used  to  prevent  phage  lysis  of bacteria  used  in  cheese 
production  by adding  7nM  of antibody.  As  these  antibodies  are  produced  in  a  food 
grade organism it makes them particularly suitable (Ledeboer et al., 2002).  Other uses 
for  antibodies  have  been  demonstrated  to  be  removal  of bacteria  using  an  immuno- 
affinity mechanism (Molloy et al., 1995)
1.4  Antibody fusion proteins and conjugates
Using standard molecular biotechnology techniques  it is possible to  create  a range of 
multi-functional  proteins  with  the  antibody  binding  domain  as  part  of that  function. 
There  are  many  possible  fusion/conjugation  partners  from  tags  to  aid  purification  to 
enzymes for use in diagnostic assays and cytotoxic agents for use in cancer therapy.  Of 
particular relevance to this study is the fusion of the Cellulose Binding Domain (CBD) 
found in many organisms.
271.4.1 Cellulose Binding Domains
The  Cellulose  Binding  Domain (CBD)  was  first observed in the  fungus  Trichoderma 
reesei and the bacterium  Cellulomonas fimi in the  late  1980’s  (Gilkes et al.  1988  and 
Van  Tilbeurgh  et  al.,  1986  and  1989).  CBDs  have  also  been  found  in  some 
polysaccharide  degrading  enzymes  such  as  hemicellulases,  endo-mannase,  acetyl- 
xylanesterase,  xylanase,  esterase  and  pectate  lyase  (Levy and  Shoseyov,  2002).  This 
has  led to them being referred to as  Carbohydrate  Binding Modules  (CBMs)  in  some 
literature.
They  are  structurally  and  functionally  independent,  noncatalytic  modules  of  the 
enzymes they are found attached to (Linder et al.,  1996).  They are commonly between 
4 and 20Kda in size and may be found internally or at either terminus of the cellulase 
enzyme.  The  two  domains  are joined by  a  linking  segment  of peptide  of sufficient 
length and flexibility to allow the efficient orientation and operation of both (Carrard et 
al.  2000).  Many organisms with a  need to degrade  cellulose produce  cellulases  with 
CBD’s.  A common feature for all CBD’s is that they will bind to cellulose without any 
hydrolytic activity themselves.
CBDs  can be  removed  from  an  enzyme  by proteolysis  or protein  engineering.  This 
results  in decreased affinity,  although the role of the  CBD in the enzymes  hydrolytic 
activity remains a matter of debate (Linder et al.,  1998).  Little or no effect is observed 
when the substrate is soluble however.  They have a typically low content of charged 
amino acids and a high content of hydroxylamine acids (Reinikainen et al., 1992).
1.4.2  Applications of CBDs
Cellulose consists of linear polymers of thousands of glucose residues linked by (3-1,4- 
glycosidic  bonds.  It  has  a  rigid  structure  and  is  insoluble  leading  to  it being  highly 
chemically inert.  This is due to the fact that it is closely packed together and forms long 
crystals that are stabilized by intermolecular forces (Linder and Teeri,  1996).
The first commercial application (and hence most studied) is the use of CBDs in fusion 
proteins as tags for affinity purification or immobilization.  The reasoning behind this is 
economically  very  attractive:  CBDs  require  little  or  no  pretreatment  as  they  adsorb 
spontaneously to cellulose from most solutions (van der Linden et al.,  1998).
28Cellulose  is  also  inexpensive  and  chemically  inert  rendering  it  suitable  for  use  in 
pharmaceutical and food applications.  This approach has been used successfully for the 
purification  or  immobilization  of  numerous  recombinant  proteins  such  as  alkaline 
phosphatase,  Beta-glucosidase  streptavidin,  blood  clotting  factor  X,  protein  A,  and 
interleukin (Reinikainen et al., 1992).
1.4.3  Function of CBDs
Early experimentation on CBD mediated protein  immobilization has  shown very little 
or no  leakage  from  cellulose  leading  to  the  hypothesis  that  the  interaction  of CBD’s 
(sourced  from  Cellulomonas  fimi)  with  cellulose  is  irreversible  (Henrissat,  1993, 
Reinikainen et al,  1997).  When considering the function of intact cellulases however, 
irreversible  binding  through  the  CBD  seems  unlikely  as  an  irreversibly  bound  CBD 
would not allow rapid progression of the enzyme to the next substrate molecule (Linder 
and Teeri, 1998).
Linder and Teeri (1996) have demonstrated that the binding of some CBDs  from this 
organism are reversible and have a relatively fast exchange rate on the cellulose surface. 
Jervis  et  al  (1997)  have  shown  that  in  some  cases  the  adsorbed  CBD  does  not  stay 
statically in the same spot, but migrates on the cellulose surface.
One  of the  first  suggestions  concerning the role  of CBDs  was  that they might  aid  in 
breaking up the cellulose molecule, prior to its actual hydrolysis (Knowles et al.,  1987). 
At least some have been known to penetrate the fibres at surface discontinuities, release 
non-covalently bound fragments and uncover new cellulose chain ends.  This tends only 
to happen with impure cellulose  (such as pure cotton) and not pure crystalline,  where 
there is no evidence for such activity (Linder and Teeri,  1998).
Linder  et  al.,  (1996a)  have  shown  that  by  linking  two  CBD’s  together  (creating  a 
“double  CBD”),  the affinity is  significantly improved.  They hypothesise that  linking 
more CBDs will increase affinity further.  This hypothesis is derived from nature itself; 
cellulases  produced  by  organisms  living  in  extreme  conditions  can  contain  up  to  ten 
CBDs.  Linder et al. (1998) also have shown that the binding of a protein to a CBD to
29form  a  fusion  molecule  does  not  affect  the  activity  of the  CBD  molecule,  and  is 
“functionally identical” to the isolated CBD.
Linder et al.  (1998) also note the apparent effect of pH on the  CBD’s  studied,  noting 
that the binding is  largely unaffected  at pH’s  of 2.5-6.5,  but above  pH  7.0  there  is  a 
clear decrease in affinity.  The interaction is estimated to have an approximate K <i of 
1   x  10'6 nMol.  They also note that although in most cases addition of a fusion protein 
has  no  affect,  the  size  of  the  protein  may  prevent  the  CBD  from  penetrating  the 
substrate as thoroughly as  if it was by itself.  Addition of another CBD  increases the 
affinity approximately ten fold.
1.4.4  CBD families
Up to  180 different CBDs have been identified (Tomme et al,  1995).  The majority of 
CBDs can be split into three families, see figure 4.
Although most CBDs belong to family I, II or III, there are another 7 families (IV-X). 
Some CBD’s have also been reported to have an affinity towards chitin  (Goldstein et 
al.,  1993),  suggested to be due to the close structural similarity of cellulose and chitin 
(Linder and Teeri, 1996).  There have been some cases of xylan binding domains (Irwin 
et al.,  1994).  Whilst some Family II residues have been reported to enhance physical 
disruption of cellulose fibres and release small particles of cellulose,  all others have no 
activity other than binding (Din et al, 1991, Tomme et al., 1995).
30Family I Found only in fungi. 
Contain 32-36 residues. 
Over 30 members.
Family II Found only in bacteria. 
Contain 90-100 residues. 
Over 30 members.
Family III Found only in bacteria. 
Contain 130-172 residues. 
Over 20 members.
Table 1: The major CBD families described prior to 1995
311.4.5 The structure of CBDs
All CBD structures characterized thus far are based on (3-sheet topologies.  Studies on 
the family I CBD from the cellobiohydrolase enzyme found in the organism  T.  reesei 
(CBHI-CBD) have shown that the CBD folds into a small wedge shaped structure.  This 
is  formed  by  a  small  irregular  triple  stranded  p-sheet,  stabilized  by  two  disulphide 
bridges.
One  side of the  CBD  contains  a  row  of three  tyrosines  together,  and  a  few potential 
hydrogen-bonding residues.  The spacing of the tyrosines equals the distance of every 
second glucose moiety in a cellulose chain.  Linder et al.  (1995) have conducted site 
directed mutagenesis experiments that establish the importance of these residues in the 
CBD-cellulose interaction.  CBDs found in  C. fimi and C.  thermocellum  show similar 
structures (Linder and Teeri,  1997).
The main interaction consists of the  stacking of aromatic rings with the  glucose rings 
along a  single  glucan  chain  assisted by hydrogen bonding  interactions  of other CBD 
residues to the neighboring glucan chains (Tormo et al.,  1996).  Tormo et al.  suggest a 
binding  model  implying  that  the  polar  residues  on  three  different  CBDs  form  direct 
hydrogen bonds to cellulose, and these interactions cause a local destabilization in the 
vicinity of the hydrogen bonded cellulose.  For the  structure of all  known CBDs  and 
similar molecules, an internet resource is available (http://afmb.cnrs-mrs.fr/CAZY/).
321.5 Quantifying protein binding
Antibodies  form  specific  complexes  via non-covalent  interactions with their antigens. 
The  large  number  of  van  der  Waals  interactions,  hydrogen  bonds,  electrostatic 
interactions and the possible hydrophobic effects lead to very strong binding strengths 
and high affinities.
The strength of binding of an antibody to its corresponding antigen can be described by 
the  affinity  constant.  This  is  a  thermodynamic  constant  that  represents  the  reaction 
between  antigen  (Ag)  and  antibody  (Ab);  see  equations  below  (Liddell  and  Weeks, 
1995).
Equation 1:  Ag + Ab— ——>AgAb  Equation 2:  AgAb— ——>Ag + Ab
Equation 3:  [AgAb]l[Ag][Ab]
Equation 4: KA  = ka / fa
Where  ka  is  the  association  constant,  k< j  is  the  dissociation  constant,  and  KA   is  the 
affinity  constant.  The  affinity  constant  has  been  determined  by  setting  up  and 
equilibrium  between  antigen  and  antibody  and  determining  the  amount  of free  and 
bound antigen.  Methods of determination, and challenges this presents will be explored 
later.
Scatchard plots of data are necessary to determine the affinity constant determined by 
plotting the ratio of bound/free  antigen against the  concentration  of bound antigen  in 
moles per litre.
The negative slope of the Scatchard plot then gives the affinity constant and the X axis 
(conc.  bound antigen)  intercept  gives the  Binding capacity (Bc)  (after extrapolation  if 
necessary).  The binding capacity represents the effective concentration of binding sites 
in moles per litre.  Both Bc and KA  may change with environmental conditions such as 
pH and ionic strength of buffers.
331.6 Methods used to quantify binding of antibodies to antigens
There are many available methods to quantify antibody-anti gen interaction.  Traditional 
methods  include  radio-immunoassay  (RIA),  equilibrium  dialysis  and  Enzyme  Linked 
Immuno  Sorbent  Assay  (ELISA  has  become  the  gold  standard  when  dealing  with 
antibodies).  More recent advances  in binding  analysis have  led to  a range  of optical 
biosensors, most notably the BIAcore and the IAsys Biosensor. Other even more novel 
techniques  include  Isothermal  Titration  Calorimetry (ITC),  Atomic  Force  Microscopy 
(AFM),  Confocal  Laser  Scanning  Microscopy  and  more  recently  the  Ultrasonic 
Spectrometer.  The more novel  the assay, the more delicate,  although they potentially 
offer ways of understanding interaction previously considered  impossible.  They may 
also require a large amount of time in assay development; whereas conventional assays 
may give faster results.
1.6.1  Radio-immunoassay
This  is the original method of antibody-antigen analysis,  and involves using a known 
amount of radioactively labeled antigen.  Antigen specific antibodies are  immobilized 
on a surface.  The radioactively labeled antigen is then allowed to bind to the  surface 
bound antibodies,  and the radioactivity is  measured.  A  known amount  of unlabelled 
antigen  is  then  introduced,  and  the  amount  of radioactivity measured  again.  As  the 
labeled  and  unlabelled  antigen  will  be  in  competition,  the  necessary  parts  can  be 
calculated for a Scatchard plot.
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Fig  4: Radioimmuno assay.  Labelled antigen competes directly with unlabelled.
35RIA  allows  the  analysis  of kinetics  in  real-time  at  low  levels  such  as  those  found 
physiologically, whereas other methods may require  large amounts that are unrealistic 
in nature or application (Banerjee et al.,  2002).  RIA also allows an accurate  study of 
dissociation, whereas some other methods  involve estimating the dissociation constant 
from the association constant.
Use  of  radioactivity  is  becoming  less  popular  with  difficulties  such  as  safety 
considerations and also  disposal  of contaminated  waste.  It  is  however still  used  as  a 
gold standard assay for investigative assay and not everyday assays such as those used 
for diagnostics.
1.6.2  ELISA
ELISA (Enzyme linked immuno sorbent assay) is the gold standard analysis method for 
quantifying antibody reactions.  Over the last forty years it has become an established 
laboratory procedure  in  the  study  of physiological,  pathological  and  pharmacological 
processes (Roitt et al., 1998).
Problems  arise  with kinetics  analysis however as a marker system  is  employed.  The 
most  common  method  is  a  simple  indirect  assay;  the  substrate  is  immobilized  on  a 
surface.  The antibody in question is then allowed to bind to the immobilized substrate. 
A second antibody is then added which is binds to the first antibody.  A third antibody 
conjugated with a marker enzyme is then added and binds to the second antibody.  The 
enzyme substrate is then added and a change in absorbance can be measured.  This is 
directly proportional over a region to the amount of first antibody present (see figure 5). 
The  most  common  method  of performing  ELISA’s  is  in  a  multiwell  plate,  allowing 
hundreds of samples to be analysed simultaneously.
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Fig 5:  Indirect ELISA.  Amount of antibody is measured by a spectra change due to 
reaction caused by substrate breakdown
37Neish et al. (2002) note that this method gives good quantitative information although it 
does not show the structure of the formed complexes or conformational change of the 
receptor.  One of the fundamental problems of RIA and ELISA is the development stage 
that can be time consuming due to the numerous optimization steps required,  and the 
time taken to analyse each step.  In practice ELISA can take a long time to perform also 
as each step can take hours, meaning a standard assay is usually at least four hours long.
1.6.3 Equilibrium Dialysis
This is used to calculate the affinity of an antibody that binds to small antigens such as 
haptens  that  can  dissolve  freely  across  a  dialysis  membrane.  A  known  amount  of 
antibody/fragment (that is too large to pass across a membrane) is placed in a dialysis 
membrane and offered various amounts of antigen.  Molecules that bind to the antibody 
cannot traverse back across the membrane.  By measuring the amount of antibody in the 
bag and outside, the bound and free antigen at equilibrium can be determined.
Given that the amount of antibody is known, the affinity and number of specific binding 
sites for the antibody can be determined via Scatchard analysis.  It was this method that 
was used to demonstrate that IgG molecules have two identical antigen binding sites.
1.6.4 Optical Biosensors
1.6.4.1  BIAcore
Optical biosensors offer the potential to monitor binding reactions in real time.  A major 
advantage  of optical  instruments  is  that  there  is  no  need  to  label  the  reactants  with 
radioactive or spectroscopic compounds.  However one of the reactants must be bound 
to a surface (Schuck,  1997).  Limitations also occur on rapid binding reactions as the 
binding partner in solution must be transported to the sensor surface in order to bind to 
its immobilized partner (Wilson, 2002).
BIAcore  uses  surface plasmon  resonance  (SPR)  technology to  monitor  the  refractive 
index change as molecules absorb on to or dissociate off of a sensor surface during a 
binding reaction.  The analyte is passed over the sensor surface using a micro flow cell 
that has been optimized to reduce mass transport effects (Myska et al.,  1997).  These 
effects  can  be  further  minimized  by  increasing  flow  rate  and  reducing  the  surface
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effects can not be eliminated completely.
SPR  occurs  when  plane  polarised  light  reflected  at  an  interface  between  media  of 
different  refractive  index  and  separated  by  a  thin  metal  film  resonates  at  a  specific 
angle.  This  results  in a dip  in the  intensity of the  light reflected at that angle.  Any 
increase in mass due to binding events on the cell surface causes the angle to change, 
and this change can be monitored in real time (Pearson et al.,  1998).  This process is 
very sensitive to changes in the media used to conduct the experiment, and care must be 
taken to minimise change wherever possible.  BIAcore has been used to  successfully 
monitor  biomolecular  interactions  including  antibody  antigen,  receptor-ligand  and 
DNA-DNA.  Binding studies  for monoclonal  antibodies have been readily performed 
(Malmborg and Borrebaeck, 1995).
The  BIAcore  measures  binding  in  an  arbitrary unit known  as  an  RU,  one  RU being 
approximately equal to one picogram per square mm of bound protein.  The majority of 
published  data  on  optical  biosensors  (approximately  90%)  involves  use  of BIAcore 
(Wilson, 2002).
1.6.4.2  IAsys Biosensor
The IAsys biosensor is a manual biosensor that incorporates Affinity Sensors resonant 
mirror technology in a single well format.  Each cuvette is agitated with a micro stirrer. 
It has been used for quantification of protein A and human IgGj interaction (Lowe et al.,
1999).  As well as the BIAcore it offers analysis in real time, with multiple data points, 
not just a beginning and end result.
The main difference between the IAsys and BIAcore is that of the cell -  the IAsys uses 
a stirred cell, making it ideal for particles, but difficult to analyse dissociation, whereas 
the  BIAcore  is  a  flow  cell,  meaning  that  particles  are  liable  to  clog  it  up  after  a 
maximum  size,  but  ideal  for  measuring  the  dissociation.  Both  machines  use  an 
evanescent field for detection of binding, but slightly different methods of generation, 
the IAsys using a resonant mirror instead of a metal film.
39IAsys measures binding in Arc seconds, which is approximately four of the BIAcores 
RU’s, or four picograms per square mm (Wilson, 2002).  There is some small concern 
over evaporation  from  the  IAsys  stirred  cell  after prolonged  assay use,  although  the 
rapid  stirring  supplies  homogenous  concentrations  of  ligand  rapidly  to  the  sensor 
surface, without mass transfer complications.
The IAsys is no longer commercially available, leaving the BIAcore as the sole market 
instrument.
1.6.5 Atomic Force Microscopy
Atomic force microscopy allows direct measurement of discrete intermolecular forces 
down to the pico-Newton range, in liquid suspension (Harada et al., 2000).  Harada et al 
point out that common methods only estimate binding strength using antibody affinities; 
AFM  actually  gives  a  direct  value.  The  actual  binding  strength  is  calculated  by 
allowing  the  molecules  to  bind,  then  pulling  them  apart  and  measuring  the  forces 
involved.
A  common  problem  with  AFM  is  that  the  lack  of control  of the  probing  molecule 
orientation and the conformational changes that proteins undergo when being adsorbed 
to  surfaces  may  affect  the  number  of binding  sites  and  the  forces  with  which  the 
molecules interact.
Neish et al  (2002) describe using atomic  force microscopy for vizualisation of ligand 
protein interactions.  It is possible to bind ligand to a surface and then add receptor and 
physically pull the complex apart and get force measurements to quantify binding also. 
It is likely that such visualization may be useful in future research of antibody/antigen 
interactions.  As  with  most  other  technologies  for  analysing  antibody/antigen 
interactions, AFM requires the binding of the ligands to surfaces (Ouerghi et al, 2002).
1.6.6 Isothermal Titration calorimetry
An ITC instrument consists of two identical cells composed of a highly efficient thermal 
conducting  material  (Hasteloy or  gold)  surrounded by an  adiabatic jacket.  Sensitive 
thermopile/thermocouple circuits detect temperature differences between the two cells 
and between the cells and the jacket.  Heaters located on both cells and the jacket are
40activated  when necessary to  maintain  identical  temperatures  between  all  components 
(Pierce et al., 1999).
The direct observable measured in an  ITC  experiment is the time-dependent input of 
power required to maintain equal temperatures in the sample and reference cell.  During 
the injection of the titrant into the sample cell, heat is taken up or evolved depending on 
whether  the  macromolecular  association  reaction  is  endothermic  or  exothermic,  this 
heat is proportional to the fraction of bound ligand.  Thus, it is of extreme importance to 
determine  accurately  the  initial  concentrations  of both  the  macromolecule  and  the 
ligand.
One  of the  difficulties  with this  instrument  is  that extreme  care  must be taken  in all 
aspects of an ITC experiment, from sample preparation to data analysis, as it is highly 
sensitive.  The  concentrations  of macromolecule  and  ligand  are  critical,  especially 
when one or both partners of a complex are difficult to obtain in large quantities or are 
of minimal solubility.  Both titrant and macromolecule should be exhaustively dialyzed 
in buffer (preferably in the same flask) to minimize artifacts arising from mismatched 
buffer components (Pierce et al., 2002).
Although a key advantage of this instrument is its high sensitivity, it is a also a double- 
edged sword -  it is often the case that binding being measured are other ancillary effects 
and not true binding.
1.6.7  Antibody kinetics analysis: conclusion
Many  methods  exist  for  antibody  kinetics  analysis.  The  majority  rely  on  the 
equilibrium  constant  or  an  estimated  or  relative  equilibrium  constant.  Fuchs  and 
Gessner  (2001)  report  that  more  than  ten  thousand  articles  are  published  every year 
dealing with this constant.
The  majority  of methods  are  based  on  linearization  procedures  of the  Law  of Mass 
Action, most commonly the  Scatchard analysis.  Methods  such as those using optical 
sensor  technologies  have  computer-supported  facilities  that  allow  the  calculation  of 
equilibrium  constants.  However  these  techniques  hold  complicated  mathematical 
procedures that can make it difficult to interpret the precision of the results (Fuchs and
41Gessner, 2001).  All methods are a compromise between ideal conditions, and require 
an understanding of the limitations of the instrument used.
The  necessity  to  label  the  proteins  in  some  methods  or bind  them  to  a  surface  is  a 
disadvantage as they may not truly represent real situations, however, these methods are 
more  established.  More  novel  methods may produce data that is hard to  understand, 
and need comparison to these established methods to be truly useful.  The best approach 
where possible is to use a combination of available methods.
1.7  Production of antibodies and antibody fragments
1.7.1  Genetic  manipulation  in  the  production  of  antibodies  and  antibody 
fragments: Antibody libraries
Approximately  30%  of  antibodies  in  clinical  trials  in  2002  were  estimated  to  be 
provided by phage display libraries (Kretzschmar and Ruden,  2002).  It is a powerful 
technology  for  selection  of  specific  antibodies  from  a  huge  library  of  possible 
candidates.  An alternative technology involves displaying the antibody on the surface 
of a yeast cell, this is known as yeast display.
Phage display libraries are constructed by cloning large repertories of genes encoding 
the  antibody or fragment  of choice  into  engineered phage  vectors  such  that they are 
displayed on the viral  capsid protein coat or the yeast cell.  A number of enrichment 
steps  are  used,  to  leave  colonies  of  organism  that  produce  specific  monoclonal 
antibodies against the antigen of choice (Kretzschmar and Ruden, 2002).
It is believed that phage display selection is at least as powerful as immune selection. 
Phages  displaying the  antibody of choice  can be  enriched in numerous ways  such as 
binding  to  antigen  coated  plates,  column  matrices,  cells,  or  biotinylated  antigen  in 
solution  (Winter  et  al.,  1994).  The  enriched phages  can  then  be  grown  in  bacterial 
culture and subjected to further rounds of enrichment, increasing the binding strength of 
candidates obtained.  Yeast display is less powerful, but may be used for commercial 
reasons.
421.7.2 Production in prokaryotic systems
Production of any biological component is most easily done by expression in bacterial 
systems  as bacteria can be  easily  fermented.  This  is not always possible;  antibodies 
cannot be produced  whole  in bacterial  expression systems  as they lack the  necessary 
glycosylation equipment to produce them.  Fragments can be produced in bacteria that 
are transformed with the genes from hybridomas or (3-lymphocytes, and are expressed 
most commonly in Escherichia coli (Skerra and Pluckthun,  1989, Verma et al.,  1998). 
The  scFv  fragment  is  the  most  commonly produced  in E.  coli.  Jurado  et  al.  (2002) 
described  an  E.  coli  strain  engineered  to  produce  scFV  in  the  cell  cytoplasm  by 
mutating glutathione oxidoreductase and thioredoxin reductase genes to aid disulphide 
bridge formation.
Expression levels in bacterial expression systems are variable and hard to predict from 
case  to  case.  Some  of this  variation  is  seemingly dependent  on the  intrinsic  folding 
capacity  and  stability  of  the  protein.  When  folding  results  in  the  uncovering  of 
hydrophobic patches, the antibodies form cytotoxic aggregates that kill or damage the 
E.  coli cells.  Even a single point mutation may have an effect on folding and hence 
production (Knappik and Pluckthun, 1995).
E. coli has difficulty in forming the intramolecular disulphide bonds of the molecule, as 
this is carried out  far more  effectively by the  endoplasmic  reticulum (ER)  and Golgi 
apparatus  of  eukaryotic  cells.  These  bonds  are  essential  for  the  correct  three- 
dimensional structure of the protein. The ER and Golgi are also responsible for folding 
and secondary protein modifications.  As prokaryotic cells do not have these organelles 
they are therefore are unable to perform these important functions.
Eukaryotic  cells  also  contain  molecular  chaperones,  such  as  Protein  Disulphide 
Isomerase (PDI) that guide and augment the folding of certain antibodies (Buchner et 
al.,  1992).  Although chaperone proteins are present in prokaryotes such as E. coli, their 
function is limited when guiding eukaryotic proteins.
A further problem with production in E. coli based systems arises down stream.  As the 
antibodies are normally produced intracellularly, the cells must be disrupted to release 
the product.  This causes problems with purification and contamination of biologically
43active  components,  such  as  endotoxins.  These  factors  contribute  to  extremely  high 
production costs in E. coli vectors meaning that their use is only economically viable for 
human  medicine  and  diagnostics,  and  not  for  large  scale  production  for  consumer 
products (Van der Linden, 1999).
1.7.3  Production in higher eukaryotes
1.7.3.1  Production in mammalian cell culture
Currently,  60-70%  of  all  recombinant  protein  pharmaceuticals  are  produced  in 
mammalian  cells  (Wurm,  2004).  Any  IgG  subclass  can be  generated  in mammalian 
cells,  using  the  original  technology  described  by  Kohler  and  Millstein  (1975). 
Productivity continues to increase because of improved recombinant expression vectors 
and enhancement of biomass accumulation (Chadd and Chamow, 2001).  Cell culture 
can now produce yields of 1  -2 g unpurified antibody per litre culture media, although 
this can be decreased on purification.  However companies involved in record levels of 
protein  production  in  cell  culture  are  very  reluctant  in  presenting  break-through 
achievements in this area, or methods to duplicate their success (Wurm, 2004).
As with all cell culture methods, problems can arise over media, which traditionally use 
about  ten  percent  calf  or  foetal  calf  serum.  With  recent  concerns  over  Bovine 
Spongiform  Encephalitis  and  similar  diseases,  raw  materials  obtained  from  animal 
products  are  becoming  increasingly unpopular with  regulatory authorities.  Although 
serum  free  media can be  obtained,  it can often be  substantially more  expensive  than 
bacterial  simple  media.  This  is  because  bacteria  are  capable  of synthesising  many 
nutrients  that  mammalian  cells  cannot,  and  must  therefore  be  present  in  the  culture 
media (Stanbury and Whittaker, 1995).  Further more, cell lines used must be prion free, 
which adds to the production cost.
Wurm  (2004)  states  that  mammalian  cells  cultivated  in  bioreactors  have  become 
superior to microbial  systems  for the production of clinical products in both levels of 
production and numbers of products.  Although the production of superior proteins in 
terms of glycosylation is a distinct advantage, often the cost of producing proteins in a 
cell culture system can be very high.
441.7.3.2  Production in plants
Complete antibodies and fragments have successfully been produced in plants (Franconi 
et al.,  1999 Gibbs,  1997).  These have been produced in certain parts of the plant, such 
as the roots and fruit that may be suitable for mass oral applications.  Although yields in 
plants  are  high  (between  1-5%  of plant  protein  produced)  purification  is  long  and 
difficult (consequently expensive) and the development phase is also time consuming. 
There is also some concern over incorrect glycosylation of proteins.
1.7.4  Production in Lower eukaryotes
Yeasts,  in  particular  Saccharomyces  cerevisiae  have  been  used  for  the  successful 
production  of  antibody  fragments.  S.  cerevisiae  has  many  advantages  over  less 
conventional yeasts in that it has Generally Regarded As Safe (GRAS) status, produces 
high cell densities rapidly in simple media and secretes only few proteins next to the 
wanted antibody.  These organisms can grow in clearly defined media without animal 
derivatives, can secrete large amounts of recombinant protein (greater than lg/1) and are 
easy to scale up, making their use common (Gemgross, 2004).  Yeasts and filamentous 
fungi  have  been  used  extensively  for the  production  of recombinant proteins  for the 
enzyme  industry,  however  they  are  typically  unable  to  provide  suitable  levels  of 
glycosylation for mammalian proteins.
Production of whole antibodies in S. cerevisiae has been reported (Horwitz et al., 1988), 
although at very low levels (micrograms per litre).  A production level of one gram per 
litre  is  needed  for an  economically viable process  (Van der Linden,  2000).  Another 
GRAS organism, the methylotrophic yeast Pichia pastoris has been successfully used to 
produce antibodies (Eldin et al., 1997).
Pichia pastoris is a very effective at secreting produced proteins and growing to high 
cell densities.  Excreted proteases can be shown to be inhibited by fermentation at pH 
3.0 instead of pH 5.5 (Curvers et al., 2001).  Common P. pastoris systems use methanol 
for  growth  and  induction  of  protein  production,  meaning  that  methanol  needs  to 
removed from the product stream.  Some  systems have been developed which do not 
use  methanol  as  a  carbon  source  (Chiruvolu  et  al.,  1997).  Some  pichia  produced
45proteins have recently entered clinical trials, although they have been noted to contain a 
level of O-mannosylation not present on the native protein (Gemgross ,2004).
1.7.5  Isolation and production of llama heavy chain only antibodies and fragments
Immunisation  of  llamas  to  produce  llama  antibodies  is  commonly  done  with  the 
antigens  in  a  water  in  oil  emulsion  (Boersma  et  al.,  1992).  Llama  serum  can  be 
fractionated using protein G  and protein A chromatography,  as described by Hamers- 
Casterman  et  al  (1993).  Fractions  containing  heavy  chain  only  IgG  can  then  be 
identified using SDS-PAGE electrophoresis and separated.
The nucleotide sequence of the long and short heavy chain hinges of Lama glama were 
identified and specific PCR primers produced which were used to amplify heavy chain 
VHH-encoding DNA fragments.  This allowed the production of separate VHH libraries 
that are not contaminated with VH  domains of conventional IgG molecules.
Production of llama heavy chain only antibodies is commonly done in the lower class 
eukaryotes,  such  as  Saccharomyces  cerevisiae.  Production  of  conventional  IgG 
fragments in S.  cerevisiae is not common as the fragments are found to accumulate in 
the  Endoplasmic  Reticulum  and  the  vacuole  (Frenken  et  al.,  2000).  Intact  and 
functional heavy chain  antibodies  derived  from camelids have  also been  successfully 
produced in mouse  B  cells,  showing potential  for the  generation  of transgenic  single 
chain antibody/ antibody fragments (Nguyen, 2003).
461.7.6 Conclusion:  Antibody production
At  the  present  time,  bacterial  expression  systems  are  only  useful  for  generation  of 
antibody  fragments  (Chadd  and  Chamow,  2001).  To  make  a  full-length  antibody, 
mammalian cell culture is the most efficient and cost effective.  Other systems such as 
recombinant  plants  must  be  evaluated  more  thoroughly,  but  offer  a  great  deal  of 
potential.  The  main  residing  problem  in  all  expression  systems  is  the  cost  of 
production.  This cost is acceptable for medical and diagnostic applications where only 
a small quantity is used, but for antibodies to realise their potential in the biotechnology 
industry, large amounts of cheap product are necessary.
The potential to use yeast based productions systems for llama antibody proteins offers 
a  considerable  cost  advantage  over  that  of  conventional  antibodies  produced  in 
mammalian cell culture.
471.8 Protein Purification
1.8.1  Introduction
It is often not possible to satisfactorily perform detailed analysis of a protein of interest 
when  in a crude  form  as  it may reside within a complex mixture of proteins,  nucleic 
acids,  polysaccharides  and  also  the  chemicals  used to  grow  the  producing organism, 
even after the cells have been removed.  Furthermore pure proteins are often essential in 
biotechnology  for  regulatory  and  safety  purposes.  It  is  essential  to  maintain 
functionality  when  purifying  proteins  for  use  in  a  product  by  retaining  secondary, 
tertiary  and  quaternary  structure,  and  hence  this  restricts  the  use  of some  damaging 
techniques.  Although  it  is  often possible to  renature proteins,  the  method  for this  is 
often expensive and time consuming (Lillehoj and Malik, 1989).
It  may  not  however  be  essential  to  obtain  levels  of absolute  purity  such  as  those 
obtained  in  the  pharmaceutical  industry,  for  example,  enzyme  purity  in  washing 
powders is often satisfactory at 70%, while a therapeutic protein may be needed at 99% 
(Parry, 2003).  Many factors will influence the choice of purification technology to be 
used, including the cost of the process, the final desired purity, the amount of desired 
product and the ability to scale-up the process to a larger level.
Down stream processing and purification of proteins often accounts for a large majority 
of their production cost (50-80%) (Roque et al., 2004).  The degree of intial purity has a 
high level of bearing on the purification cost as the more impure the protein, the higher 
the number of steps required to purify it satisfactorily.  This adds a further cost, and 
furthermore each step incorporates a loss of product, which becomes cumulative over a 
number of steps.  Doran (1995) quotes an example where a product is 80% recovered on 
each of five steps.  This leaves an overall product recovery of about 33%.
This therefore leads to a need to get the product in as high an initial level as possible by 
increasing production of the protein by the organism, and also to reduce costs associated 
with production, either by reducing steps, or increasing efficiency of steps.
481.8.2 Production and Purification of llama antibody -  CBD fusion proteins
Production  of the  proteins  of interest  is  done  in  three  organisms:  Aspergillus  niger, 
Pichia pastoris and Saccharomyces cerivisae.  The Pichia and Saccharomyces produced 
proteins are supplied in pre-purified form.  The proteins produced in Aspergillus are in 
crude form.  All proteins are secreted by the production organisms into the supernatant.
A major problem with Aspergillus secreted heterologous proteins is their contact with 
and degradation by extracellular proteases (such as aspergillo pepsin) and this has been 
shown to affect their production dramatically (Gouka, 1997).  Fungal strains deficient in 
proteases  have  been  isolated  or  created  by  molecular  genetic  approaches  and  have 
resulted  in  significantly  improved  protein  production  levels.  Gouka  et  al.  (1997) 
report that protein expression levels have reached 1-2 g/1 of fermentation broth.
1.8.3  Stages in purification
Purification of proteins can be seen to have many goals as follows (Roe, 2001):
•  Release of protein product into supernatant (If produced intracellularly)
•  Removal of bulk material such as cellular matter
•  Removal of water to concentrate the protein
•  Removal of contaminants
•  Stabilisation of protein.
It is usual to use sequential separation techniques that utilise different physicochemical 
properties of the protein involved (Lillehoj and Malik,  1989).  There can be considered 
3  main  stages  in  purification:  Initial  fractionation,  purification  and  polishing.  The 
Initial fractionation is a preparative stage that may involve the first three of the points 
above.  This typically involves techniques such as centrifugation, cell lysis, micro and 
ultrafiltration.
The  first  step  is  often  removal  of  cellular  matter  from  the  mixture,  although  the 
component  carried  on  to  the  next  step  depends  on  the  nature  of  the  protein  -  
extracellular or intracellular (Doran,  1995).  This is dictated by the expression system 
used  and  the  presence  of N-terminal  signal  sequences  that  allow  the  translocation 
through  cellular  membranes.  Each  has  advantages  and  disadvantages  considered  in
49regards to  a whole process  and purification basis by Pierce et al.  (2002).  The  llama 
VHH  fusion protein  is  extracellular -  this  means  that it  is  relatively pure  as  cellular 
constituents can be removed easily, although it is dilute and susceptible to extracellular 
proteases.  This also offers considerable advantages to the fermentation of the protein.
Separation of cells is most commonly achieved by centrifugation or filtration.  These 
methods are then often followed by precipitation and/or a number of chromatography 
steps  (Bonneijea  et  al.,  1986)  which  comprise  the  purification  stage.  Three  to  five 
chromatography  steps  may  be  used  in  sequence  to  remove  different  types  of 
contaminants (Roe, 2001).  The polishing stage then comprises removal of the last few 
contaminants  and  indeed  any  breakdown  products  of  the  protein.  Size  exclusion 
chromatography is often a key step at this stage, although adds a large expense.
It is important to understand the condition in which the protein emerges from each step, 
crucial factors being the stability of the protein in the conditions at the end of the step 
and also  the  need  for  any preparative  work before  the  next  step,  for example  buffer 
exchange (Lillehoj and Malik, 1989).
1.8.4  Scale up of process
Often a small scale purification system is the first stage in the development of a large 
scale commercial process.  When designing any purification process it is therefore wise 
to keep in mind scale-upability (Roe,  2001).  This can often mean that high expense, 
low  yield  processes  that  may  be  suitable  for  producing  pure  proteins  for  detailed 
analysis may be unsuitable for industrial scale purifications.
Purification  goals  will  also  shift  as  the  process  is  developed  -   from  a  low  level  of 
purified product where the key is  identifying protein and ensuring activity is retained 
when the process  is  in the  first  stages to the  final  stage  of purifying protein in large 
levels for large scale product testing.  It is important that any process to be scaled up is 
sufficiently robust to cope with any added process parameters (Noble, 2001).
501.8.5 Properties of proteins affect purification
Proteins  consist  of a  large  number  of amino  acids  each  having  different  properties. 
Only a small proportion of these  amino acids are exhibited on the  surface,  and these 
affect the properties greatly.  Any disruption of the protein structure can display a new 
set of amino acids and a new set of properties.
Amino acids may be hydrophobic, hydrophilic, charged and aromatic.  Charged amino 
acids may be  either basic  or acidic,  giving proteins  an amphoteric  nature:  at low pH 
proteins  are  positively  charged  due  to  the  basic  groups  and  at  high  pH  proteins  are 
negatively charged due to acidic groups.  The pH where the net charge is zero is known 
as the isoelectric point of the protein (Hagel, 2001).
1.8.6  Initial Purification or Clarification
A number of different production mechanisms exist for the production of proteins  as 
discussed  previously  (section  1.7).  The  production  of proteins  from  a  fermentation 
stream  often  leaves  the  protein  at  a  relatively  low  level  in  a  complex  mixture  of 
contaminants.
Proteins may be  located  in one  of three  locations:  extracellularly,  in the  fermentation 
medium, intracellularly in the periplasmic space or intracellularly as an active protein or 
an  inclusion body.  Generally  the  secreted protein  is  the  easiest  to  work  with  as  no 
cellular disruption is needed, although the protein may be very dilute, and susceptible to 
degradation (Pierce et al., 2002).
Pierce et al. (2002) have studied the production and purification of an enzyme produced 
extracellularly in Streptomyces lividans and periplasmically in Escherichia coli.  They 
conclude  that  three  steps  are  required  prior to  chromatography with  the  intracellular 
protein and the extracellular protein one step (cell removal).  Also the use of lyzozyme 
to destroy the cell wall  in the  intracellular organism process contributes to the protein 
loading of the system.  However the presence of the protein in the periplasm allows a 
lower level of processing volume.  The benefits of secretion of product are also reduced 
if complex media is used in the fermentation.
51In  addition,  Pierce  et al.  (2002)  note  that the presence  of cellular debris  complicates 
chromatography of the E.  coli product  stream.  It is  suggested that production in the 
periplasm  may  be  better  for  proteins  that  require  a  more  oxidising  environment  for 
disulphide bond formation and correct folding.
The most frequent first step (after cell disintegration if necessary) is to perform removal 
of suspended matter using either sedimentation or filtration (Reed and Mackay, 2001). 
Sedimentation involves separation according to  density differences between mixtures. 
Gravity sedimentation is rarely used as it is too slow, the process can be speeded up by 
flocculating or coagulating contaminants, and also the application of centrifugal forces. 
Centrifugation  is  often  the  method  of choice  for  yeast  and  fungal  cells  as  they  are 
relatively large and show a subsequently good sedimentation velocity (Thommes et al., 
2001).
Filtration is also commonly used, the goal of this being to retain any solid matter in a 
porous filter barrier.  A large range of filter equipment is available to separate a whole 
host of contaminants according to size.
After the solution containing the protein product has been clarified, it may be necessary 
to concentrate the protein by removing volume  of liquid whilst retaining product.  A 
smaller volume  of solution  is  easier to  use  in  subsequent purification  steps,  such  as 
chromatography (Harris, 2001).
Concentration is achieved by removal of water and other small molecules by addition of 
a matrix polymer with pores too  small  for the protein to penetrate,  removal  of small 
molecules  through  a  semi-permeable  membrane  which  will  not  allow  the  protein  of 
interest to pass  or removal  of water under a  vacuum,  for  example  by freeze  drying. 
Precipitation can also be used to concentrate proteins if the pellet is resuspended in a 
smaller volume of liquid (Harris, 2001).
However dilution of a sample,  as  is commonly achieved when using ultrafiltration or 
performing buffer exchange with a size exclusion column can also be advantageous as 
in addition to removing aggregates that may interfere  with later steps,  they may also 
minimise the effects of proteases (Lillehoj and Malik, 1989).
52Deciding  which  initial  step  to  use  in  a  purification  scheme  is  dependant  on  the 
concentration  and  condition  of the  protein  in  the  starting  solution.  The  higher  the 
concentration, the easier typically the purification -  proteins present in trace  amounts 
are typically very hard to purify.  Protein purification is also easier if a good source is 
available  and  it  is  always  worth  optimising  production  conditions  to  ensure  a  good 
supply of stable, functional protein (Lillehoj and Malik,  1989). The effect of production 
of the  molecule  will  not  only be  present on the  initial  step,  but  all  subsequent  steps 
(Picket and Hardy, 1984).
1.8.7  Chromatography
1.8.7.1  Chromatography Definition
“Chromatography  is  based  upon  the  principle  of differential  partition  of a  specific 
component between two phases, the mobile and the stationary phase.  The former serves 
to move the latter in a manner that optimises the physical and chemical interactions of 
the sample with both phases” (Lillehoj and Malik,  1989).  Proteins are usually purified 
using a system known as liquid chromatography that utilises a liquid mobile phase and a 
solid stationary phase.
531.8.7.2  High Performance Liquid Chromatography
A  system  to  vastly  improve  chromatography  was  developed  in  the  1970’s  (and  is 
ubiquitous  in  protein  chromatography  today)  known  as  High  Performance  Liquid 
Chromatography  (HPLC).  It  has  superior  resolution  and  separation  to  conventional 
liquid chromatography.
It employs a variety of separation matrices that are strengthened against high pressure, 
allowing  fast  flow  rates  and  hence  rapid  separation  (Lillehoj  and  Malik,  1989). 
Traditional  chromatography  methods  could  not  handle  high  pressures,  meaning  only 
low flow rates could be used.  Furthermore, advances in matrix development means that 
column packing is far more efficient, and column void volume reduced.  Matrices used 
are versatile and allow a range of separation techniques to be used.
1.8.7.3  Types of chromatography
There are many types of chromatographic steps available, but they can be separated into 
four basic groups:
1.  Ion Exchange.  This is a very common method commonly used early in the process 
to remove  bulk  contaminants  (Bonneijea  et  al.,  1986).  The protein  is  adsorbed to  a 
matrix  by  ionic  interaction  depending  on  the  conditions  in  the  column.  These 
conditions are determined by the pi of the protein, the protein is then eluted with a high 
salt concentration.  Due to the high reliability on pH and salt levels of this method, the 
protein often must be desalted/ buffer exchange prior to ion exchange.  Furthermore the 
high levels of salt present in the eluent conditions often require a further desalting step. 
Further details can be found in section 1.8.7.4.
2.  Gel filtration.  Molecules are separated by size, which affects the speed at which they 
travel down the column.  Large molecules cannot penetrate the matrix beads, and flow 
rapidly round the outside.  Small molecules can penetrate, and consequently take much 
longer, therefore big molecules are eluted first, and small ones last (Doran, 1995).
This can serve one of two separation roles.  It is often used as a final polishing step to 
separate  a small  number of proteins preparatively purified.  The  disadvantage  of this 
method is that it is relatively expensive, and can only accept a relatively low amount of
54protein.  Gel  filtration can also be used as a buffer exchange/desalting step.  Further 
details can be found in section 1.8.7.5.
3.  Affinity  Chromatography.  This  method  utilises  the  binding  function  of  the 
molecules to be purified.  Anything that has a binding function can be purified this way, 
for  example  enzymes,  hormones,  antibodies,  receptors  and  antigens  (Doran,  1995). 
Although  capable  of  giving  very  high  purities  very  rapidly,  commonly  elution 
conditions are harsh, and the protein needs to be exchanged into a more suitable buffer 
rapidly.  Also affinity matrices are often very expensive.  Further details are available in 
section 1.8.7.6.
4.  Hydrophobic  interaction  chromatography.  This method utilises the  fact that even 
proteins of hydrophilic  nature have  an amount of hydrophobic  areas on their surface. 
Although this can work for a high variety of proteins, it needs very high salt solutions 
and  is  very  temperature  dependent  (Hagel,  2001).  Further  details  can  be  found  in 
section 1.8.7.7.
Ion exchange, Affinity and Hydrophobic interaction chromatography can be considered 
to  be  adsorptive  chromatography  (ie  the  protein  binds  to  the  matrix)  whereas  gel 
filtration  is  non-adsorptive  (separation  occurs  due  to  size  exclusion  in  the 
matrix)(Hagel, 2001).
Hagel suggests five key phases in an adsorptive chromatography process:
1.  Equilibriation of the matrix using a mobile phase that allows adsorption of the 
protein to the matrix.
2.  Application of the sample in the mobile phase.
3.  Wash using the mobile phase that allows the protein to be retained in the matrix, 
but removal of contaminants.
4.  Desorption  of  the  protein  using  a  mobile  phase  selected  to  make  elution 
favourable i.e. by increasing the dissociation constant.
5.  Wash, clean and regenerate the matrix ready for the next purification.
551.8.7.4 Ion Exchange
This  is  a  very  common  preparative,  as  it  has  a  high  throughput  and  is  relatively 
inexpensive  (approximately  5  times  cheaper  than  Protein  A  media) 
(www.amershambiosciences.com,  2006).  Proteins are bound as mentioned previously 
by a charge  interaction,  caused by the molecule  of choice adsorbing to a  solid phase 
containing  the  opposite  charge  (Lillehoj  and  Malik,  1989).  Two  types  of  ion 
exchange processes are available:  cation and anion exchange.  Cation exchangers will 
bind proteins in a solution of pH below their pi and anion exchangers will bind proteins 
in a  solution of pH  above  their pi.  Matrices  can be  further separated into weak and 
strong ion exchangers, a slightly misleading term as this is due to their ionic capacity 
and not the strength of their binding.
(Levison, 2003) states five stages for development of an ion exchange process:
1.  Adjusting the conditions of the crude material such that it encourages binding to 
the solid phase.
2.  Contacting crude material with the solid phase to allow adsorption.
3.  Wash the unbound material from the solid phase.
4.  Change  conditions  of the  solid  phase  such  that  bound  molecules  desorb  and 
elute.
5.  Regenerate solid phase.
The  adsorption  itself can  take  place  either  in  a  batch process,  or  a  chromatography 
column.  Column chromatography is widely used in industry and will be focused on in 
this text.  Adsorption is commonly done at a low salt concentration and elution at a high 
salt concentration,  although  conditions may require a change  in pH.  The  strength of 
binding  between  protein  and  solid  phase  is  dependent  upon  the  solvent  pH,  ionic 
strength and selectivity of the counter ion (Lillehoj and Malik, 1989).
Ion exchange can be used in one of two ways:  to bind and elute the molecule of interest 
(known  as  positive  chromatography),  or  to  bind  and  discard  the  contaminants,  and 
collect  the  molecule  of interest  as  it  washes  straight  through  the  column  (known  as 
negative  chromatography)  (Levison,  2003).  The  selection  of these  two  methods  is 
dependant on the starting material as well as the end requirement.
56For example late on  in a process,  when the molecule of interest is of higher purity, it 
may  be  desirable  to  remove  a  particular  contaminant,  and  negative  chromatography 
achieve that.  However ion exchange is commonly used as a preparative step, and in this 
case  it  is  often  desirable  to  use  positive  chromatography.  Also  positive 
chromatography often  concentrates  the  molecule  of choice,  where  negative  does  not. 
Ion exchange is a very good method for maintaining biological  functionality (Lillehoj 
and Malik, 1989).
1.8.7.5  Affinity Chromatography
A  large  market  for  successful  purification  of proteins  to  a  very  high  purity  in  the 
pharmaceutical  industry  has  led  to  many  systems  being  developed  for  aiding 
purification of a protein product from a crude process stream.  Affinity chromatography 
methods  are  amongst  the  most  powerful  and  versatile  of chromatography  methods 
(Lillehoj and Malik,  1989).
Proteins  perform  their  biological  function  through  one  or  more  binding  events,  for 
example enzyme and substrate, inhibitor and co-factor, and antibody and antigen.  This 
can  often  be  ideal  for  adsorption  chromatography.  Key  stages  in  affinity 
chromatography are  choosing  a  suitable  ligand,  immobilising the  ligand  to  a  matrix, 
binding the protein of choice to the affinity matrix, removal of non-specifically bound 
proteins  and  then  removal  of the  protein  of choice  (Angal  and  Dean,  2001).  The 
method depends on a highly specific  interaction between the protein of interest and a 
molecule  immobilised  on  a  chromatographic  matrix,  and  the  molecules  subsequent 
release under elution conditions (Verheesen et al., 2003).
Affinity chromatography is one of the most powerful techniques for protein purification 
since  it  is  highly  selective,  allowing  purification  in  a  single  step  from  a  complex 
mixture.  Also,  along  with  all  adsorbent  chromatography  systems,  it  offers  the 
opportunity to  concentrate  the  protein  of choice.  Contaminants  present  after affinity 
chromatography are generally few and in low concentration although may comprise the 
matrix constituents (Lillehoj and Malik,  1989).
However  problems  with  affinity  chromatography  may  arise  in  obtaining  a  suitably 
specific, stable matrix  ligand that exhibits reversible binding (Angal  and Dean, 2001).
57Problems  may  be  emcountered  with  the  high  associated  cost  of the  affinity  resin, 
difficulties in scale up and leaching of bound ligand from the column (Trabbic-Carlson 
et al., 2004).
Affinity purification of a protein can be achieved either by utilising the native properties 
of  the  protein  (for  example  purification  of  IgG  molecules  using  Protein  A 
chromatography  (Lindmark  et  al.,  1983))  or by  adding  a  fusion  “tag”  to  the  protein 
using molecular biology techniques.  This involves producing the protein of interest as a 
fusion  protein  with  a  protein  or  peptide  tag  which  binds  reversibly  to  a  ligand 
immobilised on a chromatography matrix (Trabbic-Carlson et al., 2004).  The fusion tag 
is  selected  to  have  properties  that  allow  binding  of the  protein  to  a  corresponding 
affinity matrix  (such as  His tag and Nickel NT  A matrix  (Terpe,  2003)).  This method 
often allows one-step purification of the desired protein to a very high level of purity.
1.8.7.6  Affinity chromatography of antibodies
Antibodies are commonly purified using Protein A or G as a ligand.  Protein A binds 
specifically to the Fc region of immunoglobulins from a number of species and is found 
natively  on  the  cell  wall  of  the  bacterium  Staphylococcus  aureus.  The  matrix  is 
however  expensive  and  requires  low  pHs  to  elute  antibody.  Protein  G  is  found  on 
Streptococcus.  Protein  G  matrices  are  also  expensive  and  require  low  pHs  to  elute 
(Angal and Dean, 2001).
Although  both  proteins  bind  to  antibodies,  they  are  subtly  different  in  binding  to 
antibodies of different species,  for example,  Protein A binds to human, rabbit, mouse 
and guinea pig antibodies, while Protein G binds to all these, and also goat, sheep, cow 
and horse.
Antibodies bind to these  proteins with very high affinity meaning that the  conditions 
necessary to elute proteins are very harsh, and may even lead to denaturation.  Lillehoj 
and Malik (1989) quote that a 30 minute incubation at pH 3.0 or 10.0 can result in up to 
a  65%  reduction  in  antibody  titre,  meaning  that  the  eluent  must  be  neutralised  to  a 
suitable pH as rapidly as possible after elution.  Often the antibody can be irreversibly 
inactivated by the harsh conditions used in protein A and G chromatography (Huse et al. 
2002).
58It  is  also  possible  to  use  immobilised  antigen  to  purify  antibodies,  however  similar 
problems  remain in elution and there exists the chance of leaching of the antigen into 
the product (Huse et al. 2002).
1.8.7.8 Affflnity Chromatography using an engineered fusion tag
Addition of a fusion tag to a protein can provide a good way of purifying them using 
affinity chromatography.  Addition of a short peptide tag for example the hexa-histidine 
tag to a recombinant protein can allow their simple purification using immobilise metal 
affinity chromatography  (IMAC)  (Paramban et  al.,  2004).  Furthermore  addition of a 
6xHis tag has been  reported to enhance activity and stability of recombinant proteins. 
The affinity tag can be removed after purification with a site-specific protease, and has 
been  used  in  the  purification  of many  proteins  of biological  interest  (Mohanty  and 
Wiener, 2004).
Positioning of the tag is  important,  Mohanty and Wiener (2004) have investigated the 
use of an N-terminal 6-histidine, N-terminal  10-histidine, C-terminal 6-histidine and C- 
terminal  10-histidine.  They  have  shown  that  while  solubilisation  of the  protein  is 
largely unaffected, the N-terminal  10 histidine protein binds significantly more strongly 
to  the  chromatographic  matrix.  Length  of the  tag  is  also  shown  to  affect  yield  of 
protein, the 10-histidine tags reducing the yield significantly.
1.8.7.9 Use of Cellulose Binding Domains as fusion tags in affinity chromatography
(Shpigel et al.,  2000) have used Cellulose Binding Domains to create a fusion protein 
based affinity purification system for IgG molecules.  The fusion protein consists of a 
CBD used to immobilise the protein on a cellulose matrix and staphylococcal protein A, 
used to purify the IgG molecules using standard Protein A affinity procedures.
All  other affinity methods  rely on the  use  of an expensive matrix to hold the affinity 
ligand.  Cellulose  has  ideal  physical properties and is very economical,  especially for 
large-scale purification.
59Shpigel et al., (2000) purified their CBD fusion protein using a cellulose column.  They 
bound the protein to the column in PBS pH 7.4 and eluted with high pH (12.5).  The 
high pH was then neutralised with HC1 and the protein lyophilised.  Many proteins have 
been expressed with CBD affinity tags and still retain high specific activity (Levy and 
Shoseyov, 2002).  Extremes of pH used may cause damage to the protein.
1.8.7.10  Gel Filtration
Separation according to  size has been used since the mid  1950s (Porath and Flodinm, 
1959) when it was termed gel  filtration.  More recently it has been generally accepted 
that the term size exclusion chromatography is more suitable.  (Cutler, 2001).  It was the 
first of the matrices to be adapted to HPLC (Lillehoj and Malik, 1989).
The matrix consists of beads of known porosity which are packed into the column.  The 
mobile phase can penetrate into the beads, and also flow around them in what is known 
as the voids volume.  Separation occurs as molecules of differing molecular weights can 
penetrate to different degrees within the matrix.  This means that different sized proteins 
have different volumes to flow through within the column, dictating when the time they 
take to reach the end of the column.
In  an  ideal  situation  large  proteins  elute  first  as  they  gain  little  penetration  into  the 
matrix,  and small  proteins elute  last,  as they penetrate  further into the matrix  (Cutler, 
2001).  However in reality there is usually some interaction between the protein and the 
size exclusion support, and this can change the elution order.  This effect is commonly 
minimised with use of salts or detergents (Lillehoj and Malik, 1989).
The main limitations of size exclusion are that all proteins elute in one column volume 
or  less.  This  offers  low  capacity  relative  to  other  techniques  and  also  means  that 
separation of complex mixtures is difficult, rendering size exclusion most suitable for a 
polishing  step  (Cutler,  2001).  The  polishing  step  is  aimed  at  removing  distinct 
contaminants, in particular low molecular weight contaminants including salts and may 
also be used to change the mobile phase (Rojas et al., 2004).
Proteins  with a molecular weight difference  of less than  10  %  can  commonly not be 
separated satisfactorily.  Resolution can be enhanced by addition of columns in series 
containing the same  size pore  support,  although this obviously increases run time and
60cost (Lillehoj and Malik,  1989).  A good advantage with size exclusion chromatography 
however  is  the  ability  to  choose  a  variety  of mobile  phases,  reducing  the  need  for 
desalting procedures, making it ideal for a final polishing step.
1.8.7.11 Hydrophobic Interaction Chromatography
Hydrophobic  Interaction  Chromatography  (HIC)  relies  on  hydrophobic  interaction 
between  protein  sample  and the  adsorbent  (Lillehoj  and  Malik,  1989).  Although the 
exact mechanism of HIC  is unclear, the interaction is increased by high ionic strength 
and  high  temperature.  Increasing  the  ionic  strength  does  increase  the  chance  of 
precipitation and increasing the temperature may affect the stability of the protein.  It is 
thought best to use the most hydrophobic ligand that is compatible with the protein to 
allow use of low ionic strengths in the process (Hagel, 2001).
1.8.8 Other methods
Trabbic-Carlson et al. (2004) have reported a novel method of purifying proteins using 
a  fusion tag that  selectively aggregates  the product of choice  depending  on a narrow 
temperature  range.  By  sequential  steps  of  aggregation  centrifugation  and 
resolubilisation,  a  method  described  as  inverse  transition  cycling  allowed  the 
purification  of  proteins  chloramphenicol  acetyltransferase,  blue  fluorescent  protein, 
thioredoxin and calmodulin to high purity and maintained functionality.
1.8.9 Determination of Yield and Purity
Several  methods  are  available  for  the  determination  of yield  and  purity  in  a protein 
purification  process,  however  the  selection  of these  methods  will  be  dependent  on  a 
number of factors, such as the amount of protein available, the nature of the protein to 
be analysed, assay accuracy and sensitivity and the presence of any contaminants which 
may affect assay results (Baines, 2001).
A  number  of  techniques  are  available  to  determine  total  protein  concentration  in 
samples  including  UV  absorbance  at  280nm,  Lowry assay,  Bradford  assay and  BCA 
assay.  Each of these methods is subject to inherent limitations.  Often a standard curve
61is determined using a level of a highly pure protein, commonly Bovine Serum Albumin. 
(Baines, 2001).
Determination of purity is the more difficult procedure.  When a protein has an inherent 
determinable  activity,  such  as  in  the  case  of enzymes,  the  change  in  either an  added 
component, or the protein in question can be determined.  Many substrates and reaction 
products have an absorbance  measurable using a standard spectrophotometer (Baines, 
2001).  Proteins  that  have  no  recognised  biological  activity,  for  example  structural 
proteins require an alternative method for analysing purity (Lillehoj and Malik, 1989).
Assaying  other  proteins  is  often  done  using  Enzyme  Linked  Immunosorbent  Assays 
(ELIS As) as described in section  1.6.2.  This is particularly common in the case of an 
antibody product.  However this requires the presence of antibodies to the proteins to be 
assayed and the ability to immobilise the antigen in a standard level on a surface to be 
analysed  (Baines,  2001).  This  can  often  cause  a  situation  where  no  antiserum  to  a 
protein  is  available  until  the  protein  is  pure,  and  recognised  purification  can  not  be 
performed until a suitable antiserum is developed (Lillehoj and Malik, 1989).
Another method for determining purity of protein in question is to use Sodium Dodecyl 
sulfate-polyacrylamide  gel  electrophoresis  (SDS-PAGE).  This  technique,  combined 
with  Western  blot  procedures,  can  determine  the  molecular weight  of the  protein  in 
question,  the  presence  of  contaminating  proteins  and  using  gel  densitrometry 
technology,  the  approximate  purity.  Further  more,  SDS-PAGE  and  Western  blot 
technology  is  readily  available  in  commercial  formats  (Goetz  et  al.,  2004).  Two- 
dimensional  electrophoresis  is  also  a  powerful  method  for  determining  purity;  this 
involves  separating  proteins  according  to  net  charge  on  an  IEF  gel  strip,  and  then 
running  the  strip  on  a  conventional  SDS  gel.  This  has  the  ability  to  separate  and 
identify over 100 proteins on a single gel (Lillehoj and Malik, 1989).
Proteins are commonly visualised using one of two stains:  Coomassie Blue, which can 
detect  25  ng protein  (in  most  cases)  and  gives  a  good  quantifiable  result,  and  silver 
staining  which  is  a  more  sensitive  method  (0.25ng)  but  less  suitable  for determining 
protein concentration.  Both stains are also readily commercially available in differing 
formats (www.piercenet.com and www.invitrogen.com).
621.9 Intellectual property and antibodies
The  Intellectual  Property  (IP)  situation  surrounding  the  production  of heterologous 
proteins  is complex  and must be  considered and  issues dealt with before  any product 
development can occur.  A number of patents exist for key areas of antibody and protein 
production  and  a  suitable  approach  must  be  taken  to  licensing  or  circumventing 
appropriate technology.
A  number  of  key  technologies  must  be  used  in  the  production  of  antibody  based 
proteins  including  but  not  limited  to:  molecular  libraries,  vector,  lead/expression 
sequences,  phage  or  yeast  display,  library  panning  techniques,  expression  system, 
protein tag sequences, and purification techniques.  All of these are covered by different 
patents, for example a patent search (Micro Pat) yields  143 patents with phage display 
in  the  title.  Issues  such  as  the  expression  system  may be  solved  by  use  of a  novel 
organism on which no patents exist; these however require a great deal of development 
and such systems often do not have GRAS status (Punt et al., 2002).
1.10 Aims of the research
The  goal  of this  research project was to  investigate the  function of a range  of Llama 
antibodies and Llama antibody-Cellulose Binding Domain (CBD) fusions produced to a 
range of surfaces and particles with potential commercial relevence.
The  potential  application  of  this  technology  is  the  targeted  delivery  of  capsules 
containing  a  benefit  agent  payload  to  cellulosic  materials  (for  example  paper  and 
cotton).  Possible generic uses for CBDs are explored in Levy and Shoseyov (2002) and 
allow for uses in agrochemical, bioprocessing, home and personal care and diagnostic 
industries.  One  of the  applications  in  the  home  and  personal  care  industry  is  as  a 
delivery mechanism for perfume/fragrance to laundry in the laundry wash cycle.
Currently, Unilever spends approximately $160m per year on perfume for fabrics in its 
detergents, 95% of which gets rinsed straight off the clothes and wasted.  The other 5% 
of the  perfume  commonly  lasts  a  maximum  of twenty-four  hours  (Unilever  internal 
data).  The key problem is that washing and deposition are conflicting processes.  There 
is a need for better delivery, deposition and retained benefit of fragrances in the wash to 
give more cost-efficiency and a greater consumer benefit.
63The  objective  is  to  use  a  slow  release  capsule  to  retain  perfume  benefit  for  longer 
periods  of  time,  addressing  the  retained  benefit  issue.  However  as  perfume 
encapsulation is obviously a more expensive technology (approximately 3  times) than 
simple addition of perfume the added benefit brings an increased cost.  The idea is to 
use an antibody fusion protein targeting system to improve deposition of capsules and 
therefore save costs by reducing the amount of capsules needed.
The aims of this project are:
1. Research the characteristics of the fusion proteins binding function in a model system 
to a range of surfaces in order to determine proof of principle.  Although many systems 
exist  for  monitoring  antibody-anti gen  interactions,  this  often  involves  coating  a 
substrate  or the  antibody  itself onto  a  surface  in order to measure the  reaction.  This 
limitation makes the measuring of the CBD-cellulose interaction very difficult, due to 
the inert nature of cellulose.  Derivation of a suitable assay will be necessary, both for 
fusion protein to particle, and for particle to cellulosic surface.
2. Apply the findings to a more commercially relevant system.  Difficulties encountered 
with  binding  of protein  to  cellulose  will  make  the  measurement  of binding  to  some 
surfaces very difficult also: the inertness which is a benefit in the particle application is 
a hindrance in the quantification of binding.  It is possible new assays will have to be 
developed.
3. Develop a purification system for specific proteins. A further challenge will involve 
the purification of the commercial proteins; these are deliberately designed without any 
affinity fusion tags and as such will not be amenable to simple affinity purifications and 
it is unlikely they will bind protein A and G.
4.  Characterise binding to relevant  surfaces  and other characteristics of pure proteins. 
Assessment  of binding  functionality  and  stability  will  be  essential  to  determine  any 
potential commercial relevance of chosen candidate proteins.
642.0 Materials and Methods
2.1 Molecules used
The  following  molecules  were  used  in  this  study  and  kindly  provided  by  Unilever 
Research and Development, Bedfordshire:
Reactive Red 6 dye (ICI chemicals, product discontinued).
Llama VHH Anti-RR6 -  Lyophilised Cellulose Binding Domain fusion proteins A, B, 
C,  D.  For details on production and structure see  Lewis et al.  (2006) and Davies and 
Parry (1997).
Llama VHH Anti-Melamine -  Cellulose Binding Domain fusion proteins MelA -  MelK. 
Melamine particles containing fluorescent dye (Nile red).
All  other chemicals  were  obtained  from  Sigma (Dorset)  unless  otherwise  stated.  All 
solutions were made  in milliQ ultrapure water (Millipore,  Hertfordshire)  water unless 
otherwise stated.
2.2 Manufacture of RR6-BSA conjugate and determination of amount of RR6 
bound to BSA
The RR6 molecule was conjugated with BSA for ease of study and binding to surfaces 
according to the following protocol:
A IgL'1  RR6 solution (lOmL) was made in borate buffer (0.1M Na2B4O7.10H2O, 0.05M 
NaCl, pH 8.5).  A O.lgL'1   BSA solution (10 mL) was also made in borate buffer.  The 
two solutions were combined and placed on a rotary mixer overnight at 25°C.
The solution was then washed repeatedly with phosphate buffered saline (PBS,  85gL_ 1  
NaCl,  9.8IgL'1   Na2HP04.12H20,  4.53gL''  NaH2P04.12H20,  pH  7.15)  using  an 
Amicon  stirred  cell  concentrator  system  (Millipore,  Hertfordshire).  Excess  dye  was 
removed until the colour ran clear.  The conjugate was then blocked in Tris-HCl buffer
65(50mMol, pH 8.0) for  16 hours, and then washed further with PBS.  It was then stored 
at 4°C.
The RR6-BSA conjugate was analysed using MALDI-TOF mass spectrometry (analysis 
performed by M-Scan limited, Wokingham, UK).  MALDI-TOF mass spectrometry was 
performed  using  a  Voyager  STR  Biospectrometry  Research  Station  Laser-Desorption 
Mass Spectrometer coupled with Delayed Extraction.  An aliquot of BSA and of BS A- 
RR6 was dissolved in 0.1% aqueous TFA to produce approximately lmgmL'1  solutions. 
Aliquots (1 |iL) were analysed using a matrix of Sinapinic acid.  BSA (Fluka) was used 
as an external calibrant.
2.3  Standard ELISA protocol
Greiner 96 well Microlon 600 High Binding plates (E and K scientific, UK) were coated 
overnight at 4°C with 200 juL 0.25mg/ml RR6-BSA conjugate (manufactured as above) 
in carbonate binding buffer (0.018  Mol Na2CC> 3,  0.032  Mol NaHCC>3, pH  9.8  (made 
fresh on day of use).  They were then washed once with PBS-t buffer (as above, with 
0.15% tween-20).
Each plate was then blocked using a blocking buffer solution comprising  1%  BSA in 
PBS-tm (PBS containing 0.15% v/v Tween-20 and 0.1% non-azide antibacterial agent) 
for 30 minutes at room temperature on a plate shaker.  The plate was then washed three 
times  in PBS-t and gently shaken dry.  A sample  of 200pL was added to the relevant 
wells and incubated for one hour at room temperature on a plate shaker.  The plate was 
then washed three times in PBS-t buffer using a plate washer.
A polyclonal rabbit anti-llama antibody serum (kindly provided by Unilever Research 
and Development, Vlaardingen) was then added to each cell (200 p,L of 1/2000 dilution 
in PBS-t) and incubated for one hour at room temperature on a plate shaker.  The plate 
was then washed three times in PBS-t buffer using a plate washer and shaken dry.  Goat 
anti-rabbit alkaline phosphatase conjugate in PBS-t (200pL of lpgml'1   solution, Pierce, 
Illinois) was added to each well and incubated for an hour at room temperature.
The plate was then washed three times in PBS-t and shaken dry. Alkaline phosphatase 
Substrate  p-Nitrophenyl  phosphate  (pNPP)  was  diluted  in  substrate  buffer  at  a  final
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H2O)  at was  added  to  each well  in  200  pL  aliquots  and incubated  for  15  minutes  at 
room  temperature.  The  absorbance  was  then  read  at  410nm  using  a  Thermo  labs 
MRXTC revelation multi-well spectrophotometer (Thermo labs, Basingstoke, UK).
2.3.1 BSA-RR6 ELISA
A stock solution of llama anti-RR6 molecules A, B, C and D was made.  Each molecule 
was prepared in a  1   mgmL'1   solution in PBS-t and agitated thoroughly until dissolved. 
Stock solutions were stored at 4°C for a maximum of 5 days until use. Each sample was 
serially diluted in PBS-t to the desired concentration directly before use.  Each sample 
was then used in the ELISA protocol described above.
2.3.2 Competition ELISA
For each plate a serial dilution of antibody solutions A-D was prepared as above.  This 
was used to prepare a standard dilution curve.  A set of samples were also prepared by 
using  a  standard  working  stock  solution  of sample  (lmgmL'1 )  and  adding  a  serially 
diluted amount of BSA-RR6 conjugate (as described above).  This was then incubated 
at room temperature for 30 minutes before being used in the ELISA protocol above.
2.4  BIAcore
RR6-BSA conjugate was immobilized on a CM5 Biacore chip (Carboxymethyl Dextran 
surface,  BIAcore ltd.,  Uppsala,  Sweden) using a BIAcore 2000 and standard BIAcore 
EDC/NHS binding procedures (approximately 2000 Biacore Response units).  One flow 
cell was kept as a blank control, and subjected to the immobilization procedure in the 
absence of the protein conjugate.
TBS-t was used as a running buffer and wash solution (12.1  gL"1  Trizma base, 8.7 gL’1  
NaCl  and  0.15%  Tween-20  in  milliQ,  pH  7.4),  and  the  chip  was  regenerated  with 
50mMol HC1  after each use.  All  solutions were kept as similar as possible for each 
experiment, to reduce buffer effect errors.
Serial dilutions of sample in TBS-t were added to each flow cell for ninety seconds and 
then  washed  off with  TBS-t  using  the  KINJECT  command  of the  BIAcore  and  the
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from  the  BSA-RR6  chip  using  50mMol  HC1.  The  chip  was  then  washed  and  re- 
equilibriated with TBS-t before addition of a new sample.
A COINJECT command was used to improve dissociation constants by injecting buffer 
containing  blocked  RR6  (blocked  in  lOmMol  Diethylacetate  on  a  roller  mixer 
overnight) and exchanged to a TBS-t buffer using a pdlO buffer exchange column (GE 
Healthcare, Buckinghamshire) at the dissociation phase.
Initial experiments to determine affinity in running buffer were performed.  The affinity 
of the fusions in the presence of chemical components used at concentrations used in a 
popular  commercial  detergent  brand  (Alkaline  silicate,  Sodium  Carbonate,  Sodium 
Sulphate and  Sodium  tri-poly-phosphate  (STPP))  was then determined.  This  level  of 
detergent  component  was  also  included  in  the  running buffer  for  each  experiment to 
minimise addition effects.
The analysed molecules were diluted to between 40 and 200 nMol concentrations in the 
running buffer and detergent component and passed through the cell at 30 jLiLmin'1   for 
60 seconds before being washed in 0.76 mgL'1  blocked RR6 in running buffer.
2.5  Particle binding experiments
Cotton  swatches were prepared by using a pressure-operated hole-punching device to 
give  uniform  circles  of cotton  (5mm  diameter).  Plain  cotton  sheet  was  used  for the 
swatches.  Cotton  strands  were  prepared  by  pulling  a  strand  from  sections  of terri- 
towelling and cutting them to a two centimetre length.
Co-acervate  particles  were  prepared  according  to  internal  Unilever  protocols  and  a 
fluorescent dye (either Nile blue or red) was added (See appendix  1).  Solutions of gum 
arabic and gelatin were made (3% w/v, Sigma) and heated to approximately 50°C on a 
stirrer hotplate  for 4  hours.  An oil  suspension of Nile  Blue was made  (5 0 jl i1   in 3mls 
sunflower oil).  A  mixture  was  then made  of 50  ml  of heated gum  arabic  and  50  ml 
heated gelatin and the oil suspension added.
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10%  glucono-D-lactone.  The  particles  created  were  then  washed  in  PBS  before 
hardening  with  1%  v/v  glutaraldehyde  for  3  hours  on  a  rolling  mixer  in  a  fume 
cupboard.  The particles were then washed in PBS and incubated overnight with high 
pH borate buffer containing 0.1% v/v RR6 (lOOmMol borate, 50mMol NaCl).
The particles were then washed in Tris-HCl  (50mMol) twice for 30 mins on a rolling 
incubator,  spun down  at  5000 rpm and the  supernatant discarded.  The particles were 
then  washed  further in  PBS  until  the  supernatant  was  clear.  The  particles  were  then 
sieved to remove any greater than 50pm in diameter.
2.6 Determination of binding method
Sixteen  hole-punched  swatches  of woven  cotton  were  prepared  by  washing  twice  in 
PBS for 10 minutes in lOOmls PBS.  Experimentation was performed in 8ml glass vials.
The control vial  (Vial  1) contained 50pl of particles and 4 swatches in  1   ml  PBS  and 
was  incubated  for  30  minutes  on  a  rotating  incubator.  In  Vial  2  200ug  VHH-CBD 
fusion and  50pl  particles  in  1   ml  PBS  were pre-incubated for 30 minutes  and then 4 
swatches added and the mixture incubated for 30 minutes.  In vial 3 200ug VHH-CBD 
fusion and the swatches in 0.95ml PBS were pre-incubated for 30 minutes and then 50pl 
particles incubated for 30 minutes on a rotating incubator.  In vial 4, 200pg VHH-CBD 
fusion, 50pl particles and 4 swatches were incubated in  1ml PBS  for 30 minutes on a 
rocking incubator.
Each batch of differently treated swatches was then washed in 5mls PBS in a new 8ml 
glass  vial  for  15  minutes.  The  swatches  were  then  removed  and  mounted  on  a 
microscope  slide.  Particles  visible  on  each  swatch  were  then  counted  under  xlOO 
magnification.
2.7 Comparison of bifunctionality of fusion proteins
Using  the  method  chosen  as  the  most  ideal  in  section  2.6,  the  four  different  fusion 
proteins were incubated with cotton swatches as a direct comparison between fusions.
692.8 Initial Characterisation of the melamine system
As mentioned in section 2.1  the following molecules and particles were kindly provided 
by Unilever:
Fusion  protein  MelA:  Manufactured  in  house  at  small  scale  using  Pichia  pastoris 
expression  system.  This  protein  is  a  research  protein  and  contains  a  hexa-histidine 
fusion  tag.  It  is  purified  in  house  using  metal  affinity  chromatography.  Due  to 
licensing problems  with  the  purification  and  expression  system,  and  also  inability to 
scale up at Unilever, this molecule is a purely experimental one, used to test the efficacy 
of the system.  After purification, the molecule is freeze dried into vials and stored at 
room temperature.
Fusion  protein  MelB:  This  is  the  MelA  molecule  manufactured  and  purified  by
Unilever in house in Saccharomyces cerevisiae.  Differences in the production system 
may lead to differences in structure and functionality.  This protein has also been freeze 
dried into vials and stored at room temperature.
Fusion  proteins  MelC  -  MelK:  were  manufactured  by  a  different  commercial 
manufacturer in Aspergillus niger.  These proteins are secreted and hence provided in 
frozen (-20°C) crude clarified supernatant format.  They were stored at this temperature 
prior to use.
Cellulose  surfaces  studied  were  Crystalline  cellulose  (Sigmacell,  Sigma),  cotton 
(Woven  polycotton,  woven  cotton,  terry  towel,  kindly  provided  by  Unilever), 
microscope tissue (Fisher Scientific, Leicestershire) and tissue (Kimberly Clark, Kent).
2.9 Determination of protein concentration
Concentration of the proteins was predetermined and kindly provided by Unilever using 
band  densitrometry  on  SDS-PAGE  gel  and  total  protein  assay  (BCA)  (Sapan  et  al., 
1999).
2.10 Comparison of proteins by SDS gel and Western blot
All  proteins  were  diluted  to  approximately  0.5  mgmL'1   fusion  protein.  Aliquots  of 
60pL were placed into 0.5mL volume eppendorfs and 20pL loading buffer was added
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lOOmMol Tris.Cl).  The samples were denatured by boiling for five minutes.  Samples 
were then pulsed at 5000 rpm in a lab centrifuge to force the sample to the bottom of the 
eppendorf.  The samples were then loaded onto two ready-gels (12.5 % gel, Ready gel, 
Bio-rad, Hertfordshire, UK): 40 pL of sample on one gel, and 10|iL for the other gel.
Both gels were run until the loading buffer band was about to run off the base of the gel 
at 70mV using the mini-protean II gel kit (Bio-rad).  Rainbow markers (GE Healthcare, 
Buckinghamshire, UK) were used in the first lane.  The gel with the greater amount of 
sample was removed from the cassette and washed in milliQ water for ten minutes on a 
rocking incubator, and then incubated with Gelcode Blue (Pierce,  Illinois, USA) for 2 
hours  on  a  rocking  incubator.  The  gel  was  then  destained  overnight  in  milliQ  on  a 
rocking incubator, and mounted in acetate to dry.
The gel with the lesser amount of sample was removed from the cassette and placed in a 
Protean II Western cassette with Nitrocellulose paper according to supplied protocols, 
and  run  overnight  at  30mV.  The  Nitrocellulose  paper  was  then  extracted  from  the 
cassette  and  blocked  for  1   hour  in  100  mis  PBST  containing  1%  w/v  Marvel  milk 
powder on a rocking incubator at 25°C.  The nitrocellulose paper was then washed in 
100 mLs PBSt for 3  x  5  minutes, and then incubated with 0.05% v/v rabbit anti-llama 
serum  in  PBSt  containing  1%  Marvel  for  1   hour on a rocking  incubator at  25°C.  A 
further wash  step  (as above)  was performed and the nitrocellulose paper incubated in 
0.1% v/v goat-anti rabbit alkaline phosphatase conjugate in PBSt containing 1% Marvel 
milk powder.
A further wash step  (as above) was then performed and the substrate added in 20 mis 
milliQ  water  (5-Bromo-4-Chloro-3-Indolyl  phosphate/nitroblue  tetrazolium 
(BCIP/NBT)  tablets,  BCIP  0.15mg/mL,  NBT  0.3mg/mL  in  100  mMol  tris  buffer pH 
9.5)  and the colour allowed to develop (approximately 10 minutes).  The nitrocellulose 
was then washed repeatedly in milliQ to stop the reaction, and allowed to dry on tissue 
paper.
712.11 Determination of amount of fusion bound to particles
Fusion protein MelA was identified on gels using derived western blot information.  A 
20% w/v suspension of melamine particles in PBS was made.  A 500|ig/mL solution of 
MelA  fusion  in  PBS  was  made.  A  lOx  working  stock  solution  of a  two  popular 
commercial  laundry detergent bases  (detergents without perfume  and enzymes)  OMO 
France and Saturn Silver was made in PBS.
A total reaction mixture of 280|l l 1  in incubation buffer was used, containing  120|l l L 20% 
particles and 5pg - 55pg fusion.  Controls contained no particles. Each reaction mixture 
was placed in a 2 ml eppendorf.  The reaction mixture was incubated for 1   hour at 25°C 
temperature on a rotary mixer.  After incubation, the reaction mixture was centrifuged at 
13000 rpm for 5 minutes in a bench-top centrifuge.
Supernatant (30 |iL) was then extracted out of each reaction mixture and placed in a 0.5 
ml eppendorf.  lOpL of loading buffer (as in 2.10) was added.  Each 0.5mL eppendorf 
was then placed in a boiling water bath for 5 mins to denature the protein.
After  denaturation,  30  jiL  of each  sample  was  loaded  onto  a  ten-lane  ready  gel  (as 
above).  The gels were then washed and destained as above.  After drying the gels were 
analysed using gel densitrometry equipment (Bio-rad Gel doc  1000) and corresponding 
image analysis software.
Further  analysis  was  performed  on  the  binding  of the  fusion  to  gelatin  particles  to 
investigate possible cross-functionality.  A similar method to the one described above 
was used with the 20% w/v melamine particle solution being replaced with 20 % w/v 
gelatin  particles.  Analysis  of  the  fusion  binding  to  melamine  particles  was  also 
performed  in  the  presence  of two  laundry  detergents  bases  (Omo  France  and  Saturn 
Silver)  at  a  level  of  6.8  gL'1   in  27°F  water  (controlled  hardness  water  containing 
2.16mMol Ca and Mol 0.054 mMol Mg)  (level typical of average tap water).
722.12 Binding of protein to cotton in the presence of detergents
Cotton threads were extracted from a piece of Terry Towelling and cut into lengths of 
5mm.  One thread was placed into each well in a 96-well 0.45pm filter plate (MAHV 
0.45pm,  Millipore).  A  2x  stock  of detergent  bases  (no  enzymes  or  perfume)  of 7 
commercially available detergent powders were made using the levels recommended for 
use.  PBST and 27°F water were included as a control.
Aliquots  of lOOpL of each  detergent base  or control  were  added  into triplicate wells. 
Aliquots of 100pL 27°F water or PBST containing 20pg fusion were then added to the 
relevant wells,  and  aliquots  of 27°F  water or PBST  added  to  the  control  wells.  The 
filter plate was incubated on a plate shaker for 1  hour at 25°C.
After incubation the plate was washed 20 times with 200 pL PBST buffer, (the buffer 
being extracted by a vacuum  from  underneath the plate after each wash using a plate 
vacuum manifold (Millipore)) and 200pL of 1/1000 v/v diluted Rabbit anti-llama IgG 
added  (as  in  2.3).  The  plate  was  then  incubated  for  an  hour  at  25°C  on  an  orbital 
shaker.
A  further  20  washes  were  performed  as  described  above,  and  200pl  of  1/1000  v/v 
diluted  goat  anti-rabbit  alkaline  phosphate  conjugate  added.  The  plate  was  then 
incubated for 1   hour at 25°C.  The plate was then washed 10 times as described above. 
Each thread was then removed and placed in the corresponding well in a new filter plate 
(as  above).  The  new  filter  plate  was  then  washed  ten  times  and  200pL  of pNPP 
substrate added in di-ethanolamine buffer (as in 2.3).  The plate was allowed to develop 
for  approximately  20  minutes,  and  the  newly  coloured  buffer  sucked  through  into  a 
convention 96 well plate.  The absorbance was then read at 405 nm.
2.13  Visual demonstration of binding using fluorescently labeled melA.
Fusion  melA  was  labelled  fluorescently  using  a  fluorescent  protein  conjugation  kit 
(Alexafluor  labelling  kit,  Invitrogen,  Paisley)  and  supplied  protocols.  The  newly 
fluorescent protein was then stored in PBS at 4°C in the dark.  A microscopy flow cell 
was created in house at Unilever that allowed a standard microscope slide to have liquid
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the flow cell however, maximum obtainable resolution was xlOO.
Fabric microscope slides were prepared for the flow cell by attaching a thread of fabric 
(Cotton, Nylon or Polyester) to the slide and fixing the ends to the back of the slide with 
adhesive tape.  Melamine  slides were prepared by partially dissolving the melamine 
particles  in  pure  ethanol  (99.5%),  placing  the  mixture  on  the  slide  and  allowing  the 
ethanol to evaporate at 37°C in an incubator.
A  fusion  solution  was  made  (50mgr')  in  a  6.8gf'  solution  of Shakespeare  Rational 
base.  This mixture  was  flowed  over each  slide  at  20mls per minute.  A  competition 
study  was  also  performed  on  the  melamine  cell,  the  cell  being  washed  with  a  non- 
fluorescent fusion,  and then washed with a fluorescent fusion.  Pictures were taken at 
specific  time  intervals  of  1   minute  to  show  effect  of fluorescent  fusion  with  time. 
Resolution  and  measurement  variables  were  kept  identical  in  a bid  to  allow  suitable 
comparison.
2.14  Particle incubation experiments
A screening experiment was performed with available fusion proteins to determine the 
best candidates for further study.  Lens cleaning tissue was hole punched into swatches 
using  (using  the  pressure  operated  hole  punching  device).  All  incubations  were 
performed in  15ml tubes.  Into 2.6 mis PBS 25 |ig of fusion protein and  1  Ojul  10% w/v 
capsules were added and mixed for 30 minutes on a rota-mixer.
Following pre-incubation,  5  lens tissues swatches were added and further 2.4mls PBS 
added, and mixed for  1   hour on a rota-mixer.  The liquid was then removed and 5mls 
PBS  added,  and  mixed  for  5  minutes  on  a  rota-mixer.  This  wash  cycle  was  then 
repeated a further 2 times.
After  washing  the  swatches  were  removed  and . mounted  on  a  microscope  slide.  A 
photograph was taken of the approximate center of each swatch under UV light at x 100 
magnification.  The  numbers  of particles  visible  under the  xlOO  magnification  circle 
were then counted at the top, bottom, left and right of the swatch.
742.16 Purification of llama antibody fragments
All chromatography buffers were degassed using a 0.2pm Nylon filter under vacuum.
All columns were cleaned according to proscribed protocols and stored in 20% ethanol 
(degassed).
2.16.1 Identification of commercial candidates using SDS-PAGE and Western blot
SDS-PAGE and Western blot was performed on samples as described in section 2.10.
2.16.2 Concentration of proteins
Dilute proteins were concentrated using a stirred cell concentrator (Amicon) containing 
a  lOKDa membrane.  Various concentrator volumes were used, from  10 to  150mls and 
the protein concentrated to the desired volume for buffer exchange (2.5mls to  15mls for 
small  scale  or  lOOmls  for  large  scale  buffer  exchange).  Nitrogen  was  passed  under 
pressure  into  the  stirred  cell  to  push  the  filtrate  through  the  membrane  and  the  cell 
stirred using a magnetic stirrer set to approximately 120 rpm.
Both filtrate and concentrate was collected and stored at 4°C.
2.16.3 Small scale buffer exchange of proteins
Small scale buffer exchange was performed by using up to 6 PD10 desalting columns in 
parallel  (GE  Healthcare).  The  columns  were  equilibrated  in  10  column  volumes 
(25mls) of buffer to be exchanged into.  A column volume of sample (2.5 mis) was then 
added to each column and allowed to enter the matrix.  The wash was then discarded. 
The protein was  eluted  in  3.5  mis  desired buffer and the  eluate  collected  and pooled 
with other column eluates.
2.16.4 Large scale buffer exchange of proteins
Large volumes of protein solution were buffer exchanged using a 1L column containing 
Sephadex G-25.
752.16.5 Protein A chromatography
A Hi-trap protein A column (1ml volume) was used to test the potential of protein A for 
the  purification  of the  fusion  protein  melC.  Protein  was  buffer  exchanged  as  above 
(small  scale)  into  a  20mMol  pH  7.0  sodium phosphate buffer.  The protein was then 
loaded  onto  the  column  at  lml/min  using  an  Amersham  FPLC  (GE  Healthcare)  and 
washed in the 5 column volumes of loading buffer.
Bound  protein  was  then  eluted  in  0.1 Mol  glycine-HCl  pH  2.7,  collected  into  2  ml 
fractions that were immediately neutralized in  lOOmMol Tris-HCL pH 8.0.  Peaks were 
then concentrated if necessary as described above.
2.16.6 Anion Exchange Chromatography
Anion exchange chromatography was performed using a MonoQ column (5 ml volume 
(GE  healthcare).  Samples  were  buffer exchanged  (small  scale)  into pH  9.2  20mMol 
Ethanolamine  as  determined by the  pi  of the  first protein to be purified,  Jal  625,  8.2 
(estimated using a a Deleage and Roix (1987) based model using the computer program 
DNAstar (http://www.dnastar.com/).
Sample was loaded onto the column at  1   ml/min and the column washed in 5  column 
volumes.  Bound proteins were then eluted in pH 9.2 20mMol Ethanolamine containing 
1  Mol NaCl at varying concentrations in the loading buffer to give a salt gradient.
Fractions were collected in 2 ml aliquots in 5ml tubes and stored at 4°C for analysis.
2.16.7 Cation Exchange Chromatography
Cation  exchange  chromatography  was  performed  using  a  MonoS  column  (5  ml 
volume).  Samples were buffer exchanged (small scale) into pH 7.2 20mMol phosphate 
as determined by the pi of the first protein to be purified, Jal 625, 8.2 (estimated using 
the method described in section 2.16.6).
Sample was loaded onto the column at  1   ml/min and the column washed in 5  column 
volumes.  Bound  proteins  were  then  eluted  in  pH  7.2  20mMol  phosphate  containing 
1  Mol NaCl at varying concentrations in the loading buffer to give a salt gradient.
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2.16.8  Freeze drying of pure proteins
Pure proteins obtained were buffer exchanged as above into pH 7.15 PBS and aliquoted 
into  vials  for freeze  drying.  The  samples  were  then  frozen at -70°C  for 2hrs before 
being placed  in a  freeze  drier for 48  hours.  Freeze  dried samples  were  sealed under 
vacuum and capped to preserve them.  They were then stored at room temperature.
2.17  Large scale purification of proteins: sampling
Samples were taken at each stage of large-scale purification.  All samples were frozen 
and stored at -20°C in aliquots for later analysis.
2.17.1 Analysis of samples
2.17.2 Gel electrophoresis and Western blot
Samples were  analysed by  gel  electrophoresis  and Western blot as described in 2.10. 
For more sensitive analysis of protein samples Silver stain was used.  Gels were fixed in 
40% ethanol,  10% acetic acid in milliQ for 30 minutes on a rocking incubator, prior to 
following supplied protocols (Silver Quest, Invitrogen, Paisley UK).
2.17.3 Total protein assay
Total protein content of each  sample was  assessed using BCA assay (Pierce)  in a 96 
well plate format.  A standard curve was produced using BSA and used to calculate the 
concentration  of protein  present.  All  samples  were  done  in  triplicate  and  accepted 
variance below 5%.
772.17.4 Cellulose Binding
An  approximate  measure  of activity  to  cellulose  was  determined  using  a  UV  based 
method.  Protein  samples  were  diluted  to  1.5  mg/ml  in  PBS  as  determined  by  BCA 
assay (above) and  1ml  added to a 2ml  eppendorf.  0.5ml  PBS or Avicel (2%w/v) was 
then added and the mixture incubated on a rotary incubator for 1  hour at 25°C.
They  were  then  centrifuged  at  15000  rpm  in  a  lab  centrifuge  for  5  minutes.  The 
absorbance  of the  supernatant  was  then  read,  and  the  percentage  decrease  from  the 
original calculated to give a relative cellulose binding activity.
2.18  Assays with purified protein candidate
2.18.1 Stability of protein
Protein  degradation  in  crude  and  pure  form  was  assessed  using  a  SDS-PAGE  based 
method.  Proteins were diluted to approximately 2 mg/ml protein in PBS and stored at 
37°C in an incubator, with samples being taken at 0, 2, 7, 14 and 31 days.
All samples were then run on SDS-PAGE and stained according to section 2.10.  Where 
visible breakdown of proteins was apparent, the subsequent sample was diluted less to 
visualize protein present.
2.18.2  Binding  of  pure  protein  to  crystalline  cellulose  and  melamine  capsule 
material
Binding of the pure protein to crystalline cellulose and melamine capsule material was 
determined  in an adaptation of the basic  cellulose  activity assay in  section 2.18.4.  A 
concentration gradient of fusion protein (8 replicates) was created in  1   ml aliquots in 2 
ml eppendorfs.  The eppendorfs were then split into 2 batches, each of four replicates. 
Into the first batch 0.5 ml PBS was added, and into the second batch 0.5 ml of cellulose 
mixture  (avicel  in  PBS).  The  experiment  was  repeated  with  three  concentrations  of 
avicel, 2.5 % w/v, 7.5% w/v and 10% w/v.
The  eppendorfs  were  then  incubated on  a rotary incubator for  1   hour at  25°C.  They 
were then centrifuged at  1500 rpm in a lab centrifuge for 5 minutes.  The absorbance of
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used to create a standard curve.
The standard curve was then used to calculate the concentration of the unbound fusion 
protein.
793.0 Results and discussion:  Investigation and characterisation of the 
function of llama antibody fusion proteins and potential for use in a 
novel micro-particle delivery system
3.1 Introduction
In  order to  assess  the  potential  of a  llama  antibody-CBD  fusion  to  aid  deposition  of 
micro-particles  a  model  system  was  devised  for  study.  This  involved  three  stages: 
development of an antibody-CBD fusion to a known antigen that could be attached to 
the particle surface, and attachment of said antigen to the particle surface, and delivery 
of particles  to  cellulosic  surfaces  in  the  presence  and  absence  of the  derived  fusion 
protein.
The objective of this work  is to  conduct proof of principle experiments on the model 
particle  delivery  system,  including  characterizing the  antibody binding to  its  antigen, 
manufacturing particles containing antibody binding sites, and to investigate the effect 
of the conformational differences of the proteins on the delivery mechanism.
The antigen selected for use is the azo-dye Reactive Red 6 (RR6).  Reactive Red 6 is a 
hapten azo dye with a molecular weight of about 765  (see fig.  6).  This molecule was 
selected as it has been shown previously that it is possible to raise an antibody to the 
molecule (van der Linden et al.,  1999) of comparable specificity and affinity to mouse 
monoclonal antibodies for the RR6 molecule.  The protein raised by van der Linden was 
specific enough that it did not show cross reactivity to the dimer of the RR6 dye known 
as RR120.
Unilever research  and  development,  Colworth has  created and produced  a number of 
multi-functional  proteins  by  fusing  a  protein  with  known  binding  towards  the  RR6 
moiety and a fungal CBD to give proteins with  1   or 2 VHH “hands” and 0,1  or 2 CBD 
“feet”  (see  figure  7).  These  molecules  provide  the  basis  for  a  system  to  potentially 
deliver particles  coated  in  RR6  to  cellulosic  surfaces  and were designed to prove the 
concept of such a system.
80Figure 6: The RR6 dye molecule - a hapten azo-dye, approximate molecular weight 765. 
The dye will link covalently and irreversibly with amine groups present on a surface.  The 
surface then requires repeated washing and blocking, to prevent further non-specific 
interactions.
81Further more, the nature of the RR6 molecule is such that it is ideal for coating surfaces 
irreversibly, as it is a dye that attaches covalently.  As it is a relatively small molecule, it 
should provide a large number of binding sites for the raised fusion protein.  Methods 
for  production  of  gelatin-gum  arabic  particles  (Co-acervate)  have  been  previously 
described  in  literature  (Tolstuguzov  et  al.,  1997).  Particles  can  also  be  loaded  with 
benefit agent or a marker in order to assess functionality.
Llama  heavy  chain  fragments  offer  considerable  advantages  compared  to  other more 
conventional antibody fragments including ease of production in yeasts, extra stability 
and small size whilst maintaining binding function similar to that of IgG molecules (van 
der  Linden  et  al.,  1999).  The  binding  moiety  chosen  has  been  fused  in  a variety of 
configurations  using  standard  molecular  biology  techniques  to  a  cellulose  binding 
domain  (Family  1)  from  Trichoderma  reesei.  Exact  configurations  of  the  fusion
proteins studied are explored in table 2.
82Molecule Schematic Molecule Information
A Y
Anti-RR6 single VHH molecule. 
Molecular weight: 14167.86 
Length: 130 amino acids
B 1
Anti RR6 single VHH fused with a single 
CBD molecule.
Molecular weight: 19505.69
Length: 180 amino acids
C
Anti RR6 two VHH molecule fused with a 
single CBD molecule.
Molecular weight: 33656.55 
Length: 310 amino acids
n y
Anti RR6 single VHH molecule fused to two 
CBD molecules.
u w Molecular weight 2442.80 
Length: 228 amino acids
Table 2: The anti-RR6 CBD fusion model system.  Protein A is the single VHH 
anti-RR6 and is used as a control.  Proteins B-D consist of VHH anti-RR6-CBD 
fusions in varying formats.
833.2 Determination of amount of RR6 bound to BSA
The RR6 molecule is conjugated with BSA for ease of study and binding to surfaces. 
This creates  a protein molecule presenting known antigens  available  for binding,  and 
allows the use of EDC/NHS binding chemistries to bind the antigen onto the necessary 
surface  for analysis  (conjugation  chemistry is explored in  Hermanson,  1996).  It also 
inactivates the  dye,  meaning that  a soluble  antigen presenting molecule  that does not 
conjugate with any available chemistries can be used.
Spectroscopic analysis (using MALDI-TOF spectrometry) shows that between 1   and 10 
RR6 molecules were attached to each molecule of BSA, with 60% of BSA molecules 
having 1  RR6 molecule attached (data not shown).
Consequently calculations that involved the amount of RR6 molecules attached to the 
BSA was performed twice, assuming a minimum (1  per molecule) and a maximum (10 
per molecule) being used.  This allowed a range to be given, and also the result based 
upon the mode of the data, which can be assumed to be  1   RR6 per molecule of BSA.
843.3 Binding of fusion proteins to RR6 BSA conjugate.
Two methods of investigating the binding of fusion proteins to RR6 were used -  simple 
and  competition  ELISA.  In  the  first  instance  a  simple  ELISA  was  performed  on  the 
proteins to give a direct comparison of the binding of the different proteins.
RR6-BSA conjugate was coated to the surface of a 96 well plate.  Binding of fusion was 
then  measured, and  results shown  in  figure  7.  The absorbance of the curve  is directly 
proportional  to  the  amount  of antibody  bound.  Each  result  is  the  mean  of duplicate 
samples.  Negative  controls  also  studied  (sec  table  3)  and  demonstrated  the  assays 
reliability by showing no response.
A  key assumption  is  that  the  secondary antibody (a rabbit anti-llama  protein)  binds to 
each fusion protein equally, and hence allows direct comparison between all the fusions. 
This is not necessarily the case however, as the structure of the fusion proteins, i.e.  the 
presence of the CBD/CBDs and also a second VHH, may cause the  anti-llama to bind 
differently.
Protein  A  (the  single  VHH  fragment)  shows  similar  binding  to  protein  B  (the  VHH 
RR6-CBD  fusion)  and  protein  C  (the  VHH  RR6-VHH  RR6-CBD)  in  respect  to  the 
RR6-BSA  conjugate.  This  shows  that the  addition  of a  single  CBD  has  no  seriously 
detrimental effect on the binding of the protein to the substrate.
Furthermore addition of a second VHH to the VHH-CBD molecule has no determinable 
effect  on  the  binding  to  the  substrate.  However  it  could  be  that  no  added  benefit  is 
noticed because the assay only shows how the amount of binding changes with fusion 
concentration.  This means that other benefits such as  increased  strength of binding or 
increased rate of binding will not be shown with this method.
Also, due to the density of the  RR6-BSA  conjugate being tightly packed on a surface, 
an element of stearic hindrance maybe occurring.  This stearic hindrance may be in the 
fusion  depositing  onto  the  substrate,  or  the  anti-llama  protein  binding  to  the  llama 
regions on the fusion.
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Figure 7: Binding of fusion proteins to RR6-BSA coated well plates.  Fusions A-C show 
similar curves, with fusion D showing a substantially lower response.
Control Description
1 No RR6-BSA coated to well
2 No incubation with VFIH fusion
3 No incubation with secondary antibody
4 No incubation with tertiary antibody
5 No incubation with enzyme substrate
Table 3.  Controls used in ELISA assay.
86It  would  be  expected  also  that  with  twice  the  available  llama  protein  domains  in  the 
VHH  RR6-VHH RR6-CBD molecule, that twice the binding of the anti-llama antibody 
and hence twice the response per molecule of fusion protein would be observed.  If this 
were  the  case,  then  the  level  of  fusion  bound  to  the  RR6-BSA  molecule  would  be 
approximately  half  that  recorded  and  the  VHH  RR6-VHH  RR6-CBD  would  be  a 
serious disadvantage to binding.  It  is also possible that the orientation of the two VHH 
heads  means  that  the  secondary  antibody can  not  bind  as  successfully as  to  the  single 
VHH.
The molecule with two CBD's attached can be clearly seen to show a lower absorbance 
at  all  points  than  the  other  fusions/fragments.  The  lower  absorbance  shown  by  the 
molecules could be due to stearic hindrance of the fusion molecule binding to the  RR6- 
BSA on the plate or the anti-llama molecule binding to the fusion molecule bound to the 
plate.
If it is caused by steric hindrance of the protein depositing on the RR6 substrate, then it 
is  representative  of the  protein  being  less  efficient  at  binding the  substrate.  However 
limitations of the assay such as the indirect nature, and the possible existence of stearic 
hindrance in the secondary antibody stage mean that the protein may be just as effective 
at  binding  RR6.  and  it  is  not  shown.  A  further assay,  the  competition  ELISA  should 
give more data to help understand the results of the simple ELISA.
3.4  Ability  of free substrate  RR6-BSA conjugate to compete  for fusion  binding in 
ELISA
Figure 8 demonstrates the ability of free RR6-BSA to compete with RR6-BSA bound to 
the  96  wcll-platc  for  the  four  fusion  proteins.  Each  point  is  the  mean  of a  set  of 
quadruplicates,  with  error  bars  showing  2  standard  errors.  Each  curve  is  done  on 
different 96 well plates and consequently the graph is normalised data for a competition 
ELISA.  Each  point  is  shown  as  a  percentage  of the  mean  of the  final  four  sets  of 
quadruplicates for the single VHH molecule.
The  X-axis  shows  dilution  factor  of the  competing  RR6  in  parts  per  ml.  Negative 
blanks comprised  of individual  components of the assay were also performed to  show
87validity of data.  All  negative blanks showed no absorbance at  510 nm, demonstrating 
that  the  individual  components  of  the  ELISA  such  as  the  secondary  and  tertiary 
antibodies do not affect the assay by binding the plate or RR6-BSA non-specifically.
As with the simple ELISA, the VHH  RR6, VHH  RR6-CBD and VHH RR6-VHH RR6- 
CBD have very similar responses.  It can be seen there is significant difference between 
the molecule with two CBD’s and the rest of the proteins.
Competition  ELISA  shows  the  amount  of free  substrate  required  to  inhibit  binding of 
the protein to the substrate attached to the plate.  The more dilute the free substrate that 
competes  with  the  antibody  binding  to  the  substrate  attached  to  the  plate,  the  more 
efficient  the binding.  This graph  shows that the  molecule with two CBD’s appears to 
exhibit better binding strength than the other molecules, which are similar in strength.
This figure appears to directly contradict the data in section 3.1.3, which shows that the 
2-CBD fusion protein is the weakest binder.  It would however agree with the data if it 
was assumed that the protein in fact had less available binding sites per mole of protein, 
due to stearic hindrance by the presence of the 2 CBDs.  If there were less binding sites 
per mole of protein, then it would be expected that it would take less free RR6 to inhibit 
the binding.
It would also be expected that the fusion protein with 2 VHHs would require twice the 
amount of free RR6 to inhibit, as there are 2 binding sites per molecule.  However this 
is clearly not the case, as shown by the graph, as it takes the same amount of BSA-RR6 
to  inhibit the protein  binding as  it  does the  VHH  RR6-CBD and The  VHH  molecule. 
This could be due to the protein being able to use only one VHH binding site at a time, 
perhaps  due  stearic  hindrance  of  the  second  site  by  the  bound  RR6  BSA.
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Figure 8: Competition ELISA for model system fusions
Minimum RR6 present per BSA
(1RR6/BSA molecule)
Maximum RR6 present per BSA
(10RR6/BSA molecule)
VHH VHHCBD
VHH
VHH
CBD
VHH CBD 
CBD
VHH VHH CBD
VHH
VHH
CBD
VHH CBD 
CBD
3.30x1 O'1''* 5.00x1 O'1* 5.00x10'^ 1.00x 10'1 1 1.10x10™ 2.00x10'iU 2.00x10'1 U 2.00x10'1 U
Table 4: Calculated affinities of fusion molecules using Scatchard analysis on 
ELISA data.
893.5  Estimation  of  fragment/fusion  affinities  using  Scatchard  analysis  on  ELISA 
data
Scatchard  analysis  (Liddell  and  Weeks,  1995)  was  performed  on  competition  ELISA 
data  (table  4).  The  amount  of  unbound  ligand  was  determined  using  an  equation 
derived from the standard curve of the ELISA in the linear region.  It was then assumed 
that the unbound ligand detected by ELISA subtracted from the total ligand was amount 
of bound ligand.
As  mentioned  previously,  the  stronger  an  antibody's  interaction  with  its  antigen,  the 
greater the affinity.  This makes the affinity constant  lower, and hence the stronger the 
affinity, the lower the affinity constant.
Although  these  affinities appear to be very close to each  other,  it  should be  noted that 
the error margin on  ELISA  is large and also that they rely on a number of assumptions, 
most particularly that each well  is identical to the others on the plate  in terms of BSA- 
RR6  conjugate  bound.  There  may  be  variation  and  some  edge  effects  on  the  plate 
present.  A  further assumption  is that antibody that  is  not bound  to the plate  has  been 
previously bound to the competing RR6.  There may be a proportion of inactive protein.
It  is  believed  that  the  sensitivity  of this  particular  assay  is  not  good  enough  to  draw 
definitive  conclusions  from  the  data,  as  all  experimental  errors  were  magnified  in  the 
calculation  stage.  Furthermore,  as  discussed  in  section  1.6.2,  inherent  issues  with  the 
indirect nature of ELISA only cloud the issues further.
It  was  hence  decided  to  research  a  more  direct  approach,  BIAcore.  BIAcore  uses  a 
technique known as Surface  Plasmon resonance to directly measure the association and 
dissociation of a ligand with its binding partner in real time (Malmborg and Borrebaeck, 
1995).  As mentioned previously (section  1.6.4.1) the binding partner must be bound to 
the surface of a BIAcore chip for measurement, this may alter the binding parameters.
903.6 BIAcore analysis
A  box  plot  was  chosen  to  represent  the  data  to  accurately  show  the  range  of results 
obtained (figure 9).  The X-axis represents  1/affinity constant in order to show that the 
stronger the affinity, the higher on the X-axis the box  is found.  The box  section of the 
graphs shows the area in  which  75% of the data points lie and is taken as the range of 
affinities the protein exhibits.  In some cases this range is quite large.  Error bars show 
the  5lh/95,h  percentiles,  and  once  again  vary  between  samples,  with  the  single  VHH 
molecule showing the smallest error bars.
The  graph  shows  that  the  single  VHH  has  an  affinity  of  approximately  4.5nMol. 
Published affinities for IgG antibodies are in the nMol range (0.5 to 350) (Jansson M et 
al.,  1997,  Beresford et al.,  1999 and Quinn and O’Kennedy, 2001).  As the protein falls 
into  this  range,  it  is  deemed  to  show  sufficient  affinity  and  functionality  towards  its 
target  antigen.  VHH  antibody  affinities  are  commonly  slightly  lower  than 
corresponding  IgG’s  (van  der  Linden,  1999),  however,  other advantages  as  described 
previously more than compensate.
The addition of a CBD to the VHH molecule reduced the binding affinity to 23  nMol. 
However,  this drop  in  affinity appears to be  counteracted  by the  addition  of a  second 
VHH domain in the fusion protein as this VHH-VHH-CBD demonstrated an affinity of 
about  10  nMol.  The  CBD-VHH-CBD  molecule  format  shows  an  affinity  of about  20 
nMol,  indicating that adding a  further CBD did not have a significant negative  effect.
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Figure 9: BIAcore affinities for model system fusions.  The box plot shows the 
interquartile range, with the error bars demonstrating the 5,h/95,h percentiles.  The white 
bar shows the mean of the data.  The Y-axis is inverted to demonstrate the strongest 
affinities at the top of the graph.
92Previous work on a range of llama VHH anti-RR6 fragments has demonstrated affinities 
of 22 to 83 nM as determined by IAsys biosensor (Spinelli et al., 2004).  This difference 
could  be  due  to  a  difference  in  protein  structure  and  consequently  function  or  the 
difference in method of affinity determination used.  As discussed in section  1.6.5,  Iasys 
uses a similar method of affinity constant determination to BIAcore.
It  is  postulated  that  the  reduction  in  affinity  caused  by  the  presence  of the  CBD  is 
caused  by  a  greater  steric  hindrance  due  to  the  increased  size  of the  molecule.  This 
effect was apparently limited, as the addition of another CBD had no greater detrimental 
effect  than  that  of the  single  CBD.  This  may  suggest  that  optimising  the  molecular 
structure  between  the  CBD  and  the  first  antibody  fragment  may  return  the  antibody 
binding strength back to its single domain counterpart. The addition of another VHH, as 
indicated  in  the  VHH-VHH-CBD  protein,  reduced  this  hindrance  by  offering  another 
binding site.
Addition of two CBD's shows no discernible difference from addition of one -  perhaps 
indicating that the detrimental effect is limited.  The molecule with two VHH heads and 
one  CBD  shows  increased  binding  over  the  molecule  with  one  VHH  head  and  one 
CBD,  indicating  that  addition  of another  VHH  goes  part  of the  way  to  correct  the 
problem caused by the CBD.  The increased binding of the two VHH molecule could be 
caused  by  both  heads  binding  to  the  ligand  or just  one  head  binding  and  the  other 
holding the CBD section out of the way, reducing stearic hindrance.
933.7 Binding of fusion in the presence of industrial chemical components
Figure  10  shows  the  effect  of chemical  components  on  the  fusion  protein  affinities. 
These chemicals are used as key components in the laundry industry.  Binding affinities 
were calculated using BIAevaluation  analysis software.  The effect of the components 
plotted in  Figure  10 varies with fusion molecule. The most stable of the fusion proteins 
was the protein  C  (VHHRR6-VHHRR6-CBD) that  maintained an affinity of about  10 
nM in the presence of each component.
STPP,  which significantly reduced  the affinity of the single  VHH  molecule to 48  nM, 
appeared to have little or no effect on the other fusion molecules.  It is plausible that the 
presence of the CBD conveys an extra stability to the molecule, perhaps by affecting the 
charge  layer  around  the  molecule,  or  by  physically  preventing  the  STPP  from 
interacting with the VHH component.
Figure  11  shows  the  affinities  of the  various  fusions  in  the  presence  and  absence  of 
alkaline silicate.  It can be seen that alkaline silicate has a severely detrimental affect on 
the  fusion  molecules  to  a  large  extent,  in  particular  with  the  single  VHH  molecule, 
reducing the affinity to approximately 550nMol.  The VHH-CBD and VHH-VHH-CBD 
affinities  were  reduced  to  approximately  250nMol,  and  the  CBD-VHH-CBD  to 
approximately 300nMol.  This appears to suggest that the presence of the  CBD, whilst 
having a minor negative effect on antibody affinity under an idealised condition, convey 
an  additional  stability  in  more  extreme  reaction  conditions.
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Figure 10 a-d:  demonstrate the effects of some commercial chemical components on 
fusion protein binding affinity, with the letter corresponding to that of the proteins in table 
2.  The box plot shows the interquartile range, with the error bars demonstrating the 
5th/95th percentiles.  The white bar shows the mean of the data.  The Y-axis is inverted to 
demonstrate the strongest affinities at the top of the graph.
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Fig 11.  Binding affinity of fusion proteins in the presence and absence of the 
chemical alkaline silicate.  The box plot shows the interquartile range, with the 
error bars demonstrating the 5,h/95,h percentiles.  The white bar shows the mean of 
the data.  The Y-axis is inverted to demonstrate the strongest affinities at the top of 
the graph.
963.8 Fluorescent Co-acervate Particle experiments
Coaccrvatc  particles  represent  the  potential  end  use  for  the  fusion.  As  described 
previously RR6 can be bound to the particles conveying a binding site for the antibody 
fusion.  Experiments that involve counting particles on cotton samples are useful as they 
represent  both  binding events  in  an  end  use  situation:  the antibody to the  RR6 and the 
C   BD to the cotton, and the effect of the proteins on particle delivery.  The particles can 
be  fluoresccntly  labeled  by  including  a  fluorescent  dye  in  a  manufacturing  step  as 
demonstrated in the appendices (see section  10.1).
3.9 Particles bound to cotton
Further  experiments  studied  the  binding  of particles  to  cotton  threads,  fragments  and 
swatches.  Photographs  (figures  12  and  13)  were  taken  to  show  the  technology 
qualitatively, and counts were performed for quantitative analysis.
The  particles  arc  naturally  “sticky"  and  will  bind  to  cotton  by  themselves.  Although 
these  photographs  show  the  bound particles, there  is no guarantee that the  presence of 
the  antibody  fusion  is  affecting  the  binding.  As  such  a  quantitative  method  was 
required.
It was investigated whether the presence of the fusion molecule increased the number of 
particles bound to the cotton.
97Fig 12. Particles bound to cotton swatch xlOO magnification
Fig 13. Particles bound to cotton thread xlOOx magnification
983.10 Determination of ideal binding method
As can be seen from  figure  14, the presence of the VHH  -RR6 CBD has a large impact 
on  the deposition of particles to the cotton  surface  if applied  in the right  manner.  It  is 
clear that  if the protein is prebound to the particles prior to addition of the cotton  there 
is a distinct benefit  in deposition.  It is interesting that this benefit is only noticed using 
the  pre-binding  to  particles  method  and  not  the  pre-binding  to  cotton  or  the  self- 
assembly approach.
It  is possible that because in the other methods the fusion gets spread too thin to have a 
noticeable effect,  however  in  the  pre-binding to particles  method  the  fusion  is  focused 
specifically on the particles activating them into specific cellulose binders.
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Figure  14. Determination of ideal binding method.  The Y axis represents the 
number of particle visible under x 100 magnification on a randomly selected 
spot on the cellulose swatch (approx radius of area 0.2 mm).3.11  C  omparison of effect of different fusions on bifunctionality
Figure  14 shows the effect of the fusion protein on the deposition of particles to a cotton 
surface.  The single  VHH  with no CBD attached has no effect on the deposition of the 
particles  to  the  surface,  and  is  very  similar  to  that  of the  control.  The  addition  of a 
single  C'BD  to  the  VHH  significantly  increases  the  deposition  of the  particles  to  the 
surface.  This  is  further accentuated  by  use of either a double  VHH  or CBD,  with  the 
double C’BD giving the highest deposition.
It  is interesting that the molecule with 2 C’BD’s has the greatest level of bifunctionality, 
yet the lowest affinity for the  RR6.  It is likely that the addition of the extra CBD gives 
the  particle  an  increased  chance  of  tethering  strongly  to  the  cellulose,  and  by  pre­
binding the fusion to the particle; it has a chance to convey the extra binding ability.
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Figure  15.  Comparison of effect of different fusions using pre-binding 
method.  The Y axis represents the number of particle visible under 20000 
times magnification on a randomly selected spot on the cellulose swatch.
1023.12 Summary
The  different  fusion  proteins  have  been  analysed  by  ELISA  and  BIAcore.  ELISA 
methods  demonstrated  ineonelusive  data,  and  proved  of  too  low  a  sensitivity  to 
aeeurately  render  affinities.  The  use  of the  BIAcore  has  successfully  defined  the 
affinities  of  the  proteins  to  RR6  and  also  confirmed  their  stability  under  different 
chemical conditions.
I  he affinity of the single VHH  molecule is the best  in terms of binding, however it is 
demonstrated  that  the  presence  of additional  protein  domains  conveys  an  additional 
stability to the protein.  The protein with 2 VHH s is shown to be the best, most stable 
binder to RR6 by BIAcore analysis.
RR6 coated particles have been successfully manufactured containing sunflower oil as a 
neutral  component to represent what eventually would be the particle active load. The 
load can be seen clearly in microscope pictures of the particles, and can be seen bound 
to  cotton  fragments  in  the  presence  of  the  fusion  qualitatively  and  backed  up 
quantitatively with  particle counts of particles and  fusion compared to a particle only 
control.
Esc of the fusion proteins and particles in bifunctionalitv assays shows that binding is 
enhanced  in  the  presence  of the  fusion  protein  when  the  particles  have  been  pre- 
lncubated with the  fusion protein prior to addition to cellulosic substrates.  The fusion 
protein containing 2 CBDs appears to convey the best bi-functionality.
These  initial  “proof  of  principle"  experiments  confirm  that  the  proteins  bind 
successfully  to  the  RR6  substrate  and  that  they  successfully  aid  the  deposition  of 
particles containing RR6 to cotton surfaces.  These results were sufficient to encourage 
further research  in  this area,  and  further work  will  be  in  the  investigation  of proteins 
raised directly to a particle surface.
1034.0: Initial Characterisation of the Melamine Particle System and 
selection of suitable candidate proteins
4.1  Introduction
A  number  of  problems  are  foreseeable  with  using  the  reactive  red  6  system  in  a 
commercial  application.  Sources  of reactive  red  6  are  very  limited  as  it  is  no  longer 
manufactured;  and  stored  supplies  are  at  the  gram  level,  never  able  to  meet  a 
commercial need.  Also the use of what is essentially a red dye in clothing applications 
raises some issues.
fhe coacervate particles are problematic as they contain gelatin, which is an undesirable 
component in commercial  formulations due to concerns over the bovine source and the 
presence of disease causing prions (Silveira et al., 2004).  Furthermore the Coacervate 
particles have a very poor release profile, as shown in figure  16.
It can be seen that although the initial free perfume level is low, the coacervate particles 
release  the  perfume  rapidly,  within  30  minutes at  25°C  and  60°C.  This  level  is  then 
comparable to free perfume.  In fact a slow, steady release profile over a period of days 
is the desired effect.
Three other main types of particle were considered:  latex, melamine urea formaldehyde 
polymer  and  silica  particles.  Latex  particles  were  not  chosen,  as  although  they have 
good  release  profiles,  the  allergy of latex  is  well  documented  in  literature  (Warshaw, 
2003).  Similarly silica particles were discounted due to fears over silicosis (Merget et 
al., 2002 and  Ding et al.,  2002).  Due to this, the melamine urea formaldehyde polymer 
particle  was  chosen,  as  this  has  good  release  profiles.  Melamine  is  a  reactive 
compound  which  forms  highly  inert  polymers  (the  structure  of melamine  is  given  in 
figure  17).
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Figure 16.  Release profile of perfume from coacervate particles compared to that of free 
perfume.  Free perfume is detected by Solid-Phase Micro Extraction Gas-Chromatography Mass 
Spectrometry (SPME-GCMS) of headspace above particles/perfume (Source:  Unilever Research, 
Vlaardingen).
NH
N ^   N
HoN NH
Fig 17.  Chemical structure of melamine.
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Figure 18.  Release profile of perfume from melamine formaldehyde particles as determined 
by a panel of twenty experts.  Topnote is the name of a very volatile yet popular perfume 
used in laundry.  An average person cannot detect a perfume with an intensity panel rating 
of below 2.5. (Source:Unilever Research, Vlaardingen).
106As  can  be  seen  from  figure  IS,  the  melamine-formaldehyde  (MF)  particles  have  a 
slower  release  profile.  The  perfume  level  of the  MF  particles  shows  a  slow  steady 
decline  over  seven  days,  whereas  the  level  of  the  free  perfume  shows  a  dramatic 
decrease over the first day.
I he  I  mlever  llama  antibody  phage  display  library  was  panned  for an  anti-MF  fusion 
and  a  candidate  chosen  and  fused  to a  CBD.  The  discovery of such  an  antibody  was 
remarkable, due to the  general  inertness of the  MF particle.  This  inertness also makes 
the particle an ideal candidate for inclusion in commercial formulations, although makes 
it  a  very  difficult  system  to  analyse,  as  it  is  very  difficult  to  conjugate  or  bind  to 
surfaces.
In order to incorporate  fusion proteins and melamine particles into laundry detergents a 
detailed analysis is needed to determine the amount to add to have maximum benefit at 
minimum cost.  As such  it  is important to find a level  where the melamine particles are 
saturated  with  fusion  protein  to determine the  maximum  binding,  and the  point  where 
further addition becomes unnecessary.
Butler  et.  al  (1992)  investigating  antibody  mono-layers  on  polystyrene-latex  surfaces 
determined a maximum possible surface coverage of 0.5 |igcm'“  of a random monolayer 
of  antibodies.  This  figure  is  a  maximum  and  is  highly  dependant  on  pH,  salt 
concentration  and  the  nature  of the  surface.  It  is  likely  that  surface  coverage  can 
commonly be 5-10 times less than 0.5|jgcirf\
Internal  Unilever  data  suggests  a  maximum  coverage  of 0.3|igcnf“   of  IgG  (Badley, 
1993).  This  figure  can  be  used  to  model  particle  coverage  of antibody  and  potential 
amounts to use and these calculations can be found in the appendix (section  10.2).
Using  this  data  it  can  be  estimated  that  approximately  10  mg  of protein  per  kg  of 
washing powder assuming 0.2°<»  loading of  perfume (loading varies between detergent 
types, but 0.2°<> is an average (Parry. 2003)) is needed.  This is comparable to dosing of 
other  proteins  such  as  enzymes.  It  is  important  to  assess  whether  this  level  is 
achievable, and what percentage of the protein actually binds to the particle, in order to 
understand the commercial potential of this technology.
1074.2 Quantification of level of fusion bound to melamine particles
Figure  19  shows  an  example of the  SDS  PAGE gels used to determine disappearance 
assay  data.  The  melA  protein  can  be  observed  to  be  approximately  20  KDa  in  size, 
which corresponds closely with  the derived value  (18759  Da)  (as described in section 
2.16.6).  A second band can be seen at approximately  15KDa, in about 50% abundance. 
It  is  likely that  this  is the  antibody section  -  VHH  M1E7  or part  of VHH  M1E7 as  it 
shows  disappearance  in  the  presence  of the  particles,  and  also  shows  positive  on  a 
Western blot labeled with an anti-llama antibody (data not shown).
10843 KDa
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Figure 19:  Example Gel used to calculate disappearance assay data below.  The arrows identify 
the fusion used.  Key: M: Marker, c: Control, t: Test.  The number represents the concentration 
of the fusion used (pg).  The lowest band is believed to be a fusion protein fragment.
109figure  20 shows the binding of fusion  melA to blue melamine particles in  PBS buffer. 
The  line  of best  fit  is  derived  from  the  Weibull  5-parameter sigmoidal  curve  function 
available on  Sigma plot  and  has a  R-squared value of 0.9805.  This curve was used to 
calculate  the  maximum  loading  of  fusion  to  particles,  and  therefore  the  number  of 
fusion molecules per particle, as described below.
fhe blue melamine particles have a mean diameter of 7.5|im and a density of 
1.51  gem
fhe volume of 1   particle, calculated as the volume of a sphere,  4/ 3/z?*3   is 220.89|inr\
fhe total volume of melamine particles in  1   cm3  20% suspension is calculated using the 
density of melamine to be 0.155 cnv\
fhe number of particles  is therefore equal  to the total  volume of melamine divided by
s
the volume of one particle, 7.01  x  10  .
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Figure 20: Graph of melA fusion bound to melamine particles in PBS with increasing 
concentration of fusion.
IllThe number of particles therefore in the reaction mixture (120fil of the 20% suspension) 
is S.40 x  Kf.
The  maximum  amount of fusion  that binds to  120|il of 20%  suspension of particles is 
derived from figure 2 to be 26.431 1   |ig.
I he amount of fusion binding to each particle is calculated at 3.15  x  10'7  fig fusion per 
particle.  Using  the  molecular weight  of the  fusion  (18579)  it  is determined that there 
were  1.70 x  10 1   Moles of fusion per particle.
Multiplication of the number of moles per particle by Avogadros number (6.022 x  102^) 
gives the number of fusion molecule bound per particle:  1.024 x  1()7.
The surface area of one particle  is calculated previously as  1.77  x  10 6 cm2.  The total 
surface area available for binding in the reaction mixture can therefore be calculated as 
148.68 cirf using the number of particles as calculated previously.
■ * >
fhe amount of fusion bound per enf can be calculated as:
2.6431 12.vl0  6  /148.68 =   \   J X x \ Q  1   g p e r   c m 2
This gives a maximum value of 0.178 fig fusion M1E7 per cirT or 0.944 mg fusion per 
gram of capsule.  To obtain this level of binding in the reaction mixture requires 34jng 
fusion, of which 26.431 1  gig binds, giving a percentage binding of 77.7%.  Therefore to 
achieve 0.1 78pg per cm2  binding requires 0.228jig fusion in total.
1124.3 C  ross functionality with coacervate particles
Figure  21  demonstrates  that  the  anti-melaminc  fusion  shows  some  binding  to 
coacervate,  but  only  a  third  to  a  half of the  binding  to  the  melamine  particles.  The 
difference is to be expected, as the M1  E7 antibody domain found on melA was raised to 
the melamine surface of the particles and should demonstrate  little cross-functionality, 
fhe speeifieity of llama VHHs is well known, and commented on by van der Linden et 
al., (1999) who compares VHHs with binding affinities for reactive dyes as being highly 
specific  and  not  binding  to  dimers  of the  antigen  dye,  or  indeed  chemically  closely 
related dyes.
This  is a  measure of the  specificity of the protein and  indicates that the protein has a 
specific binding functionality towards the melamine particle as desired.
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Figure 21: Binding of the fusion melA to melamine and co-acervate particles.
1144.4 Anti-niclaminc binding in the presence of detergent bases
Figure  22  demonstrates  the  binding  of  the  fusion  in  the  presence  of  two  laundry 
detergent  bases,  OMO  France  and  Saturn  Silver.  As  described  previously a  laundry 
base is a complete detergent formulation without the presence of perfume and enzymes. 
As can been seen from the graph, the fusion shows little change when in the presence of 
OMO  France,  still  reaching the  same  level  of deposition,  but just at a  slightly higher 
amount of total  fusion - 43pg instead of 37.5.  Saturn Silver however has a massively 
detrimental effect, and within the range studied there were only initial signs of binding 
at the higher end of total fusion concentration.  As a consequence, further work with this 
protein will not include Saturn silver.
It  is  important  that  the  fusion  works  in  available  detergent  bases,  and  the  above 
information would seem to indicate that OMO France is a better choice for formulation 
than Saturn Silver.  Llama antibodies that bind in the presence of surfactants have also 
been  selected  by  Dolk  et  al,  (2005),  with an aim of treating scalp complaints such as 
dandruff by placing the antibodies in shampoo.  Dolk et al. add a further comment on 
the potential of these antibodies to be able to work in a wide variety of conditions.
115~o
c
o
-Q
c o
C O
ID
c
=3
O
E
<
CD
:d
C/3
0)
O
tr
03
Q_
O
35 
30  -  
25 
20 
15  -  
10 
5 
0
-5
▼ ▼
0  20  40  60
Total amount of fusion available (ug)
Fusion M1E7 and melamine particles  in PBS
Fusion M1E7 and melamine particles  in OMO  base  Fr (6.8 g/l) and  tap water
Fusion M1E7 and melamine particles  in Saturn  Silver (6.8  g/l) and tap water
x column 3 vs y column 3 
x column 9 vs y column 9 
x column 10 vs y column 10
Figure 22:  Binding of melA fusion protein to particles in the presence of detergent bases 
OMO France and Saturn Silver.
1164.5 Binding of fusion to cotton in the presence of detergent
Fortunately binding of the fusion to cotton is easily measured using a simple filter-plate 
HLISA protocol.  This method is not practical  for measuring of the proteins binding to 
particles  as  the  particles  were  observed  to  totally  block  the  filters.  There  is  also  a 
measure of non specific binding of the protein to the plate.  This binding is counteracted 
by the remov al of the cotton swatch/thread at the final step into a new filter plate; this is 
not possible with particles without suffering loss to the filter.
Figure 23 demonstrates the binding of the fusion molecule to cotton in the presence of 
detergent bases.  As can be seen  a  level  of binding comparable to that of the positive 
controls  27r  F  water  (A  controlled  hardness  water  designed  to  represent  standard  tap 
water) and  PBST can be observed in the majority of detergent bases, with Shakespeare 
rational apparently the strongest binder.  Although OMO MA has the most detrimental 
effect  on  binding,  clear  evidence  of  binding  is  observed  over  the  control.  It  is 
interesting that in the presence of PBST the error bars for both the control and the test 
were at their largest, this could be due to a surfactant effect of the tween in the PBST. 
This chart shows that all the available detergent bases have potential to be used in this 
system.
In this experiment the detergent base Saturn Silver had been eliminated from study due 
to its poor performance in section 4.4.  OMO France can be seen to have an active CBD 
and antibody functionality to the particle and cellulose surfaces.  Unfortunately due to 
the  time  necessary to  perform  the assay detailed  in  section 4.4  it  was not possible to 
perform detailed analysis of protein-capsule binding in the presence of each detergent 
base.
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Figure 23.  Binding of the fusion to cotton strands in the presence of laundry detergents.  27°F 
water and PBST are include as a control.  The Error bars represent the standard error and the bars 
the mean of the triplicate results obtained.4.6 V  isual demonstration of binding Fabrics and Melamine
As a qualitative measure it is useful to actually visualize the binding.  This can be done 
with particle deposition studies to determine bifunctionality, as described for Reactive 
Red 6  in section  3.1.20 and  3.1.21.  Binding assays can also be done by using fusion 
protein that has been “tagged" with a fluorescent marker.
The fusion can be studied by conjugating the fusion protein with a fluorescent dye.  The 
actual  deposition  of protein  can  be seen on a real  time basis using a  microscope flow 
cell that allows a substrate (cellulose/melamine) to be bound to a microscope slide and a 
liquid containing the fluorescent fusion to be flowed over it.
The flow cell is basically a syringe pump capable of pumping volumes of liquid at low 
speeds over the surface of a closed cell which comprises a transparent microscope slide 
and coverslip.  This allows a real time study of the fusion depositing to surfaces.  Due to 
the depth of the cell, the maximum resolution obtainable using the flow cell is xlOO.
1194 min
8 min 6 min 7 min
Figure 24.  Fluorescently labelled fusion flowing over a melamine slide.  The fusion can be seen 
to adhere to the melamine, making it fluoresce.
120Figure 24 shows the deposition of the fluorescent fusion onto the melamine surface, and 
the consequent  fluorescing of the melamine.  A substantial increase in the fluorescence 
can be observed at the end, after the fluorescent cloud of fusion protein has washed off 
the  slide.  It  is  also  retained  over  the  time  and  appears  not  to  wash  off easily  (not 
shown).
figure  25  shows  another  melamine  slide,  but  this  one  is  pre-washed  with  non- 
fluorescent  fusion.  If the  fusion  is  successfully  binding  to  the  melamine,  the  non- 
fluorescent  fusion should block the majority of the binding of the fluorescent fusion is 
subsequently added.  As can be seen when comparing figures 24 and 25, figure 25  is a 
lot less fluorescent at the end of the cycle than 24.  This is because it is believed that the 
binding of the non-fluorescent fusion inhibits the binding of the fluorescent fusion.
12115 min  1 H U B   16 min  1 M   18 min
Figure 25.  Binding of fluorescent labelled fusion to pre blocked melamine slide.  Non 
fluorescent fusion is added at 0 minutes and fluorescent added at 12 minutes.  The binding of the 
non-fluorescent fusion inhibits the binding of the fluorescent fusion.
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Figure 26 Binding of fluorescent labelled fusion to a cotton strand.
123Figure 26 shows the binding of the fluorescent fusion to a cotton strand removed from a 
piece of terrv-towel.  This shows that the CBD end of the protein is functional, and the 
fusion  remains  with  5  minutes of washing.  Figure 27 and 28 show the binding of the 
fusion to Nylon and Polyester demonstrating a degree of some cross-reactivity, possibly 
brought about by charge interactions.  It can be noticed that Nylon only binds the fusion 
slightly,  whereas polyester binds the  fusion  very strongly.  It  is believed  that this  is a 
non-specific  binding,  as  it  is  more  pH  dependent  (data  not  shown)  than  that  of the 
cellulose binding.
124Figure 27 Binding of fluorescent labelled fusion to Nylon.Figure 28 Binding of fluorescent labelledfusion to Polyester.4.7 Potential commercial anti-melamine candidate proteins
Due  to  the  successful  function  of  the  melamine  binding  protein  discussed  and 
characterised  in  section  4.1-4.6,  a  number of potential  commercial  protein  candidates 
have been produced by a contract manufacturer for study.  These proteins were based 
upon the anti-melamine melA protein although have key structural differences.
This is necessary as Unilever does not have the capabilities for large scale production of 
these  proteins.  This  signals  a  move  towards  a  commercial  product,  as  the  contract 
manufacturer  has  the  facilities  necessary  to  produce  the  proteins  on  a  pilot  and  then 
commercial scale if the need arises.
The  contract  manufacturer  uses  a  different  expression  system  which  will  likely  alter 
their functional characteristics.  In order to anticipate functional variability a number of 
potential  candidates  with  structural  differences  been  made  to  screen.  These  contain 
varying types of VHH and also one or two CBD’s of varying types in varying formats.
fhe proteins also exhibit different production characteristics which will affect selection 
further.  An initial screening assay has been used to select candidates for purification (if 
necessary),  further  analysis  and  eventual  selection  of  a  lead  candidate.  Protein 
candidates are explored in table 5.
127Protein name  Structure Expression  Notes
mclA MlE7::CBDlr Good Produced in Pichia pastoris 
Research lab-scale protein; 
not producable large scale
melB MlE7::CBDT r Good Produced in Saccharomyces 
cervisiae
Research lab-scale protein; 
not producable large scale 
Appears  highly 
glycosylated
melC CBD0 ,5::M1E7::CBDE gv variable Produced  in  Aspergillus 
niger
Batch to batch variability. 
Very impure.
melD CBD015::KR::M 1  E7::CBDir Good Produced  in  Aspergillus 
niger
Pure due to KR region
melE CBDOI5::KR::MlE7::L27::CBDTr Good Produced  in  Aspergillus 
niger
Pure due to KR region
melF CaLipBprepro: :M1C8::CBDE gv Good Produced  in  Aspergillus 
niger
Pure  due  to  CaLipBprepro 
region
melG CBDC3I5::KR::M1C8::CBDegv Medium Produced  in  Aspergillus
niger
Impure
melH CBDC3,5::KR::M1C8::L27::CBDegv Medium Produced  in  Aspergillus
niger
Impure
mell CBDc3I5::M1G11::CBDEGv Good Produced  in  Aspergillus
niger
Impure
melJ CBDC3i5::M1C8::CBDegv Good Produced  in  Aspergillus
niger
Impure
melK CBDoi5::M 1  E7::L27::CBDE G v Good Produced  in  Aspergillus
niger
Impure
Table 5:  Structure of available proteins for testing.  The KR or CaLipBprepro regions allow 
affinity purification of the protein by selective adsorption followed by cleavage at that site.
1284.8 Initial screening of commercial candidate proteins
Due to the crude nature of some the proteins produced, they need purification to allow 
more detailed study and also for the end-use application.  The screening procedure was 
used to determine suitable candidates for purification.
Figure 29 shows digital  microscope pictures (xlOO magnification) of the particles and 
their interaction with ccllulosic tissue.  Crude demonstrates where the protein has been 
used  in  its  impure  form,  a  clarified  fermentation  supernatant.  The  tissue  that  was 
selected  is  very  strong  and  thin  and  hence  ideal  for  incubation  in  liquids  and  then 
viewing under a microscope.  The particles were “activated” by pre-incubating with the 
fusion protein or PBS in the case of the control.
It can be seen that some of the fusions show a noticeable increased particle deposition 
over  control,  equivalent  or  higher  than  that  of  a  100  fold  increase  in  particle 
concentration  alone  (eg proteins  melA,  melC  and  melK).  Some  fusions  showed  no 
added binding effect and were removed from the study.
Further  considerations  must  be  taken  into  account  when  selecting  fusion  proteins  to 
continue  studies  with,  such  as the production characteristics of the protein.  As such, 
fusion  proteins  melA  and  melB  are  not available  for commercial  purposes  (they can 
only be produced in house and at small scale) and were retained only for benchmarking 
studies.  In-house  proteins  were  expressed  in  Saccharomyces  cerevisiae  or  Pichia 
pastoris,  while  proteins  produced  by  the  contract  manufacturer  were  expressed  in 
Aspergillus niger.
Concerns  over  batch  to  batch  variability  of protein  melC  were  highlighted  in  the 
apparent difference between binding exhibited.  The low quantity of batch  1   means that 
only simple studies can be conducted with it, and there is a limited amount available for 
purification.
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Fig 29. Screening experiment to determine suitable candidates for further study and 
purification.  Particles are shown as orange spheres (demonstrated with arrows) as they 
contain the red fluorescent dye Nile Red.  The auto-fluorescence of the cellulose is also 
shown.
130I•urthcrmore  problems  with  the  production  of melC  raise  doubts  as  to  its  commercial 
relevance,  although  its  strong  functionality  means  it  was  chosen  as  a  candidate  for 
further study.  Proteins  mclJ  and  melK  were much  more easily produced  reproducibly, 
and were chosen for purification and further study.
It  is  interesting  to  see  that  the  proteins  that  demonstrate  successful  binding  from 
Aspergillus niger are  closely  related  structurally (Table  5),  suggesting a  move towards 
an  ideal  protein  structure.  They  all  contain  one  VHH  and  two  CBDs  in  the  same 
orientation.  Protein  melK  is  structurally  very  similar  to  melC,  just  containing  a 
shortened linker.
Therefore,  the  following  fusion  proteins  were  chosen  for  further  study,  and  where 
appropriate, purification:
•  melA
•  me IB
•  melC
•  melJ
•  me IK
As mentioned previously, proteins melA and melB were produced at a small  scale and 
are  used  for  initial  benchmarking  studies.  Only  low quantities  were  available  for use. 
Proteins melC, melJ and melK need purification prior to use.
Proteins melC, melJ and melK have no affinity tags such as the histidine tag to facilitate 
purification  for commercial  reasons  and  also  it  is  believed  that  the  presence  of such  a 
tag may  inhibit  the expression  of the  protein  in the Aspergillus production  system.  As 
such  a  purification  system  needs  to  be developed  that  uses either the  binding domains 
incorporated into the protein, or a generic purification system.
1314.9 Summary
Initial  characterisation  of the  protein  has  been  performed.  The  binding of the protein 
melA to the particle surface  has been successfully researched using a gel  densitometry 
based method and subsequent calculation done as to the possible loading of the protein. 
It is possible to use this data in future cost calculations for the system.
The protein is able to bind successfully to the particle surface in the presence of certain
detergent bases suggesting their commercial  relevance.  Little cross reactivity with co- 
acervatc  particles  seems  to  be  observed,  as  expected  due  to  the  specific  nature  of the 
protein.
Further  studies on  the  binding of the  protein  to  the  cotton  surfaces  in  the  presence  of 
different  detergents  suggest  suitable  detergent  bases  for  the  proteins  successful 
operation.  Visual  demonstration  of the  protein  binding  to  both  melamine  and  cotton 
surface is performed using a fluorescent fusion protein.  Some binding of the protein is 
confirmed with Nylon and Polyester.
The  protein  melA  shows  definite  potential  for  use  in  this  system.  However  it  is 
produced on a small  scale on site, and hence is not a viable commercial prospect in its 
current  format.  Proteins  melC,  melJ  and  melK  showed  potential  but  need  further
purification prior to further analysis and use.
1325.0 Purification and analysis of suitable protein candidates
5.1  Introduction
Different  applications  for  antibody  based  proteins  require  different  degrees  of purity. 
For  example,  in  the  bio-pharmaceutical  industry,  very  high  levels  of  purity  are 
necessary,  and  the downstream  process  used  may  include  up to  9  steps (not including 
buffer  exchange  steps).  The  process  encompasses  a  number  of chromatography  and 
virus  inactivation/clearance  steps  (Sommerfeld  and  Strube,  2005)  demonstrated  in 
figure  30,  leading to purification contributing to  up  to  80% of the  total  manufacturing 
cost.  These  high  process  costs  are  acceptable  due  to  the  relatively  low  amounts  of 
antibody  needed  and  the  high  profit  margins  associated  with  pharmaceutical  products 
(Roque et al., 2004).
Although  some  of  the  high  process  costs  associated  with  antibody  production  are 
eliminated  with  the  use  of  yeast  expression  (Muyldermans  et  al,  2001),  a  large 
percentage  of process  costs  are  in  down  stream  processing.  In  other  sectors  of the 
biotechnology  industry  (such  as  the  target  market  for  this  product)  however  the 
converse  is  often  true;  a  large  amount  of product  is  needed  relative  to  a  low  profit 
margin.  There  is  therefore  an  essential  need  to  employ  alternative  down-stream 
processing options to reduce cost.
A  potential  for affinity chromatography exists utilising the binding domains present in 
the  fusion  protein  i.e.  the  anti-melamine  particle  fragment  and  the  cellulose  binding 
domains  present.  These  were  chosen  to  be  strong  binders,  and  hence  were  likely  to 
need  harsh  chemical  elution  conditions,  which  will  affect  yield.  The  suitability of the 
particles  is  questionable  as  they  are  designed  to  release  their contents  under  shear  or 
damage such as that that may be incurred in such a process.
As  mentioned  previously,  the  use  of  cellulose  binding  domains  in  affinity 
chromatography  is common  (and  the cost of cellulose  is  very low  compared to that of 
other adsorbents), however the cellulose binding domains present have been specifically 
chosen  to  bind  at  a  very  high  strength,  and  would  require  extreme  elution  conditions, 
which were likely to inactivate the protein.
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Fig 30 A generic purification process for a biopharmaceutical monoclonal antibody protein 
produced using mammalian cell culture.  The many steps are shown, including virus 
inactivation and removal and three different chromatography steps
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Fig 31  The three candidate proteins chosen for purification.  They are all approximately the same 
size (45-46KDa).  The band is also quite broad, this maybe cause by their varied glycosylation.
134melC •  46 Kda M.W.
•  pi 8.2
•  Fusion of  2 CBD  Domains and  1  
VHH domain
Most  promising  protein  (as 
demonstrated  in  figure  29),  but 
one of most impure (about 5%)
•  Suffers  with  batch  to  batch 
variability
melJ •  46 Kda M.W.
•  pi 8.2
Fusion of  2 CBD  Domains and  1  
VHH domain.
Same  protein  as  melC  but  with 
different  antibody  head.  May 
suffer similar problems with batch 
to batch variability 
Purity varies
melK Molecular Weight 46KDa
•  pi 8.18
Fusion  of 2  CBD  domains  and  1  
VHH domain
•  Incorporates  a  shorter  linker than 
melC, to aid in production.
Similar  structure  and  function  to 
melC.
•  Purity varies from batch to batch: 
Batch A  10%, Batch B 55%.
Table 6.  The three candidate proteins in detail.  Molecular weight and pi are derived from the 
available model in the DNAstar programme, as discussed previously in section 2.16.6.
135In  keeping with the application of this technology being in the home and personal care 
sector  a  final  level  of 60-70%  purity  was  chosen.  This  is  similar  to  purity  level  of 
laundry enzymes in commercial detergents (Parry, 2003), and is believed to represent a 
good compromise between cost and purity.
As  mentioned  previously  a  degree  of  pure  protein  is  required  to  allow  detailed 
characterisation  of function  and  also  for regulatory and  safety reasons  within  the  final 
product.  The  need  to  purify  is  also  exemplified  by  the  presence  of fungal/bacterial 
proteases  in  the  fermentation  product  stream  which  may  degrade  the  protein  product 
(Ciouka et al,  1997).
The  lower  level  of  required  purity  means  that  step  number  can  be  reduced,  which 
reduces cost.  Also the ability to successfully produce the protein in GRAS yeast means 
that the safety steps associated with cell culture lines and endogenous virus populations 
are circumvented.
Figure 31  demonstrates the starting conditions of the crude fusion protein derived by gel 
electrophoresis.  As can be seen,  MelC  is the most impure protein, and hence the most 
difficult  to  purify.  However due  to  its  high  functionality it  is an  important candidate. 
The structure of the proteins is explored further in table 6.
As  mentioned  previously,  the  expression  of these  proteins  in  a  fungal  based  system 
gives  many  advantages,  and  one  of these  is  in  the  downstream  processing  area.  The 
product  stream  is  not  contaminated  by  endotoxins  as  found  in  bacterial  expression 
systems, or the possible presence of mammalian viruses as found in cell culture systems 
(Vcrma et al,  1998).
5.2  Small scale purification of candidate proteins
Whole  VHH  antibodies  have  been  previously  purified  by  protein  A  and  G 
chromatography (Muyldermans 2001),  however the VHH  fragments have no Fc region 
necessary  for this method of purification.  Lack  of adsorption was confirmed by initial 
experiments using protein A/G which showed no binding affinity.  Due to the modelled 
pi  of the  candidate  proteins  being  relatively  high,  cation  exchange  was  chosen  as  a 
suitable method (Amersham biosciences guidebook,  11-0004-21).
136Recommended  protocols  for  cation  exchange  (GE  Healthcare  instructions  71-5107-89 
AE)  involve  the  loading  of the  crude  mixture  at  lpH  below  the  pi  of the  protein  and 
elution  with a salt gradient (up to  1   mol) at the same pH.  This  is  usually sufficient to 
separate  proteins  according  to  varying  surface  charges  (Amersham  biosciences 
guidebook.  11 -0004-21).
The recommended protocol (as described above) was tried; however, an adaptation was 
required  to  give  satisfactory  purification  and  recoveries.  The  adaptation  was  made 
taking into account the known structural properties of the protein, and the best ideal pH 
conditions for separation.
The  failure  of  the  suggested  approach  was  perhaps  due  to  the  modelled  pi  being 
inaccurate, or the multi-domain nature of the protein affecting the charge distribution on 
the protein.  Experiments to determine ideal pH for binding determined a pH of 6.7 (1.5 
pH  units below the estimated pi).  However, up to a 2M  salt solution did not elute this 
protein,  and  a  pH  shift  and  salt  was  needed to elute  the  protein  successfully (data  not 
shown).  The loading buffer used was 50mMol MES pH 6.7 and elution buffer used was 
50mMol HEPES pH 8.2,  1M NaCl.  The elution pH is the calculated pi of the protein.
Figure 32 demonstrates successful small scale purification of melC.  As can be seen, the 
protein  appears  to  be  extremely  pure  after  the  ion  exchange  step,  and  this  result 
precipitated  a  further  study  using  a  greater  amount  of protein.  However,  during  the 
second run, and subsequent runs it can be observed that a second band purifies with the 
protein melC as well.  It  is believed that this is a breakdown product of the protein and 
demonstrates questions marks over the proteins stability, and therefore whether this is a 
suitable candidate.
A larger scale purification run was attempted with the melC demonstrated in figure 33.
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14.3 KDa
Figure 32.  Initial  purification of protein  melC.  The protein can be seen to be  successfully 
purified, the contaminant bands removed in the wash through.  The arrow shows the location 
of the band representing melC.
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Figure 33 Second purification of melC. Bands are labelled with arrows. The second 
band can be seen to purify at this stage at approximately 23KDa, the lower band
14.3  KDa
Step % Purity Total % Recovery
Process input 6
After PD  10  column 9 Approx 98%
After mono S 89 Approx 90%
Table 7.  Purity and recovery of protein in the lab scale process
139Percentage purities and  recoveries  were calculated by the  use of gel densitometry.  As 
such  they are approximate,  due  to  inherent  variability’s  in  the  method.  It can be  seen 
that the ion exchange method successfully purifies the protein at a small scale, with high 
recoveries demonstrating the suitability of this method.
The second band can be seen clearly in figure 33 (band X).  A smaller, third band (band 
Y) can  also be seen.  The  longer the crude  is stored at 4°C, the more substantial  these 
bands  become,  indicating  that  some  factor,  likely  to  be  the  presence  low  levels  of 
secreted  proteases  in  the crude  mixture degrading the protein.  As this protein  purifies 
with the  fusion protein  it has similar ionic properties, so may perhaps be a fragment of 
the  llama  VHH  protein.  This  is  further  suggested  by  the  presence  of llama  protein 
determined by Western blot.
This rapid degradation of the protein, coupled with inherent instability of the production 
process  which  could  often  lead  to  low  quantities  of product  (due  to  cleavage  of the 
protein during fermentation) or inactive product mean that further research on melC was 
stopped.  The contract manufacturer attempted to correct this problem by insertion of a 
shorter  linker to add  stability,  and  this  gave  the  protein  melK,  that could  be  produced 
easily  at  high  concentrations  and  appeared  relatively  stable  during  fermentation. 
Although  initial  studies  have  shown  it  is  not  as  active  as protein  melC,  it  is  the  most 
suitable candidate, offering a compromise between stability and function.
As  such  it  was  necessary  to  develop  the  process  further  for  protein  melK  and  also 
another  protein  of interest  melJ.  As  discussed  previously  protein  melJ  is  similar  to 
melC, containing a different VHH antibody clone, but identical structure and CBDs.  An 
initial study was performed with the method developed for melC due to the similarity of 
the  proteins  structure  and  their  similar  pi’s.  The  results  of that  study can  be  seen  in 
figure 34.
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Figure 34: Scouting purification of proteins melJ and melK.  As can be seen both 
are purified successfully to similar levels of purity to that of melC. C: crude, 
W/T: wash/through, P: Purified.
141This  initial  study  has  showed  that  the  potential  remains  for this  system  to  purify this 
group of fusion  proteins successfully at  small  scale,  to a high  level  of purity,  with one 
easy (and economical)  ion  exchange  step.  It  is then  necessary to  select one candidate 
protein  for  pilot  scale  production  and  purification  to  allow  accurate  studies  into 
functionality and determine the commercial potential of the particle delivery system.
5.3  Scale up of developed process to purify gram-levels of protein
Figure  35  shows  the  method  used  to  scale  up  purification  of the  protein  to  the  gram 
level.  The  first  two steps of the process were performed by the contract manufacturer 
that produces the protein.  It was then  shipped  frozen at -20°C  to  Unilever.  After this 
the crude supernatant filtrate is buffer exchanged before ion exchange.
This  is a  simple  and  easily  up-scaleable  approach.  Fig 36  shows  a  gel  of each  of the 
purification  steps  involved  in  the  process  stained  with  Coomassie  blue.  The  total 
protein  content  of each  well  is  identical  (determined  through  BCA  assay).  As  can be 
seen  the  protein  is  purified  to  a  high  level  by  the  ion  exchange  step,  demonstrating 
successful  scale  up  from  the  small-scale system.  The major contaminants can  also be 
seen to be removed by the ion exchange step and were present in the wash through.
It can be shown that the buffer exchange steps do not affect the purity visible in the 5- 
5()kDa  range.  In  order  to  demonstrate  the  presence  of minor  contaminants,  a  more 
sensitive stain was also employed.  Silver stain is not quantifiable like coomassie blue, 
but is much more sensitive (Fig 37).
The  silver  stained  gel  clearly  shows  more  contaminating  bands  in  the  crude  mixture 
than the gel  stained  with  Coomassie, demonstrating its sensitivity.  It is noticeable that 
these  bands  were  not  present  in  the  purified  protein  mix,  showing  that  the  system  is 
removing the  majority of both  major and  minor contaminating proteins.  The Western 
blot  is  used  to  determine  the  presence  of llama  proteins.  It  shows  that  contaminating 
proteins  were  not  of  llama  origin.  Although  it  is  demonstrates  presence  of  llama 
proteins in all wells, it is very sensitive and also not quantifiable.
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Figure 35 Flow Diagram for scaled up purification of protein melK.
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Figure 36: SDS-PAGE stained with Coomassie Blue. M: marker,  1: Crude fusion protein, 
2: Protein after desalting into 50mMol pH 6.7 MES, 3: Protein eluted from Cation 
exchange column, 4: Wash-through from cation exchange column, 5 Protein after 
desalting into pH 7.15 50mMol PBS, 6 Protein after freeze-drying (re-suspended).  The 
bulk of the protein of choice can be seen to be eluted in the cation exchange step to a very 
pure level.  Likewise the contaminant proteins can be seen to be removed in the wash.
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Figure 37: SDS-PAGE stained with Silver stain.  M: marker,  1: Crude fusion protein, 
2: Protein after desalting into 5()mMol pH 6.7 MES, 3: Protein eluted from Cation 
exchange column, 4: Wash-through from cation exchange column, 5 Protein after 
dCvSalting into pH 7.15 50mMol PBS, 6 Protein after freeze-drying (re-suspended). 
The higher sensitivity of the silver stain shows no additional bands in the eluted 
section.  The wash through sample shows many contaminating bands.
M  1   2  3  4  5  6
Figure 38: Western blot of SDS-PAGE.  M: marker,  1: Crude fusion protein, 2: Protein 
after desalting into 50mMol pH 6.7 MES, 3: Protein eluted from Cation exchange column, 
4: Wash-through from cation exchange column, 5 Protein after desalting into pH 7.15 
50mMol PBS, 6 Protein after freeze-drying (re-suspended).  The band is labelled initially 
with a rabbit anti-llama polyclonal and then a goat anti-rabbit alkaline phosphatase 
conjugate.  The colour is developed by addition of BCIP-NP.  The band can be seen to be 
present in all samples, but seemingly more weakly in the wash through stage of ion 
exchange.
144Tabic 8 shows a mass balance  for the purification process.  This has clearly shown the 
bulk of the protein removed in purification is during the cation exchange step, although 
the  first buffer exchange step also removes some contaminating proteins as well.  This 
is  believed  to  be  low  molecular  weight  contaminants  that  elute  very slowly and  were 
left  behind  on  the  gel  filtration  column.  This  effect  is  not  present  in  the  second  gel 
filtration step,  showing that these contaminants have been removed by this stage.  It is 
also  shows,  as  expected,  that  freeze  drying  has  no  effect  on  the  concentration  of the 
protein present.
Figure  39  demonstrates  the  successful  removal  of total  protein  across  the  process  and 
subsequent  increase  in  percentage  cellulose  binding  activity.  Total  protein  was 
calculated  using  a  BCA  assay  as  described  above  and  the  total  protein  added  to  each 
step  calculated.  It  can  be  seen  that  approximately  20%  of the  original  total  protein 
content is remove in the first buffer exchange.  It is believed that this reduction is due to 
the  long  retention  time  of  small  proteins/protein  fragments  in  the  buffer  exchange 
column,  and  their  subsequent  removal  from  the  process.  A  further  50%  of the  total 
protein is removed in the ion exchange step, and can be seen to wash though the column 
(data not shown).  Activity is increased by approximately 40%.
A small amount of protein is lost in the final desalting column, but it is only 2-3 percent, 
this  is acceptable  for the column, and no protein  is  lost in the freeze drying step.  The 
decrease in total percentage protein is followed by a close negative correlation with the 
percentage binding to avicell, representing percentage purity.
Over  the  whole  process  the  percentage  binding  to  avicell  increases  by  approximately 
50%, while the percentage protein  is reduced by 70%.  This difference could be due to 
the  percentage  cellulose  binding  being  approximate,  as  it  is  only  measured  as  a 
percentage  reduction  in  absorbance  at  280nm,  or  the  presence  of  another  cellulose 
binding protein in the crude mix, that skews the assay.
145Protein in
i_ „ .  _ ______
Protein Eluted 
_ _  ,  ________
Protein waste 
.   .  _......... Total protein out
Desalting  1 7470 6025.8 46.7 6072.5
Cation
exchange 5386.7 2337.1 2637.7 4974.8
Desalting 2 1926 1784.22 0 1784.22
Freeze
Drying 1702.5 1700 0 1700
Tabic 8: Mass Balance of total protein through out the developed process
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Figure 39:  Percentage decrease in total protein as detected by BCA assay versus 
percentage increase in cellulose binding to Avicell.  It can be seen that the ion 
exchange step decreases the total protein by approximately 50%, whilst 
increasing cellulose binding activity by about 40%.
146Alternatively,  it  could  just  be  due  to  non-binding  of the  protein  to  the  ion  exchange 
matrix,  which  would  correlate  with  an  approximate  recovery of 80%.  This  indicates  an 
increase  in  percentage  specific  activity,  and  quantifiably  demonstrates  purification  of 
the protein.
The  purification  of the  protein  melK  to  the  gram  level  provided  suitable  quantities  for 
detailed  analysis.  As  mentioned  previously  the  selection  of  MelK  is  a  compromise 
between  functionality  and  ease  of production  and  purification.  The  process  developed 
proved  very successful  in purifying the protein to a high  level of purification.
I he  next  step  is  to  determine  certain  properties  of the  protein  -   such  as  stability  in 
solution,  binding to  melamine and  cellulose,  and  the bifunctionality o f the  protein.  The 
properties  of the  protein  melK  can  then  be  compared  to  those  o f the  benchmark  lab 
scale  proteins.  It  is  very  important  to  build  a  good  knowledge  base  o f this  proteins 
activity  and  function  in  order  to  be  able  to  make  key  decisions  at  a  later  stage  in  its 
development, and to determine the commercial potential of the protein.
The  function  of the  protein  may  be  different  to  the  original  benchmark  proteins  due  to 
its different  expression  host (Aspergillus niger as opposed to Saeeharomyees cerevisiae 
o\' Piehia pastoris).  Further more it is structurally different, having two VHH  heads.
5.4  Stability of melK
The overall  protein  stability is very important  in both product formulation and shelf life. 
Whilst  freeze-drying  has  proved  very  successful  at  preserving  both  crude  and  pure 
proteins  for a  very  long time,  it  is  very expensive  on  a  large  scale.  As  such,  it  is  likely 
that  in  final  product  formulation,  the  protein  will  stored  in  an  alternative  manner.  An 
important  consideration  then  is  how  stable  the  purified  protein  is  over  the  crude  in  a 
liquid.
As  can  be  seen  from  figure  40  the  purified  version  of the  protein  offers  considerable 
stability benefits over the crude  in  the conditions shown.  The crude protein can  be seen 
to  breakdown  rapidly  at  37°(’,  and  needs  substantially  less  and  less  dilutions  to  make 
the protein  visible on the gel.
147The  pure  protein  stays  intact  across  the  31  days  at  37°C  demonstrating  the  advanced 
stability  of the  llama  fusion  protein.  This  is  very  important  in  terms  o f final  product 
formulation,  demonstrating  that  the  protein  has  the  robustness  to  be  suitable 
commercially.
As  can  be  seen  from  Lane  A,  the  fusion  protein  that  has  been  stored  at  4°C  for  three 
weeks prior to this study is already demonstrating signs of breakdown, with three bands 
visible  around  the  45KDa  region.  It  is  believed  that  these  were  initial  breakdown 
products o f the fusion protein.
As  the  time  course  continues,  the  other  crude  protein  samples  (b-c)  begin  to  show 
degradation  products  by  2  days  (40x  dilution),  noticeable  as  a  darkening  under  the 
45KDa  region.  By  7  days,  the  fusion  protein  in  crude  form  is  not  visible  at  all  at  20x 
dilution,  and  by  14  days  is  not  visible  at  lx  dilution.  This  corresponds  with  a  denser 
band  at  around  20  KDa,  which  may  be  due  to  the  higher  concentration  used  and 
consequently  does  not  get  broken  down,  or  is  an  advanced  breakdown  product  of the 
fusion protein.
Protein  F (crude batch 2 of melK) shows a similar degradation to that o f crude batch 3 -  
although  it  is  noticeably  a  lot  less  pure  than  that  of batch  3.  It  is  interesting  that  all 
proteins  in  protein  F  show  obvious  degradation.  This  is  less  noticeable  in  the  crude 
form of batch 3  (proteins a-c), perhaps due to its purer nature.
It  is  believed  that the degradation observed  in the crude protein  mix  is caused by extra­
cellular  proteases  secreted  by  the  expression  host.  As  the  fusion  protein  is  secreted  it 
makes  purification  easier  by  meaning  that  it  is  not  in  contact  with  a  large  number  of 
intracellular  proteins,  however  it  means  that  the  protein  will  come  into  contact  with 
these extracellular proteases.
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Fig 40 Stability of fusion protein melK crude versus pure as demonstrated by SDS- 
PAGE.  The fusion is highlighted by the box on the first gel.  Time is represented in 
days at 37°C.
149Aspergillus species are known to secrete a number of extracellular proteases -  although 
the  strain  used  in  the  fermentation of melK  is a low protease  strain,  it still  produces a 
low level.  Over a period of time, this is believed to degrade the fusion protein, even at 
4°C,  as  observed  by  the  condition  of protein  A  at  To.  At  37°C,  this  degradation  is 
accelerated.
The pure protein contains either no protease, or protease at a substantially lower level. 
This makes the pure protein much more stable and resistant to degradation. This would 
be essential  for final product formulation, as it is impractical for the protein to be stored 
frozen or even at 4°C  if it  is to be  used  in  the  home and personal  care  industry.  This 
also means that  it  is essential  that the protein  is purified as rapidly after production as 
possible, in order to minimise loss in yield.
The  stability  of  the  llama  antibody  based  protein  at  37°C  is  also  observed  in  a 
bifunctional  llama  antibody  construct  produced  for research  by  Conrath  et  al.  (2001). 
The  protein  is  seen  to  be  stable  for  over  72  hours  at  37°C  in  either  a  PBS  or mouse 
plasma preparation.  However it is shown to have lost approximately 20% in that time, 
suggesting  that  the  protein  melK  is  substantially  more  stable.
1505.5 Binding of the pure protein to crystalline cellulose
Fusion protein binding to crystalline cellulose has been investigated, as demonstrated in 
figure 41.  The newly purified melK was compared at three different levels of cellulose 
(avicell) suspended  in  PBS  buffer- 2.5% w/v,  7.5% w/v and  10%.  As is expected, the
10% w/v avicell showed higher binding than the 7.5%, and the 7.5% higher than the 2.5
°/ /o .
All  graphs  were  fitted  with  a  Weibull  5  parameter  curve  as  detailed  in  the  computer 
program Sigmaplot.  The R2  value of the 2.5 % curve is low (around .8), perhaps as the 
majority of the reaction appears finished even at the lowest fusion level, and any added 
increase  in  fusion  has  no  further  effect.  Consequently  this  curve  was  not  used  any 
further.
The other two R2  values were high (0.99) showing the goodness of fit of the curve.  It is 
interesting that  the curve  fitted  is  sigmoidal,  and  identical  to that  fitted  for the protein 
melA  to melamine.  This suggests that they share similar binding characteristics,  even 
though the substrates and binding domains were different.
At  10% w/v avicell, the maximum binding protein per ml  using the derived equation is 
0.76 and at 7.5  % avicell  it  is 0.56.  Using these two numbers it is possible to derive a 
maximum binding of 7.6 and  7.4 mg fusion protein per gram of cellulose respectively. 
This gives an average of 7.5 mg fusion protein per gram of Avicell.  This is a very high 
level  compared to that derived previously for the protein melA to melamine (0.948mg 
per gram of capsule),  nearly 8 times higher.
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Figure 4 1.  Binding of fusion protein MelK to different quantities of crystalline cellulose. 
The data is fitted with a Weibull 5-paramcter sigmoidal line of best fit.
1525.6 Binding of the fusion protein to melamine
In order to derive the binding of the protein to melamine capsules,  it was essential  that 
they pellet strongly upon centrifugation.  The density of melamine is approximately  1.5 
so they should pellet;  however due to the encapsulated active volatile ingredients being 
in a carrier oil, the density of the capsules varies greatly.
It  can  be  observed  upon  centrifugation  that three  fractions of capsules  form:  those that 
pellet, those that stay in suspension and those that float.  It was postulated therefore that 
those that  pelleted  have  lost  the  majority of their encapsulated  material  (it  is obviously 
of no  use  to  have capsules  so strong that  they do  not  release their ingredients).  Those 
that  were  in  suspension  have  some of their encapsulated actives present,  and those that 
float  were  high  in  encapsulated  actives.  It  is also possible that  the  amount of material 
encapsulated varies capsule to capsule on formulation.
It  is known that the use of certain solvents destroys the capsule integrity and  is capable 
of removing the encapsulated material (internal  Unilever data), indeed such a method is 
used  to  quantify  the  amount  of encapsulate  present.  Consequently  it  was  decided  to 
employ a solvent washing step to remove the capsule contents and attempt to make the 
capsules pellet - if the hypothesis was correct, then this should happen.
C  apsules were washed repeatedly with Acetone and spun down.  It was observed by the 
third acetone wash that all capsules pelleted, and they were then washed repeatedly with 
PBS to remove all traces of the solvent.
Fig  42  demonstrates  the  binding  of the  protein  MelK  to  the  melamine  capsule.  It  is 
noticeable that more capsules were required (25%) to produce a similar response to that 
noted  in  avicell  (10%).  This  demonstrates  a  lower  level  of binding  to  the  melamine 
capsule surface than  to that of cellulose,  likely due to a higher number of binding sites 
available on the cellulose surface.
The  pure  protein  has  shown  positive  binding  to  melamine  and  cellulose,  and  hence  a 
bifunctionality assay was performed comparing it to other proteins.
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Figure 42:  Binding of the protein melK to melamine particle surface.
1545.7 Bifunctionality of purified melK compared to that of other mel fusion proteins
The  bifunctionality  of purified  melK  protein  is demonstrated  as  comparable  to  that  of 
the  other  candidate  proteins  in  figure  42.  The  protein  demonstrates  an  increase  in 
binding equivalent to that of a  100 fold increase in particles alone.
In  this  study  the  ratio  of fusion  protein  to  particle  was  kept  at  a  constant  level.  The 
amount  of particle/fusion  protein  mix  was  then  adjusted  to  a  suitable  level  to  conduct 
particle counts.  The control (particle only) showed no particle deposition at the level at 
which the particle and fusion protein test demonstrated deposition (0.02% v/v capsules). 
Consequently, higher levels of the control  were selected (0.2 and 2% particles) in order 
to determine a level of control that gave equivalence of bifunctionality to that of the test 
mix.
Although this assay shows relatively high variability as demonstrated by the error bars, 
there  were  still  some  significant  differences.  The two  fusion  proteins  melA  and  melC 
demonstrate  similar  bifunctionality  at  a  high  level,  and  then  the  proteins  melB  and 
melK, and then the protein melJ.
As  discussed  previously,  the  proteins  melA  and  melC  demonstrate  superior 
hi functionality to that of melK.  However melK was selected as a compromise between 
functionality  and  ease  of production.  As  can  be  seen  the  protein  melJ  demonstrates 
inferior bifunctionality to melK confirming melK as the lead candidate.
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Figure 43:  Bifunctionality of fusion proteins
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1565.8 Summary
A simple one step cation exchange based method has been developed at the lab scale for 
the  proteins  melC.  melJ  and  melK.  Production  and  stability  issues  with  the  protein 
melC  have  meant  that  it  is  not  suitable  for  use  in  the  particle  delivery  system.  Two 
close  relatives.  melJ  and  melK  were  purified  at  a  larger scale,  with  the  purification  of 
melK being focused on.
Ion  exchange  was chosen  as a  suitable  cost  effective  method  for purifying the protein, 
however  the  developed  process  required  a  llow  pH  to  bind  to  the  column  matrix, 
followed bv a pH equivalent to the derived pi of the protein and  IMol  salt to remove it. 
This was a  far stronger binding and elution condition than  published proteins;  however 
it appeared to give very high purity.
The fusion protein melK was purified to a high level of purity with good recoveries, and 
then freeze dried prior to further use.  Stability of the fusion protein was assayed using a 
SDS-PAGE  method  to  visualize  break-down  products  of the  protein.  Binding  of the 
protein  to cellulose and melamine particles was also assayed prior to use of the protein 
in a hi functionality deposition study.
1576.0  Conclusions
6.1  Investigation and characterisation of the function of Hama antibody fusion 
proteins and potential for use in a novel micro-particle delivery system
A  model  system  based on a  llama antibody fragment showing a binding moiety to the 
azo-dye reactive red 6 has been developed and fused to a cellulose binding domain from 
Trichoderma reesei.  The objective was to study this protein and determine its capability 
for use to deliver micro-particles to cellulosic surfaces.
A number of different  formats of the fusion protein have been researched using ELISA 
based  assays  and  surface  Plasmon  resonance  (BIAcore)  to  determine  functionality 
towards the azo-dye.  Although ELISA data was interesting, variability proved too high 
to  conclusively  determine  binding  affinities.  BIAcore  data  however  allowed  binding 
affinities to be calculated and these tallied with published data, in the low nMol region.
This  research demonstrated  that all  proteins could  successfully bind the  azo-dye  RR6, 
however  the  presence  of an  additional  antibody  fragment  conferred  an  extra  stability 
when  the  protein  was  binding  in  the  presence  of  some  commercial  detergent 
components.  Binding affinities were calculated, and the presence of the CBD shown to 
have little effect on binding to RR6.
Increased deposition of particles to cellulose surfaces was demonstrated using a particle 
deposition  assay,  determining  bifunctionality  of the  protein.  Use  of bifunctionality 
assays shows  that  binding  is  enhanced  in  the  presence  of the  fusion  protein  when  the 
particles have been pre-incubated with the fusion protein prior to addition to cellulosic 
substrates.  The  fusion  protein  containing  2  CBDs  appears  to  convey  the  best  bi­
functionality.
Issues  with  the  particles  source  and  release  profile  meant  that  this  system  was  only 
suitable  as  a  model  system  for  study,  however  the  research  supported  the  further 
development of a potential commercial system utilising a more suitable melamine based 
particle.
1586.2 Initial Characterisation of the Melamine Particle System and selection of 
suitable candidate proteins
A  protein  raised  to  the  surface  of  melamine  particles  was  created  for  study.  This 
protein,  known  as  melA  is  a  proof of principle  protein  produced  at  a  lab  scale.  The 
melamine particles  show  the  stability and  release profile suitable  for cellulose binding 
applications.
Initial  characterisation  of the  fusion  protein  binding  to  the  particle  surface  has  been 
studied using a gel densitometry based method.  This allowed calculations to be done as 
to  the  possible  loading  of  the  protein,  and  provided  data  suitable  for  use  in  cost 
feasibility studies.
The  protein  has  been  proven  able  to  bind  successfully  to  the  particle  surface  in  the 
presence  of certain  detergent  bases  demonstrating  commercial  relevance.  Little  cross 
reactivity with co-acervate particles has been observed, as expected due to the specific 
nature of the binding of the protein.
Further  studies on  the  binding of the  protein  to  the  cotton  surfaces  in  the  presence  of 
different  detergents  suggest  suitable  detergent  bases  for  the  proteins  successful 
operation.  Visual  demonstration  of the  protein  binding  to  both  melamine  and  cotton 
surface is performed using a fluorescent fusion protein.  Some binding of the protein is 
confirmed with Nylon and Polyester.
The  success  observed  with  the  protein  melA  led  to  the  creation  of  a  number  of 
commercial  candidates  from  commercial  protein  suppliers.  These  have been  screened 
for  suitability,  giving  rise  to  a  number  of potential  candidates  comprising  a  similar 
structure -  two CBD’s and  1   VHH.  The  suitable  commercial  candidates  (melC,  melJ 
and melK) required further purification prior to use.
1596.3 Purification and analysis of suitable protein candidates
Due  to  the  impure  nature  of  the  candidate  proteins  produced  by  the  commercial 
manufacturers  it  was  necessary  to  purify  selected  candidates  for  storage  and  further 
analysis.  A  cation  exchange  chromatography  based  method  was  developed  which 
successfully purified the protein melC to a high level of purity.
This  method  utilised  an  optimised  binding  condition  for  the  protein  to  the 
chromotgraphy  matrix,  and  elution  conditions  utilising  a  pH  shift  and  high  salt.  The 
fusion protein  melC  was however proved to be unsuitable  for further development due 
to production issues.  As such, the method was applied to proteins melJ and melK.
Both  fusion proteins were successfully purified at  microgram  scale prior to scale up to 
the  gram  scale.  The  method  developed  used  only  one  ion  exchange  step,  and 
consequently  is  substantially  more  cost  effective  than  other  antibody  purification 
techniques such as those used in the pharmaceutical industry.
Due to the apparent generic nature of the developed process and its simplicity it shows 
great promise.  The production of gram  levels of protein also allowed a more detailed 
analysis of the process.  Fusion protein was followed through the process, and after ion 
exchange,  the  majority  of contaminant  proteins  were  observed  in  the  wash  through -  
down to silver stain levels of detection.
The  purified  protein  was  then  studied  for  stability  using  a  gel  densitrometry  based 
method  to  look  for degradation  of the  fusion  protein  after timed  incubations  at  37°C. 
Pure fusion protein was shown to be stable after 31  days at 37°C, where the crude was 
seen  to  have  totally  degraded  after  7  days,  and  partially  after  just  2  days.  This 
demonstrated the potential  of the protein to be stored as a product without the need for 
expensive freeze-drying.
Due  to the higher  levels of pure  protein  available,  it was possible to  use  an  assay that 
required  more  protein  allowing  a  detailed  study  of the  protein  binding  to  crystalline 
cellulose and melamine capsule materials.  A binding curve of the protein was generated 
for  3  different  levels of cellulose  demonstrating  a good  relationship  between  cellulose 
available for binding, and total protein bound.
160Binding  of the  protein  to  melamine  was  studied  and  the  binding  curve  shown.  The 
bifunctionality  of the  pure  protein  was  then  shown  and  compared  to  that  of the  other 
crude  candidate  proteins.  It  was  shown  to  be  an  effective  aid  to  deposition  of the 
particle to cellulosic surfaces.
6.4  Future work
The work done  in this project has focused on the development of the protein for use in 
the particle delivery system.  As such it is possible to perform more detailed analysis in 
the area of the protein characterisation of both the  RR6 base protein and the melamine 
based protein.  Studies  into the structure of the proteins utilising techniques such as x- 
ray crystallography would be beneficial.
Further  work  into  ideal  binding  conditions  would  also  be  beneficial.  There  are  two 
areas which can be further optimised:  the ratio and conditions of binding of the protein 
to  the capsule  and  the  ratio  and  conditions  of binding of the  activated  capsules  to  the 
cellulosic surface.  The type of cellulosic surface can also be researched, as applications 
can  be  envisaged  in  other  areas  such  as  paper  manufacture,  wood  treatment  and  the 
agrochemical  industry.  It  is also worth  studying other similar cellulosic  surfaces such 
as chitin.
Further work in the area of purification should focus on the use of new matrices that can 
handle salt level such as the Capto MMC  matrix from Amersham and also the removal 
of the two buffer exchange chromatogrpahy steps  from the process.  This could either 
be  done  with  ultrafiltration  or  by  loading  fermentation  crude  onto  the  matrix  after 
primary clarification, and by adapting the elution buffer to the final desired conditions.
Further  research  into  the  area  of particle  surface  chemistry  should  also  be  performed. 
The fusion protein has been selected according to ability to bind the particle, however it 
may  be  possible  to  further  increase  binding,  and  subsequent  bifunctionality  by 
comparison and selection of new melamine particles.
Pilot  studies using initially scaled down  washing machines and appropriate conditions, 
followed by full scale washing machine trials to determine efficacy of the system under 
wash conditions including water hardness and detergent type will also be performed.  If
161this is successful, storage and consumer trials will be undertaken to determine perceived 
benefit, prior to any consideration of formulation into a product.
Development of the system  for other applications also has good potential.  The concept 
of using these  fusion  proteins to deliver capsules has been demonstrated  in  this thesis, 
and a  logical  progression  would be transfer of the system  for use  with other cellulosic 
surfaces:  such as the delivery of particles to paper for the diagnostics industry, delivery 
of encapsulated actives to plants and untreated wood to prevent pest infestation.
6.5  Summary
A  novel  llama  fusion  protein  has  been  studied  and  used  successfully  in  a  system  to 
deliver  particles  to  cellulosic  surfaces.  Proof of principle  was  demonstrated  with  a 
model system and then further in a system designed to have commercial relevance.  Due 
to  the  success  of the  protein  in  the  commercially  relevant  system  a  range  of proteins 
were produced which were screened  for bifunctionality prior to development of a one- 
step  ion-exchange based  purification  system  for the  lead candidates.  The pure protein 
was  then  assayed  for  stability  and  functionality  to  the  capsule  surface  and  crystalline 
cellulose, and also bifunctionality.
1627.0 Bioprocess project management and validation of bioprocesses at 
Unilever
7.1  Bioprocessing at Unilever
Unilever  is  a  diverse  company  featuring  many  arms  which  have  products  in  the 
following  areas:  home  and  personal  care,  frozen  foods  and  ice  cream,  teas  and  other 
beverages and also processed foods.  As such its research needs are constantly changing 
and adapting to meet the market requirements in specific areas.
Historically the  majority of Unilevers research  in the home and personal  care area has 
focussed  on  chemical  formulation;  indeed  they  used  to  own  chemical  industries  now 
part  of ICI.  Use  of biotechnology  was  limited  to  enzyme  technology  in  the  laundry 
detergent industry.
Although  a  great  deal  of expertise  has  been  developed  in  the  area  of laundry enzyme 
production,  Unilever  therefore  has  limited  experience  of  developing  biotechnology 
products and in particular their production.
With  the  pressures  of a  competitive  market  comes  the  need  to  adapt,  and  Unilever  is 
embracing the opportunities biotechnology has to offer.  This has required a paradigm 
shift in the core thinking of Unilever:  it has to think increasingly like a pharmaceutical 
company in respect to its product development.  However it cannot afford some of the 
luxuries that pharmaceutical companies have in regards to bioprocessing.
The use of biotechnology brings new challenges in all areas of research, and process to 
product must be considered and acted upon from the earliest stages of development.  As 
such the route from research candidate to product must be managed carefully.
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Figure 44: Yield of fermentation products compared to selling cost.  As can 
be seen as yield decreases, selling price increases.  Unilever must operate in 
the area demonstrated by the blue box, hence high yield, low cost bio- 
processes are necessary.
164Whilst  pharmaceutical  companies  can  operate  in  a  low  yield  -   high  cost  environment 
though  it  is the opposite  for  Unilever,  as demonstrated  in  figure 43,  the  selling cost of 
Unilevers products can not approach that of pharmaceutical companies such as Pfizer or 
Merck.  Products  must  be delivered cheaply and  in  large quantities.  However this can 
be  partly  achieved  due  to  the  lower  specification  of  product;  for  example  purity 
requirements are often much lower.
Biotechnology  production  options  are  also  limited  in  Unilever.  Manufacturing 
capabilities focus on the processing of food products and the  formulation of chemicals. 
Fermentation  capabilities  are  limited,  and  hence  sourcing  products  from  contract 
manufacturers is often the method of choice.
Use  of  contract  manufacturers  allows  Unilevers  research  and  development  group  to 
focus  on  its  area  of  expertise,  namely  production  of  small  scale  candidates  using 
molecular  biology,  and  allow  scale-up  development  to  be  performed  by  the 
manufacturer.  The  early  aim  is  simply  a  production  of  a  low-level  of  protein  for 
analysis  and  proof of principle  experiments  and  then  passing of the  technology to  the 
manufacturer who is then under pressure to produce the protein as rapidly as possible in 
order to maximize profit margins.
Production of the antibodies  for use  in  laundry products was at  the  late developmental 
stage  at  the  time  of completion  of this  thesis.  The  development  of an  Aspergillus 
production  system  with  the  contract  manufacturer and  their expertise  in  such  systems 
should allow a relatively easy transition to a much larger scale if necessary.
A  close  liason  with  the  manufacturer  is  necessary  to  define  acceptable  process 
parameters based on cost and regulation.  Regulation for the product is similar to that of 
laundry enzymes -  not  nearly as  strict as those  for that of the pharmaceutical  industry, 
making the cost substantially lower.
7.2  Validation of the antibody purification process
Initial  research  into  the  purification  of  the  antibody  using  ion  exchange  proved 
successful.  If the process were to be scaled up a number of measures would need to be 
taken to validate  its efficacy, robustness and repeatability.  The successful  repeated use
165of each  piece of process  equipment  also  needs  to be  validated  and  sufficient cleaning 
and  sanitization  processes  developed.  Removal  of  contaminants  from  the  process 
equipment needs to be demonstrated, as indeed does removal of any cleaning chemicals.
As  the  equipment  is  already  in  place  in  the  contract  manufacturers,  it  will  already be 
qualified  for use,  and  capable of being  used  for generic  purification.  The  system  will 
need to be thoroughly tested  with the candidate protein using methods similar to those 
used  in  section  5,  such  as  SDS-PAGE  (with  silver  staining  sensitivity).  Detailed  and 
repeated  mass-balances  need  to  be  performed  to  demonstrate  that  productivity  and 
recovery  is  not  lost  over  time.  Studies  into  suitable  lifetimes  for  all  perishable 
equipment need to be determined such as filter and chromatography matrix usage.
The  contract  manufacturer  will  have  many  protocols  in  place  and  standard  operating 
procedures for validations of their processes, it is just a case of adapting them to suit the 
antibody  product.  This  will  involve  supply  of  suitable  assays  in  order  to  monitor 
protein concentration etc.
Once a suitable validation method is in place the process can be tightly monitored and 
maintained.
7.3  Conclusion
The  structured  path  and  transition  of  early  development  at  Unilever  research  and 
development to scale up and production at a contract manufacturer is the most suitable 
method for production of a biotechnology protein product.  The contract manufacturers’ 
expertise  and  plant  capablities  in  bio-processing  and  validation  of  bioprocesses  is 
essential for production; whilst the ability to retain ownership of the science behind the 
product is essential to Unilevers interests.
166Abbreviations
Ab Antibody
AFM Atomic force microscopy
BSA Bovine serum albumin
CBD Cellulose binding domain
CDR Complementary determining regions
ELISA Enzyme linker immuno sorbent assay
ER Endoplasmic reticulum
GRAS Generally regarded as safe
HIC Hydrophobic interaction  chromatography
HPLC High performance liquid chromatography
Ig Immunoglobulin
IMAC Immobilised metal affinity chromatography
ITC Isothermal titration calorimetry
PBS Phosphate buffered saline
PCR Polymerase chain reaction
PDI Protein disulphide isomerase
RIA Radio-immunoassay
RU Response unit
RR6 reactive red 6
SDS-PAGE SDS poly-acrylamide gel electrophoresis
SPR Surface Plasmon resonance
STPP Sodium tri-poly phosphate
UV Ultra-violet
167Appendix  1: Production of particles
Particles were examined at two stages in their manufacture: After initial production and 
after hardening.
As  can  be  seen  from  the  photographs,  the  fluorescence  is  concentrated  in  the  small 
globules inside the particles after initial production.  The globules consist of sunflower 
oil that is used as a carrier base for the benefit agent.  The particles at this stage are quite 
soft  and  susceptible  to degradation.  Detrimental  osmotic conditions  in  particular may 
lead to lysis of particles.
As  can  be  seen  from  the  above  pictures  the  hardening  process  has  the  effect  of 
spreading the fluorescence labeling (Nile Blue) throughout the particle.  The individual 
globules  can  still  be  seen  indicating  that  they  are  intact,  but  it  is  likely that  physico­
chemical  changes  have  drawn  some,  or  all  of the  fluorescence  out  of the  oil  carrier. 
Indeed the globules may exhibit no fluorescence and only seem to fluoresce because of 
the particle casing behind them.
168Figure 45: Particles after initial production x200 magnification.  Identical pictures, the 
one on the right showing the Nile Blue labeling.
Figure 46: Particles after initial production xlOO magnification.  Identical pictures, 
the one on the right demonstrates the fluorescent labeling with Nile Blue.
Figure 47: Particles after hardening xlOO magnification, picture on the right shows 
fluorescence with Nile Blue labeling.
169Figure 48: Particles after hardening 20000x magnification, pictures on the right 
shows fluorescence with Nile Blue labeling at different depths of focus.
170Appendix 2:  Fusion particle binding calculations
The surface area of one particle is calculated as a sphere of diameter 7.5 pm as:
m l1   =1.77*10 ~ 6cm2
The molecular weight of the fusion molecule is  18579 therefore the amount of fusion
molecule per particle can be calculated as
(5.31 a ! 0  n )/18579 = 2.86*10  1 7  Moles a f  fusion per particle
The number of fusion molecules bound to each particles can then be calculated using 
Avogadros number
(2.86*10”1 7  )*(6.02*1023) = 17205555  fusion molecules per particle
Although  this  figure  is a  maximum and the actual  figure may be as  5-10  times  less. 
The melamine particles consist (by weight) of 42.3% “Topnote” perfume of a density 
1.0  and  57.7% of melamine polymer with  a  density of 1.51.  The  overall  density  is 
calculated as
(57.7x1.51) + 42.3x1.0/100 = 1.29 gem 5
The  desired  levels  of perfume  are  0.2%,  0.4%  and  1.0%  in  laundry  powder.  This 
requires  0.47%,  0.95%  and  2.35%  particles  respectively,  in  1kg of laundry powder, 
4.7g,  9.5  and  23.5  g  particles.  Taking  1kg  of  0.2%-perfumed  powder,  the  total 
volume of the particles can be calculated from the density
4.7/1.29 = 3.643 cm'
The volume of one particle calculated as a sphere is given by the equation
Therefore the number of particles needed for 0.2% perfume in  1kg of powder would
Therefore in a monolayer of 0.3 pgem'2 there are
0.3.v(l .77*10  6) = 5.3 1*10“7   jug fusion per particle
5.31  x  10'1 3  g fusion per particle
be
3.643 / 2.2 Lvl 0  1 0   = 1.65*10 H )particles per kg powder
171The mass of fusion molecules per particle was previously calculated at 5.31  x  10'13 g. 
Therefore for 1  kg powder
(1 .65jt1 O1 0  )jc(5.3 IjcI 0-13) = 8.76x10-3 %   fusion per kg powder
Percentage perfume Fusion required per kg powder (mg)
0.2 8.76
0.4 17.7
1.0 43.8
Table 9.  Estimated amount of fusion required per kg washing powder according to 
internal data.
So it is estimated that approximately  10 mg of protein per kg of washing powder at 
0.2% loading of perfume is needed.  This  is comparable to dosing of other proteins 
such as enzymes.  It is important to assess whether this level is achievable, and what 
percentage of the protein actually binds to the capsule.
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